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Abstract
Diabetes is a chronic epidemic compounded by a burden of vascular complications
including diabetic nephropathy. Diabetic nephropathy affects ∼40% of patients and is char-
acterised by increased urinary albumin excretion and decreased glomerular filtration rate.
Diabetic patients exhibit ∼75% decreased plasma thiamine concentration, linked
to increased renal thiamine clearance. In streptozotocin-induced diabetic rats, decreased
plasma thiamine concentration was also associated with a reduction in expression and ac-
tivity of transketolase. Transketolase is a thiamine pyrophosphate-dependent enzyme and a
critical component of the reductive pentose phosphate pathway, a metabolic pathway leading
from glycolysis involved with the synthesis of ribose sugars. It is proposed that increasing
the relative flux of glucose through the pentose phosphate pathway can ameliorate hypergly-
caemic damage. This thesis investigates mechanisms mediating the increased renal thiamine
clearance and the effects of thiamine therapy on type 2 diabetic patients with nephropathy.
The hypothesis that hyperglycaemia increases flux through the hexosamine pathway, lead-
ing to increased O-glycosylation of the transcription factor Sp1 and subsequent decreased
expression of thiamine transporters is investigated.
Thiamine transporters in normal human kidney sections were found to be localised to
the proximal tubule. Investigations in primary cultures of human proximal tubule epithelial
cells and the HK-2 cell line have shown that there is a decreased expression (−48 to −80%)
and abundance (−52 to −77%) of thiamine transporters in cells cultured in high glucose
concentrations (26 mM) with respect to low glucose concentrations (5 mM). There is only
limited evidence supporting the involvement of the hexosamine pathway in these decreases.
A double-blind, placebo-controlled study investigated the effect of thiamine supple-
mentation on type 2 diabetic patients with microalbuminuria. Thiamine therapy restored
plasma thiamine concentrations from 11 nM to 98 nM, exceeding the published median con-
centration observed in normal patients (64 nM). After three months, thiamine therapy,
but not placebo, caused a decrease in the urinary albumin excretion rate relative to base-
line (−18 mg day−1). These results show promise for thiamine as a therapy for diabetic
nephropathy.
xv
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Chapter 1
Introduction to diabetes
1.1 Definition and classification
Diabetes mellitus is a chronic disease of sugar metabolism relating to the hormone insulin.
It is increasing in incidence to epidemic proportions globally and is divided into two main
subtypes. Type 1 diabetes is insulin-dependent and occurs when the body does not produce
insulin or produces a defective insulin; type 2 diabetes is traditionally non-insulin-dependent
and occurs when the body becomes less responsive to available insulin. In both types, the
outcome is an increased fasting plasma glucose concentration from between 3–7 mM to 7–
30 mM [American Diabetes Association, 2010a].
1.2 Aetiology and prevalence
Type 1 diabetes is characterised by an auto-immune mediated destruction of pancreatic
β-cells, often developing early in life. Pre-clinical histological analysis of the diabetic pan-
creas reveals a state of insulitis, characterised by the infiltration of a large population of
mononuclear lymphocytes responsible for attacking the β-cells [Gepts and Lecompte, 1981;
Qu et al., 2003]. Most of the attacking cells are T-cells (some CD4+ with a majority of
CD8+) along with a small subset of macrophages and B-cells (reviewed by Bach [1994]).
Despite this sustained attack on the only cells capable of producing insulin, over 80% of
β-cells must be destroyed before clinical symptoms become apparent [Gepts, 1984]. The
cause of this auto-immune attack is not clear. There is a sizeable genetic element to the
disease—studies with twins and type 1 diabetes have consistently shown that there is a
1
higher concordance rate for monozygotic than dizygotic twins [Kyvik et al., 1995; Kaprio
et al., 1992; Lo et al., 1991]. However, monozygotic concordance is only 40% which leaves
a substantial non-genetic environmental component to the disease. Genetic susceptibility
to type 1 diabetes is not only linked to autoimmune attack of the β-cells. Kida [1999]
demonstrated that the insulin gene (chromosome 11p15.5) is linked to type 1 diabetes with
symptoms arising through the manufacture of a defective insulin, not through destruction
of the β-cells.
Type 2 diabetes is not traditionally a disease of young people and tends to develop
later in life. Its progression is more gradual than type 1 diabetes and clinical symptoms often
follow a period of symptom-free pre-diabetes. Pre-diabetes is often associated with impaired
glucose tolerance (IGT), impaired fasting glucose (IFG) and other risk factors which combine
in a state called the metabolic syndrome. Metabolic syndrome is a collection of risk factors
for coronary heart disease (CHD) and there is a strong link between these risk factors and
incidence of type 2 diabetes. Its World Health Organisation (WHO) definition is outlined
in Figure 1.1. Despite its use as an educational concept, a recent WHO working party
concluded that the metabolic syndrome has limited practical use as a diagnostic or clinical
management tool [Simmons et al., 2010].
Figure 1.1: Metabolic syndrome as defined by the World Health Organization [1985]. Insulin
resistance is defined as being within the highest quartile for the relevant population. Hy-
pertension is defined as blood pressure (BP) ≥140/90 mmHg. Obesity is defined as a body
mass index (BMI) ≥30 kg m−2, or a waist-hip ratio (WHR) >0.90 for males and WHR >0.85
for females. Hypertriglyceridaemia is defined as ≥1.7 mM triglycerides. Low high-density
lipoprotein (HDL) is defined as <0.9 mM for men; <1.0 mM for women. Microalbuminuria
is a urinary albumin excretion (UAE) rate ≥20 µg min−1 or an albumin creatinine ratio
≥30 mg mmol−1. Adapted with permission from Zimmet et al. [2001].
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The number of diagnosed diabetes patients in the UK has increased from around
1.4 million in 1996 to 2.6 million today, around 4.3% of the population [Diabetes UK, 2010].
By 2025, Diabetes UK estimates that there will be around 4 million diagnosed diabetes
patients. Most of these patients will have type 2 diabetes driven by an ageing population
and an increasing incidence of obesity [Dixon, 2010]. Indeed, Thomas et al. [2005] have
estimated that one fifth of older men and women in the UK (aged 60–79) currently have
either impaired glucose tolerance or undiagnosed diabetes. Within the UK, 90% of adult
diabetic patients have type 2 diabetes and only 10% have type 1 diabetes. Children of age
17 and under have predominantly type 1 diabetes with 97% of diagnosed diabetic children
being type 1 patients. The prevalence of type 1 diabetes in UK children is around one case
per 700–1000 population for a total of around 21 500 under-18s with type 1 diabetes. Type 2
diabetes has historically not been evident in children but this trend is changing recently.
The first cases of type 2 diabetes in children were diagnosed in overweight girls aged 9–16
of Indian, Pakistani or Arabic ethnic origin [Ehtisham et al., 2000] with the first cases in
Europid children being diagnosed two years later [Drake et al., 2002]. Children of South
Asian origin are 13 times more likely to have type 2 diabetes than white children [Ehtisham
et al., 2004].
Globally, the estimated diabetes prevalence is 285 million (4.3% of the population,
as in the UK) and is expected to rise to affect 438 million people by 2030 with the economic
and social impact expected to be greatest in developing countries [Diabetes UK, 2010;
International Diabetes Federation, 2009]. In response to the predicted scale of the epidemic,
the United Nations has passed a resolution which declared that diabetes is an international
public health issue [Atkins and Zimmet, 2010]. Within the UK, 10% of the NHS budget is
now spent on diabetes care. This figure is around £9 billion per year, equivalent to £286
per second or £150 per capita per annum.
1.3 Historical perspective
Diabetes was known to antiquity with the Greeks first coining the term diabetes, διαβη´της,
meaning “siphon” and referring to the large quantities of urine produced by diabetic patients
[Kirchhof et al., 2008]. In 1675, Thomas Willis added the suffix mellitus meaning honey to
signify the sweet taste of the urine. Diabetes insipidus is the other main form of diabetes
and has similar symptoms including increased urination (polyuria) and increased thirst
(polydipsia). However, diabetes insipidus is caused by hormonal imbalances producing more
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urine directly e.g. antidiuretic hormone deficiency [Onuigbo and Skalski, 2010]. Due to the
lack of glucose, urine produced by in this manner is not sweet. The distinction between type
1 and type 2 diabetes was first made by Harold Himsworth who recognised the difference
between insulin-sensitive and insulin-insensitive diabetes pathologies [Himsworth, 1936].
Despite knowledge of the symptoms, diabetes remained difficult to treat. Before the
differentiation of type 1 and type 2 diabetes, they were identified and treated as one disease.
Various dietary treatments were used with limited success throughout the 19th century.
The role of the pancreas in glucose metabolism was not understood until 1889 when two
Germans, Joseph von Mering, a doctor, and Oskar Minkowski, a scientist, removed the
pancreas from a dog and discovered that it developed all the symptoms of diabetes before
dying shortly after [v. Mering and Minkowski, 1890]. By 1910, Edward Sharpey-Schafer had
made progress with understanding the function of the pancreas. He had discovered that the
islets of Langerhans within it produced the chemical used to control glucose metabolism
which he called insulin from “insula”, the Latin for “island”. This was followed by the 1921
discovery in Canada by Frederick Banting and Charles Best that an extract of islets from
a healthy dog could cure a diabetic dog of its disease. Their subsequent work led to the
purification of insulin which was first injected as a treatment into a diabetic patient in 1922
[Banting et al., 1991]. Fourteen year old Leonard Thompson, who received the insulin, lived
for 21 more years after his first treatment due to regular dosing with insulin—an outcome
not previously imaginable.
1.4 Diagnosis and symptoms
In modern times, type 1 diabetes is often diagnosed early in life after patients have presented
with symptoms such as increased thirst, increased urine production or unexplained weight
loss. Criteria established by the World Health Organization [1999] allow diagnosis based on
one of several characteristics including a fasting plasma glucose ≥7 mM or a plasma glucose
≥11.1 mM two hours after an oral glucose tolerance test (glucose loads vary for children at
1.75 g per kg body mass with a standard 75 g dose for adults). Additional diagnosis criteria
are recommended by other organisations. For example, the American Diabetes Association
recently suggested that an HbA1c of ≥6.5% is also a valid diagnostic criterion [American
Diabetes Association, 2009, 2010b].
The primary symptoms of diabetes noticeable to a patient are polydipsia coupled
with a dry mouth, polyuria, weakness and fatigue, loss of weight and blurred vision. As the
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disease progresses, secondary complications arise including nephropathy, retinopathy and
neuropathy (Sections 1.6.2, 1.6.4 and 1.6.3). It is these secondary complications which are
the main burden of the disease, not only on the patient but also on the economy.
1.5 Therapy
Therapies for diabetes are wide-ranging and address associated risk factors such as dys-
lipidaemia and hypertension as well as attempting to maintain a normal blood glucose
concentration. Maintaining good glycaemic control is key in reducing the risk of microvas-
cular complications [The Diabetes Control and Complications Trial Research Group, 1993;
UK Prospective Diabetes Study (UKPDS) Group, 1998; Stratton et al., 2000; Stolar, 2010].
To achieve this goal a variety of therapeutic strategies are employed.
The therapy of type 1 diabetes is dependent on the administration of insulin. Modern
therapy uses recombinant human insulin produced in E. coli or yeast rather than insulins
purified from animals. Insulin therapy has advanced considerably over time and there is now
a wide range of insulins available for different uses. Despite this, there has been no effective
therapy developed that provides normal glycaemic control for patients with type 1 diabetes.
Until that time, insulin therapy supplemented with careful diet control will remain the most
important strategy.
For some type 2 diabetes patients it may be possible to maintain adequate glycaemic
control through dietary restriction alone, especially if diagnosed early [Gross et al., 2005].
More often, pharmacological intervention is required. The United Kingdom Prospective
Diabetes Study (UKPDS) group have shown that more intensive control of blood glucose
is key in controlling microvascular complications in patients with type 2 diabetes. Patients
studied over a ten year period showed a significant 12% reduction in risk with intensive
glycaemic control when compared to conventional therapy for any diabetes endpoint [UK
Prospective Diabetes Study (UKPDS) Group, 1998]. This 12% decrease corresponded to a
change in HbA1c from a median of 7.9% to 7.0%. The UKPDS also showed a strong link
between glycaemic control and microvascular complications: a 1% decrease in HbA1c across
the cohort decreased microvascular complications by 37% [Stratton et al., 2000]. Thus, a key
target for pharmacological intervention is a reduction in the plasma glucose concentration
and it is upon this premise that many diabetic therapies are based.
Treatment of type 2 diabetes often starts with a single oral agent before progress-
ing as the need arises to multiple agents, possibly including insulin [Blonde, 2009]. There
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are many classes of drugs available for clinicians to choose from and these are summarised
in Table 1.1. Often, drugs are combined to form a more convenient therapy such as the
GlaxoSmithKline product Avandamet which combines the thiazolidinedione rosiglitazone
with metformin. Recently there have been problems highlighted regarding the use of tight
glycaemic control as a target for therapy. The Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial investigated the effects of intensive glycameic control versus reg-
ular glycaemic control in 10 250 type 2 diabetic patients over a mean 3.5 years of follow-up.
The ACCORD group concluded that relative to the regular therapy group, the intensive
therapy group had an increased relative and absolute risk of mortality during the follow-up
period with no decrease in risk of cardiovascular events [Action to Control Cardiovascular
Risk in Diabetes Study Group et al., 2008]. They propose that this increased risk in mor-
tality may be due to increases in hypoglycaemic episodes, effects of the multiple drugs in
combination required to lower the plasma glucose and unforseen effects of rapidly lowering
plasma glucose. More recently, the ACCORD group also concluded that targeting systolic
blood pressure to lower than 120 mmHg compared to lower than 140 mmHg did not reduce
a composite outcome of fatal and non-fatal cardiovascular events [ACCORD Study Group
et al., 2010]. There has also been controversey over the use of some thiazolidinediones as
therapies in type 2 diabetic patients. Both rosiglitazone [Nissen and Wolski, 2007] and to a
lesser extent pioglitazone have been linked to an increased risk of cardiovascular events in
type 2 diabetes patients due to increased water retention (reviewed by Stafylas et al. [2009]).
Only recently, pioglitazone was looked upon as a promising agent to lower risk of cardio-
vascular events due to its favourable effect on patient lipid profiles [Betteridge, 2007]. Even
now, the situation is not clear because the beneficial effects of pioglitazone may outweigh
the harmful effects [Erdmann et al., 2009].
1.6 Chronic complications of diabetes mellitus
1.6.1 Micro and macro-vascular complications
Since the introduction of insulin therapy, chronic diabetic complications have been the
major cause of morbidity and mortality associated with the disease [Deckert et al., 1978].
Diabetic complications can be broadly divided into categories based on the size of blood
vessels affected. Macrovascular complications affect larger vessels and include coronary heart
disease (CHD) and stroke. Microvasular disease affects tissues which rely on the non-insulin-
dependent glucose transporter GLUT-1 for their glucose uptake. These tissues are prone to
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high intracellular glucose concentrations during periods of hyperglycaemia and include the
retina and the kidney (sites of retinopathy and nephropathy respectively) which have dense
networks of capillaries. Other tissues with poor circulation through capillary beds are also
affected e.g. the extremities of the limbs where neuropathy is common.
The macrovascular cardiovascular disease (CVD) is the largest single cause of mor-
bidity and mortality amongst diabetic patients: it is cited as the cause of diabetic mortality
in 65% of cases in the USA [Engelgau et al., 2004]. The UKPDS group also observed that
macrovascular complications were over twice as common and 70 times more likely to be fatal
as microvascular complications in diabetes patients after 9 years of follow-up [Turner et al.,
1996]. This means that whilst preventing macrovascular complications is likely to extend
lives, unless the microvascular complications are also addressed, the quality of those lives is
likely to be lower than necessary or desired.
1.6.2 Diabetic nephropathy
Diabetic nephropathy (DN) is a pathology of the kidney which is defined symptomatically by
an increase in albumin excretion in the urine without the presence of other renal diseases.
DN affects approximately 40% of type 1 and type 2 diabetic patients throughout their
lives [Gross et al., 2005], and is associated with increased morbidity and mortality from
cardiovascular effects. The percentage of patients starting renal-replacement therapy due to
DN-associated end-stage renal disease (ESRD) is globally variable but in the USA it is 40%
[US Renal Data System, 2009] and is a maximum in Malaysia where it is 58% [Williams,
2010].
1.6.2.1 Progression
DN has a progressive pathology with the disease being categorised into different stages de-
pending on the severity of the albumin excretion. Type 1 diabetes patients have a relatively
well-defined disease progression from the mildest forms of the disease because diagnosis is
during the earliest stages [Najafian and Mauer, 2009]. Type 2 diabetes patients have a less
well defined progression since the diabetes, and the associated period of pre-diabetes, may
have gone undiagnosed for a period of years.
The first stage is present at diagnosis and is characterised by acute renal hyper-
trophy and hyperfiltration. This takes the form of increased kidney and glomerular size
accompanied by a 20–50% increase in glomerular filtration rate (GFR). Urinary albumin
excretion (UAE) is usually in the normal range at this stage and the patient’s blood pressure
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is usually normal. Within the first five years after diagnosis, patients progressively develop
a thickening of the glomerular basement membrane and tubular basement membrane along
with accumulation of extracellular matrix (ECM; mainly fibronectin, laminin and collagens
IV and VI [Bruneval et al., 1985; Ayo et al., 1990]) material in the tubulointerstitium and
mesangium. This is seen histologically as a thickening of the affected areas as well as pos-
sible Kimmelstiel-Wilson nodular lesions in the mesangium ([Scheinman et al., 1978] and
reviewed by Mason and Wahab [2003]). This whole process, called glomerulosclerosis, is
the physical hallmark of DN. Figures 1.2 and 1.3 show the progression of glomerulosclerosis
with Figure 1.4 showing the details of a thickened basement membrane. The initial increase
in filtration rate seen in DN is caused by an increase in the glomerular hydrostatic pressure
but as glomerulosclerosis progresses it causes scarring and progressive loss of glomerular
function. This stage is still characterised by normal UAEs of <20 µg min−1 or 30 mg day−1.
Although timings are not exact, between 7–15 years after diagnosis some patients de-
velop microalbuminuria, or incipient nephropathy. This is defined by a UAE of>20 µg min−1
and ≤199 µg min−1 (>30 mg day−1 and ≤300 mg day−1). GFR is still supranormal at this
stage and blood pressure is typically increasing at a rate of 3 mmHg year−1. Some of these
microalbuminuric patients will progress to clinically persistent proteinuria (defined as a UAE
>200 µg min−1 or >300 mg day−1). This marks the start of clinically overt renal disease and
often occurs around 15–20 years after diabetes diagnosis. At this stage, there are clear ab-
normalities in the kidney structure, blood pressure is often high and increasing at around
5 mmHg year−1 and GFR begins to decline steadily at a variable rate with a median about
12 mL min−1 year−1. Within 10 years, 50% of type 1 diabetic patients with overt nephropa-
thy progress to end stage renal disease (ESRD). This figure rises to more than 75% by 20
years [American Diabetes Association, 2004]. During ESRD, glomerular closure is complete
and the GFR is <10 mL min−1. At this stage, the patient must move onto renal replace-
ment therapy to survive. Typically patients start with peritoneal dialysis and progress to
haemodialysis as complications arise. It is, however, more common for a macroalbuminuric
patient to die of cardiovascular disease in any given year than to progress to more severe
forms of nephropathy requiring renal replacement therapy [Adler et al., 2003].
The UKPDS estimated the rates of progression from normoalbuminuria to microal-
buminuria to macroalbuminuria to elevated plasma creatinine or renal replacement therapy
as 2.0%, 2.8% and 2.3 % year−1 respectively [Adler et al., 2003]. Generally, a patient will
start with microalbuminuria and progress to albuminuria before developing overt nephropa-
thy. Patients regressing from micro- to normoalbuminuria are an exception, not the rule.
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Figure 1.2: A histological section through a normal glomerulus without the diffuse thick-
ening of the glomerular basement membrane. 240x magnification with periodic acid–silver
methenamine (PASM) stain and haematoxylin and eosin (H&E) counter-stain. Reprinted
with permission from Lai et al. [2004].
Figure 1.3: A histological section through a diabetic glomerulus exhibiting glomerulosclerosis
with mesangial sclerosis and Kimmelstiel-Wilson nodule comprised of deposited mesangial
matrix (arrowed). 240x magnification with PASM stain and H&E counter-stain. Reprinted
with permission from Lai et al. [2004].
Figure 1.4: Uniform and homogeneous thickening of the glomerular capillary basement
membrane. 4800x magnification using lead citrate and uranyl acetate electron microscopy.
Reprinted with permission from Lai et al. [2004].
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1.6.2.2 Diagnosis
The American Diabetes Association [2004] recommends that the albumin:creatinine ratio
measured in a spot urine sample is used as the primary means to diagnose DN. Another
method suggested is to measure the albumin content of a timed urine collection, typically 24
hours long. After diagnosis, GFR is commonly followed as a proxy for renal function. GFR
may be determined by measuring the renal clearance rate of creatinine but this method is
prone to overestimation due to the secretion of creatinine by the tubules. A more accurate
method uses secretion of inulin, an exogenous plant-derived polysaccharide, which is com-
pletely filtered and neither re-absorbed nor secreted by the tubules. The GFR can then be
suitably estimated using an equation similar to the Cockroft-Gault equation [Tsinalis and
Thiel, 2009].
1.6.2.3 Risk factors
The rate of progression of DN from one stage to the next is influenced by a group of risk
factors. Key members of this group include glycaemic control and arterial blood pressure.
Maintaining good glycaemic control is key to lowering the risk of progression of nephropathy
[The Diabetes Control and Complications Trial Research Group, 1993] and tight control of
blood pressure lowers the risk of micro and macrovascular complications [UK Prospective
Diabetes Study Group, 1998]. Normotensive patients have a slower rate of decline in GFR
with respect to hypertensive patients [Hovind et al., 2001]. Other modifiable factors such as
serum cholesterol and albuminuria act as progression markers [Hovind et al., 2001] whilst
dyslipidaemia and smoking are risk factors. Non-modifiable risk factors for DN include age,
a genetic predisposition and time since diagnosis of diabetes [Gross et al., 2005]. Genetic
predisposition appears to be both complex and important since around 70% of type 1 and
60–75% of type 2 diabetic patients do not develop nephropathy, irrespective of glycaemic
control. The genetics of DN is often based around propensity for developing certain risk
factors such as hypertension and is reviewed by Schena and Gesualdo [2005].
1.6.2.4 The glomerulus
The glomerular capillary wall has three main layers: the epithelial podocyte cells face the
urinary side, the endothelial cells face the circulatory side and the glomerular basement
membrane with its associated mesangial cells lies in between [Steffes et al., 2001; Deen,
2004; Mathieson, 2009]. These layers act in combination to provide the complete glomerular
filtration capability. The endothelial cells lining the capillary walls have large pores between
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them called fenestrae which block the passage of erythrocytes and larger cells but do little to
prevent passage of small molecules and proteins. Beyond the endothelial cells, the glomerular
basement membrane provides the next filtration step. Secreted mainly by the mesangial
cells, it is extensively covered in negatively charged glycosaminoglycans including heparan
sulphate which form an effective barrier to prevent the passage of most plasma protein.
Further filtration is achieved by the slit-like pores between the foot processes of the final
cellular layer, the podocytes. Once past the podocytes and into Bowman’s space, glomerular
filtration is complete and the ultrafiltrate is free to pass down the proximal tubule.
1.6.2.5 Molecular pathology
Structural changes in the kidney during diabetes can be subdivided into early adaptive
changes and later pathological changes associated with the progression of DN [Phillips,
2003]. The early changes, such as glomerular hypertrophy, are not indicative of progressive
renal disease but the later changes are. The latter pathological changes are characterised
by a gradual scarring of both the glomerulus and the tubulointerstitial region.
Traditionally DN was considered a predominantly glomerular disease with mesangial
expansion and the thickening of the glomerular basement membrane being of primary im-
portance. This view has changed more recently to include changes in the tubulointerstitial
region as well as other cell types within the glomeruli. The hallmark of DN, the progressive
deposition of extracellular matrix material, first manifests in the glomerulus before becom-
ing more apparent in the tubulointerstitium as the disease progresses [Najafian and Mauer,
2009]. In both cases, the deposited material is predominantly made up of the ECM colla-
gens type I, III, IV and VI and fibronectin [Mason and Wahab, 2003]. The abundance of
ECM material is a function of both synthesis by mesangial cells and degradation by matrix
metalloproteinases (MMPs). The synthesis rate is increased in DN, driven largely by an
increase in transforming growth factor-β (TGF-β) signalling [Schena and Gesualdo, 2005]
and is discussed more thoroughly below. Also, the degradation rate of ECM by MMPs is
decreased in DN. Mesangial cells cultured in hyperglycaemic conditions exhibit increased
expression and activity of plasminogen activator inhibitor 1 (PAI-1), decreased expression of
MMPs and increased inhibition of MMPs by tissue inhibitor of metalloproteinase-1 (TIMP1)
[Abdel Wahab and Mason, 1996].
There is also evidence that it is the podocytes that are key in the progression of
DN, both prognostically and mechanistically. Work by Pagtalunan et al. [1997] showed that
podocytes are lost in early stage DN and that each remaining podocyte spreads its foot pro-
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cesses wider. Meyer et al. [1999] further showed that podocyte number is a key predictor for
long term urinary albumin excretion in Pima Indians. Nakamura et al. [2000] demonstrated
that DN patients had podocytes present in their urine whereas healthy volunteers did not.
In 2005, evidence that experimentally-induced podocyte loss alone was sufficient to induce
albuminuria and glomerulosclerosis was published by Wharram et al. [2005]. More recently,
work by [Dessapt et al., 2009] demonstrated that either increased TGF-β expression or me-
chanical stretching is sufficient to decrease podocyte adhesion via reduced α3β1 integrin
expression. The evidence that hyperglycaemia and mechanical stress are both important
factors in podocyte loss was reviewed by Lewko and Stepinski [2009].
The exact cause of the presence of albumin in the urine is not clear. Persistent albu-
minuria represents the result of leakage past the glomerular basement membrane at a rate
that exceeds the metabolic and re-absorptive capacity of the proximal tubular epithelium.
The classical view is that albuminuria is caused by a failure of the glomerular filter to retain
albumin, either through loss of podocytes [Stitt-Cavanagh et al., 2009] or through changes in
the glomerular basement membrane or through haemodynamic factors or a combination of
all of the above [Ziyadeh, 2008]. The loss of the glomerular endothelial glycocalyx, mediated
by growth factors and inflammatory cytokines in diabetes may be a key mechanism [Satchell
and Tooke, 2008]. The timecourse for the regeneration of a lost glycocalyx after intevention
of therapy is unkown but may be several weeks [Potter et al., 2009]. The alternative view
explaining the presence of albuminuria in DN is that there could be a failure of the tubule
reclamation and degradation pathways for albumin [Comper and Russo, 2008]. However,
this view is controversial because there is direct evidence from two-photon microscopy that
albumin is filtered very effectively in normal rat kidneys [Tanner, 2009].
1.6.2.6 The role of TGF-β
TGF-β is the collective name for a family of three multifunctional secreted proteins (TGF-β-
1, TGF-β-2 and TGF-β-3) which signal through one of three membrane-bound transforming
growth factor receptors (TGFRs), TGFR-1, TGFR-2 and TGFR-3. The receptors are
serine/threonine kinases which collectively signal to a multidude of different down-stream
processes. Importantly for DN, these down-stream processes include the deposition of ECM
material during fibrosis. This process is naturally found during wound-healing after the
release of TGF-β by platelets [Border and Noble, 1994] but is also found in disease states such
as rheumatoid arthritis, radiation-induced fibrosis and myocarditis as well as DN [Pohlers
et al., 2009].
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The effects of TGF-β may be direct through the activation of a kinase cascade or
propogated by induction of other factors such as connective tissue growth factor (CTGF).
CTGF is an immediate early gene that can be induced by TGF-β [Grotendorst, 1997] and has
been shown to be involved in both early and late-stage DN [Riser et al., 2000; Twigg et al.,
2002]. Recently, CTGF has also been shown be induced by advanced glycation endproducts
(AGEs) in a TGF-β-independent manner [Chung et al., 2010]. Increasing expression of
TGF-β has been linked to many of the proposed pathways of hyperglycaemia-induced dam-
age. Its expression is increased by hyperglycaemia [Murphy et al., 1999; Wahab et al., 2001],
exposure to AGEs and ROS [Park et al., 2001] as well as de novo synthesis of diacylglycerol
and subsequent activation of protein kinase C [Brosius, 2008]. Glycated proteins also appear
to be partly involved in changes to the ECM: exposure of glomerular endothelial cells to
glycated albumin causes increased expression of collagen IV and fibronectin [Cohen et al.,
1997]. Also, podocytes and glomerular endothelial cells are less able to adhere to type IV
collagen modified by methylglyoxal [Pedchenko et al., 2005; Dobler et al., 2006], potentially
leading to anoikis. The proposed mechanisms behind increased ROS and AGE production
are discussed in Section 1.7.
TGF-β abundance and activity in the kidney is controlled at multiple levels—
trancription, translation, secretion and also by activation of the inactive form of the protein
[Phillips, 2003]. Glucose is a potent stimulator of TGF-β transcription although higher
abundances of the protein are often only observed after stimulation with a synergystic fac-
tor [Fraser et al., 2002]. Examples of such factors include platelet derived growth factor
(PDGF) or interleukin-1β (IL-1β) [Phillips et al., 1996, 1997]. Hyperglycaemia-induced
TGF-β transcription was blocked in primary rat mesangial cells by the addition of an Sp1-
decoy oligodeoxynucleotide which blocks Sp1 binding to the promoter region of TGF-β
[Chae et al., 2004]. TGF-β is also known to upregulate expression of glucose transporter
1 (GLUT-1) which promotes higher intracellular glucose concentrations through increased
glucose upatake [Schena and Gesualdo, 2005]. Work by Heilig et al. [1995] demonstrated for
the first time that overexpression of GLUT-1 in rat mesangial cells cultured in 8 mM glucose
was sufficient to induce increased collagen synthesis in the same manner as culturing wild-
type mesangial cells in 30 mM glucose. Follow up work demonstrated that knocking down
GLUT-1 can prevent glucose-induced expression of GLUT-1 and fibronectin in mesangial
cells [Heilig et al., 2001]. Most recently, Wang et al. [2010] have demonstrated that overex-
pression of GLUT-1 in mouse mesangial cells alone was sufficient to induce a renal disease
similar to diabetic glomerulosclerosis in non-diabetic animals. This work demonstrates that
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it is the intracellular, and not extracellular, concentration of glucose which is key in driving
downstream effects such as the production of ECM proteins. This also introduces the idea
of a positive feedback loop with hyperglycaemia inducing TGF-β expression which in turn
promotes expression of GLUT-1 leading to still higher intracellular glucose concentrations.
TGF-β activity is not just found in one cell type; it has important roles throughout
the glomerulus. Glomerular visceral epithelial cells exposed to hyperglycaemia upregulate
both TGF-β and fibronectin expression [van Det et al., 1997]. Podocytes exposed to hyper-
glycaemia increase expression of the receptor TGFR-2 [de la Cruz et al., 2002] allowing for an
autocrine or local paracrine signalling within the glomerulus [de la Cruz et al., 2002]. Thus
the emerging picture is that TGF-β signalling is induced by hyperglycaemia and associated
downstream effects, and is invovled in mediating the overproduction of ECM proteins as well
as changes in cell population in the glomeruls leading to glomerulosclerosis and albuminuria.
1.6.3 Diabetic retinopathy
Diabetic retinopathy is the leading cause of new cases of blindness amongst adults aged
20–74 years [National Institute of Diabetes and Digestive and Kidney Diseases, 2008]. Its
progression passes through four stages of increasing severity: mild, moderate and severe non-
proliferative retinopathy followed by proliferative diabetic retinopathy (PDR). Symptoms
progress in severity beginning with microaneurysms from the capillaries of the retina in
mild non-proliferative retinopathy. The moderate and severe stages are both characterised
by blockages in increasing numbers of retinal capillaries leading to localised ischaemia where
parts of the retina are deprived of oxygen and nutrients. Eventually, larger sections of the
retina become malnourished stimulating progression to proliferative retinopathy. In PDR
these ischaemic sections signal for nutrient provision by the release of pro-angiogenic factors.
Uncontrolled release of these factors leads to neovascularisation of the surface of the retina
and vitreous humour characterised by a diffuse microvasculature with abnormally fragile
walls. These new vessels do not cause blindness per se but because of their fragility they
frequently leak blood into the humour which leads to severe vision loss.
Macular oedema is another factor which can cause vision loss associated with dia-
betic retinopathy. It is caused by fluid leakage into the central part of the retina, or macula,
from damaged or fragile vessels leading to fatty deposits called exudate. This causes swelling
in the macula and subsequently blurred central vision. In addition to these symptoms, pa-
tients may eventually experience retinal scarring or detachment. Figure 1.5 is an example
image of the fundus of an eye exhibiting PDR. There are no warning symptoms of retinopa-
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thy to the patient until vision begins to decline in proliferative retinopathy so frequent eye
checks are recommended.
Risk factors for diabetic retinopathy include hypertension, duration since diabetes
diagnosis and HbA1c levels [Chatziralli et al., 2010]. Retinopathy is also more common in
males than females. The best strategies for combating the advance of the disease include
lowering blood pressure [Schrier et al., 2002] and tight glycaemic control [Diabetes Control
and Complications Trial writing team, 2002; Prescrire Group, 2010]. In common with other
diabetic complications, common pathways of damage have been implicated including protein
kinase C activation, oxidative stress and increased AGE accumulation. In addition, PDR is
characterised by a high level of growth factors in the vitreous humour such as insulin-like
growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) [Simo´ et al., 2002].
As well as minimising risk factors, early diagnosis is key to preventing vision loss.
If prevention strategies do not work, retinal photocoagulation is the standard treatment for
PDR. Photocoagulation was developed in the 1950s and uses a laser to denature protein
and seal vessels. It causes some scotomas, or areas of visual darkening, but overall the
effect on the visual field is minor compared to the total blindness which could develop
in untreated PDR. Figure 1.6 is an image of a retina after photocoagulation. As well as
sealing vessels, photocoagulation decreases production of vasoproliferative factors such as
VEGF [Aiello et al., 1994]. Other strategies for VEGF reduction include anti-VEGF drugs
including pegaptanib (Macugen™ [Cunningham et al., 2005]), bevacizumab (Avastin™ [Scott
et al., 2007]) and ranibizumab (Lucentis™ [Nguyen et al., 2006]) injected intraocularly. A
final strategy is to use a vitriectomy for patients with advanced vision loss.
Figure 1.5: Ophtalmogram showing details of proliferative diabetic retinopathy with active
neovascularisation over the optic disk (white arrow) and deposition of exudate around the
neovascularisation of the macula i.e. macular oedema (black arrow) (UCSF Department of
Ophthalmology)
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1.6.4 Diabetic neuropathy
Diabetic neuropathy is the most common microvascular complication of diabetes, affecting
high percentages of all diabetic patients (up to 50% depending on the study [Boulton, 2005]).
It is a major contributor to the “diabetic foot”—a term encompassing a wide variety of
problems including ulcers [Boulton, 2008]—with at least 15% of diabetic patients being
affected by foot ulcers at some point [Brem and Tomic-Canic, 2007]. Diabetic neuropathy is
the leading cause of non-traumatic limb amputation with around 60% of non-traumatic lower
limb amputations in the US occurring in diabetic patients [National Institute of Diabetes
and Digestive and Kidney Diseases, 2008].
There are four main types of neuropathy. The first and most common is peripheral
neuropathy which is diffuse and starts as a loss of feeling in limbs or a lack of control.
It often develops into shooting pains and numbness in the extremities although not all
patients experience painful symptoms. In these cases, small wounds often go unnoticed and
untreated which leads to the development of more complex lesions including ulcers [Brem
and Tomic-Canic, 2007]. The second type is autonomic neuropathy which is characterised
by damage to the unmyelinated nerves throughout the autonomic nervous system [Ewing
and Clarke, 1982]. Symptoms include poor digestion, erectile dysfunction and incontinence.
The third type, proximal neuropathy is characterised by weakness of the legs accompanied
by pain in the hips and upper leg whilst the fourth type, focal neuropathy, is characterised
by a sudden weakness or pain caused by a single nerve or group of nerves.
In all cases, neuropathy progression is associated with a steady lowering of nerve
conduction velocities [Brown et al., 2004]. Research published by the Diabetes Control and
Complications Trial writing team [2002] identifies hyperglycaemia as the main risk factor
Figure 1.6: Ophtalmogram showing scatter photocoagulation scars on the fundus of an eye
in a PDR patient (UCSF Department of Ophthalmology)
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for neuropathy and states that tight glycaemic control is the best approach for lowering
incidence and severity. Other risk factors include age, hypertension, dyslipidaemia and
smoking status. As with other diabetic complications, the pathogenesis of neuropathy is
connected to increased oxidative damage, increases in flux through the hexosamine and
polyol pathways, increases in AGEs and the activation of protein kinase C [Brownlee, 2001].
As a specific example, glycation damage by glucose and methylglyoxal to laminin, fibronectin
and collagens I and IV in the ECM around neurons leads to impairment of axon re-growth
[O¨ztu¨rk et al., 2006; Duran-Jimenez et al., 2009].
As a supplement to tight glycaemic control, there are several possible palliative
therapies for neuropathy. These include a wide range of drugs that include local anaesthetics
such as lidocaine, anticonvulsants such as gabapentin (also the gold standard for chronic
pain) [Boulton, 2005], and other alternatives such as topical capsaican which depletes the
tissue of substance P thereby reducing nervous transmission of pain [Zhang and Po, 1994].
Other strategies which target the pathogenesis of the disease are discussed in Section 1.8.
1.7 Biochemical theories on mechanisms of hypergly-
caemia-induced damage
The five main hypotheses concerning the mechanism of glucose-induced damage in diabete
are: increased polyol pathway flux; increased accumulation of advanced glycation endprod-
ucts (AGEs); activation of protein kinase C (PKC); increased flux through the hexosamine
pathway and oxidative stress [Brownlee, 2001]. Each of these is outlined below.
1.7.1 Polyol pathway flux
The polyol pathway, also called the sorbitol-aldose reductase pathway, is a two step pathway
that converts glucose to fructose via sorbitol (Figure 1.7). Aldose reductase (AR), which
converts glucose to sorbitol, was first described as being capable of reducing glucose by
Hers [1956]. Subsequently, van Heyningen [1959] showed that there is a high AR activity
in rat lenses and that there is an accumulation of polyols in the lens during formation of
diabetic ‘sugar’ cataract formation. AR has a relatively high K m for glucose of around
200 mM [Jedziniak et al., 1981]. This means that at physiological concentrations (3–7 mM)
there is only a small flux from glucose to fructose. This situation changes, however, in
the hyperglycaemic environment found in diabetic patients where an increased intracellular
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glucose concentration leads to increased production of sorbitol with a concomitant lowering
in the concentration of NADPH. It is worth noting that sorbitol dehydrogenase (Figure 1.7)
has a K m for sorbitol of only 1.4 mM and is unlikely to limit the flux through the pathway
[Jedziniak et al., 1981].
Figure 1.7: The reactions of the polyol pathway
In the hyperglycaemic state there is a relatively large flux through the polyol path-
way varying from 33% of total glucose in rabbit lens to 11% in human erythrocytes [Brown-
lee, 2001]. There were several competing theories as to how this increased flux could be
detrimental to the cells. The first was the sorbitol osmotic stress theory which proposed
that sorbitol is membrane-impermeable and high concentrations of sorbitol would therefore
accumulate, producing osmotic stress and damage to cells. In favour of this theory, high
concentrations of sorbitol have been found in the lenses of diabetic rats. In contrast, sorbitol
permeases have been found in human erythrocytes [Kracke et al., 1994], schwannoma cells
[Mizisin et al., 1997] and rat renal inner medullary interstitial cells [Schu¨ttert et al., 2002]
which could potentially relieve any osmotic stress. These osmotic effects could therefore be
limited to certain cell types lacking sorbitol permeases.
A more recent proposal is that the shift in the NAD+:NADH ratio in favour of
NADH, as effected by sorbitol dehydrogenase, is the resposible for the damage induced
by increased polyol pathway flux. This shift in ratio would have the effect of inhibiting
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an enzyme dependent on NAD+ as
a substrate. As the NAD+ pool decreased GAPDH would become less active, which in turn
would increase the concentrations of the glycolytic precursors glyceraldehyde-3-phosphate
and dihydroxyacetone phosphate [Williamson et al., 1993]. These would act not only as
precursors for AGE formation but also for diacylglycerol (through α-3-glycerophosphate)
which activates protein kinase C; both are discussed later.
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It is also proposed that the reduction in NADPH as a result of the activity of aldose
reductase leads to an increase in oxidative stress: NADPH is required for the regenera-
tion of reduced glutathione (GSH). Evidence for this theory was put forward by Lee and
Chung [1999] who observed decreased concentrations of glutathione in the lenses of mice
that overexpressed aldose reductase. The clinical effects of the inhibition of aldose reductase
vary between different models. The aldose reductase inhibitor zenarestat increased nerve-
conduction velocity in a dose-dependent manner in a double-blind placebo-controlled trial
in humans [Greene et al., 1999]. The increase in oxidative stress as a result of decreased
NADPH availability is a recurring theme and is also important for consideration of the
pentose phosphate pathway and thiamine metabolism.
1.7.2 Advanced glycation endproducts
The second proposed mode of action of hyperglycaemia is though the production of advanced
glycation endproducts (AGEs)—a term coined by Cerami [1986]. AGEs are formed when
glycating agents react non-enzymatically with target molecules including proteins, lipids
and nucleic acids thereby altering the shape or function of the target [Thornalley et al.,
1999]. There are at least four main glycating agents in cells: glucose, glyoxal (formed from
lipid peroxidation, the degradation of glycated proteins and the auto-oxidation of glucose),
methylglyoxal (formed from the fragmentation of triose-phosphates, acetone metabolism and
the catabolism of threonine) and 3-deoxyglucosone (formed from the degradation of glucose-
modified proteins and fructosamines phosphorylated by fructosamine 3-phosphokinase).
The formation of the toxic α-oxoaldehyde methylglyoxal is an unavoidable corollary
of glucose metabolism via glycolysis (the Embden-Meyerhof pathway). One of the gly-
colytic intermediates, dihydroxyacetone phosphate, is relatively unstable and is capable of
undergoing spontaneous dephosphorylation to yield methylglyoxal [Thornalley, 2003a]. It
is not possible to eliminate this conversion but its flux is diminished by keeping the steady
state concentrations of triose-phosphates as low as possible. The net result is that these
dicarbonyl compounds account for only 0.1–0.4% of the glycolytic flux [Thornalley, 2003a].
The glyoxalase system exists to detoxify these molecules and convert them to the
relatively harmless d-lactate. The system comprises two enzymes, glyoxalases I and II
(GLO1 and GLO2 respectively) along with a catalytic amount of reduced glutathione (GSH)
[Lohmann, 1932]. Methylglyoxal reacts non-enzymatically with GSH to form a hemithioac-
etal which is then converted to S -d-lactoylglutathione by GLO1 [Marmst˚al and Mannervik,
1981]. GLO2 then recovers the GSH from the S -d-lactoylglutathione yielding d-lactate in
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the process. The majority d-lactate is metabolised by mitochondrial 2-hydroxyacid dehy-
drogenase [Tubbs, 1965]. Despite the specificity constant for GLO1 (k cat/K m) being close
to the limit of diffusion, damage to molecules can still be caused by dicarbonyl molecules
escaping the system.
AGE production can damage three main classes of protein. The first is intracellular
proteins. Glycation of these can affect their structure and function, often by damaging
critical residues such as arginines in active sites which are more chemically reactive and more
prone to glycation. Secondly, extracellular matrix proteins can be damaged. These modified
proteins then interact abnormally with both other extracellular matrix proteins and with
integrins on the surface of cells [Dobler et al., 2006]. The third class of proteins which can be
damaged is plasma proteins. Damage here can lead to proteins which bind to receptors on
endothelial, mesangial and macrophage cells causing receptor-mediated production of ROS.
AGE receptor activation activates the transcription factor NF-κB which causes pathological
changes in gene expression. AGEs are found in increased concentrations in streptozotocin-
induced diabetic rat retinas, glomeruli and nerves as shown by mass spectrometric detection
of analytes in the samples [Karachalias et al., 2003].
1.7.3 Activation of protein kinase C
The activation of protein kinase C (PKC) is the third proposed route of damage mediated
by hyperglycaemia. There are at least 11 isoforms of PKC, of which 9 are activated by
the same signalling molecule: diacylglycerol (DAG)—a lipid secondary messenger. The
increased activity of PKC in vivo appears to be due to increased de novo DAG synthesis.
DAG concentrations are chronically increased in the diabetic state because of the elevation in
glucose concentration and thus elevation in the concentration of dihydroxyacetone phosphate
(DHAP). DHAP is reduced to glycerol-3-phosphate before being acylated twice to yield DAG
[Koya and King, 1998].
Many isoforms of PKC are activated by DAG, thus the increased DAG concentration
leads to an increase in the activity of PKC (primarily the β- and δ-isoforms) which has
myriad consequences within the cell: PKC isoforms are involved in a very wide range of
cellular processes. A decrease in endothelial nitric oxide synthase (eNOS) and an increase
in endothelin-1 (ET-1) leads to blood flow abnormalities; an increase in VEGF leads to
changes in vascular permeability and increases in angiogenesis; an increase in TGF-β leads
to an increase in collagen and fibronectin (two major extracellular matrix proteins) and thus
capillary occlusion and increases in the thickness of the ECM; an increase in plasminogen
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activator inhibitor 1 (PAI-1) leads to a decrease in fibrinolysis, thickening of the ECM
and vascular occlusion; an increase in NF-κB activation leads to a pro-inflammatory gene
expression response and an increase in NAD(P)H oxidases leads to an increase in reactive
oxygen species which damage multiple proteins [Brownlee, 2001; Geraldes and King, 2010].
1.7.4 Activation of the hexosamine pathway
The fourth proposed mechanism of damage originated in research from the late 1990s
[Sayeski and Kudlow, 1996; Kolm-Litty et al., 1998] and involves an increase in flux through
the hexosamine biosynthesis pathway (HBP). The HBP is a branch of metabolism off glycoly-
sis involved in the production of UDP-N -acetylglucosamine and other amino sugar products.
Thse are used for the synthesis of O- and N -linked glycoproteins as well as nucleic acids
(Figure 1.8). These products are used for the enzymatic addition of O-GlcNAc residues to
proteins in a manner similar to phosphorylation. These modifications can alter the proper-
ties of the target protein dramatically and in the case of transcription factors there can be
far reaching consequences in terms of gene expression. Inhibition of the first committed step
in the HBP, the enzyme glutamine fructose-6-phosphate amidotransferase (GFAT), blocks
hyperglycaemia-induced overexpression of TGF-α, TGF-β1 [Kolm-Litty et al., 1998] and
PAI-1 [Du et al., 2000]. The role of the HBP in the alteration of transcription in cells in
hyperglycaemia is considered in more detail in Chapter 3.
1.7.5 Oxidative stress
It has been proposed by Brownlee [2001] that the common theme connecting each of the
four theories put forward above is oxidative stress. Each is involved in the common process
of overproduction of superoxide by the mitochondrial electron transport chain. Specifically,
hyperglycaemia induces high levels of electron donation from the citric acid cycle electron
donors NADH and FADH2 to complexes I and II respectively. This leads to an increase in
mitochondrial membrane potential as protons are pumped out which inhibits complex III.
This inhibition increases the half-life of free radical intermediates of ubiquinone (coenzyme
Q) which leads to O2 being reduced to superoxide (O2·−). Above a certain threshold, the
mitochondrial membrane potential-driven production of superoxide is markedly increased
[Korshunov et al., 1997] from the current estimated base-rate of 0.15% of all O2 being
reduced to O2·− [Brand, 2010]. If manganese superoxide dismutase (MnSOD—the mito-
chondrial SOD) or uncoupling protein 1 (UCP1) is overexpressed in hyperglycaemic cells
then the superoxide is removed more quickly or the proton gradient collapses to the point
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Figure 1.8: The reactions of the hexosamine biosynthesis pathway. Glc: Glucose; G6P:
Glucose-6-phosphate; F6P: Fructose-6-phosphate; GlcN-6P: Glucosamine-6-phosphate;
GlcNAc-6P: N -acetylglucosamine-6-phosphate; GlcNAc-1P: N -acetylglucosamine-1-
phosphate; UDP-GlcNAc: Uridine diphosphate-N -acetylglucosamine
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where superoxide production is decreased. This prevents increased polyol pathway flux,
increased intracellular AGE formation, increased PKC activation and increased hexosamine
pathway flux. The linking event appears to be the inhibition of glyceraldehyde-3-phosphate
dehydrogenase by reactive oxygen species [Du et al., 2000]. Whether this is a direct inhibi-
tion of the enzyme or as a result of the decrease in cellular levels of NAD+ and activation of
poly (ADP-ribose) polymerase (PARP, an enzyme which poly(ADP-ribosyl)ates GAPDH)
is unclear but cellular glutathione levels remain high during this inactivation. This decrease
in GAPDH activity causes a build up of all glycolytic intermediates preceeding it in the
Embden-Meyerhof pathway. These include the triosephosphates, precursors for methylgly-
oxal; fructose-6-phosphate, precursor for the hexosamine pathway; glucose, precursor for the
polyol pathway and glycerol, which although not a direct glycolytic intermediate is required
for PKC activation.
Further sources of ROS in the cells are NADPH oxidase (used to manufacture super-
oxide in macrophages and phagosomes) and uncoupled nitric oxide synthase (NOS) which
forms both NO and O2·− or ONOO− (peroxynitrite—formed by NO reacting with O2·−)
[Sullivan and Pollock, 2006]. NADPH oxidase appears to be activated in hyperglycaemia by
PKC [Nakagami et al., 2005] which could further stimulate more mitochondrial superoxide
production.
Additionally, the cellular glutathione pool which is involved in sequestering and
neutralising ROS is dependent on the availability of NADPH for regeneration. NADPH is
produced primarily by the thiamine-dependent reductive pentose phosphate pathway. The
role of thiamine in this process is discussed in more detail in Section 2.5 on page 39.
1.8 Therapeutic approaches to prevent diabetic compli-
cations
Secondary to the treatment of the underlying diabetes is the need to treat complications as
they arise. Since it is the complications, not the disease per se, which are the main cause
of morbidity and mortality such treatments are an invaluable tool in battling the disease.
Several major classes of therapies are discussed below.
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1.8.1 Antioxidants
Diabetes leads to an elevation in reactive oxygen species (ROS) production that is capable of
overwhelming the body’s natural defence systems. In such a situation, it is a logical strategy
to attempt to counter this increase in ROS with antioxidant therapies. An antioxidant is any
chemical which can be oxidised itself in a sacrificial manner to protect other potential targets
of oxidation by ROS. These chemicals are often regenerated using enzymatic systems, for
example, glutathione re-reduces ascorbic acid before itself being re-reduced by glutathione
reductase. When these endogenous systems are overwhelmed, addition of further ready-
reduced exogenous antioxidants helps to maintain homeostasis.
The diet is a major source of antioxidants with many fruits and vegetables containing
high concentrations, for example, apples [Huber and Rupasinghe, 2009], strawberries [Azzini
et al., 2010] and many other foods [Dilis and Trichopoulou, 2010]. Studies in mice with the
antioxidants N -acetyl-l-cysteine and vitamins C and E have demonstrated that they can
protect β-cells against glucose-toxicity [Kaneto et al., 1999], possibly by protecting the
β-cells against glucose-induced apoptosis whilst not depressing their natural division rate.
Vitamin E is the combined name for a set of eight tocopherols and tocotrienols
including the well-known α-tocopherol, the member of the group with the highest bioavail-
ability (Figure 1.9) [Brigelius-Flohe´ and Traber, 1999]. Vitamin E is fat-soluble and acts
by scavenging the peroxyl radical and preventing lipid peroxidation in membranes. Each
member of the group has similar antioxidant properties and combined they are amongst
the antioxidants shown to have a specific benefit to combat diabetes side-effects, at least
in animal models. In human patients the evidence is a little less clear with further studies
needed to draw significant conclusions [Pazdro and Burgess, 2010].
It is likely that not all of the effects seen upon vitamin E administration are due
to its antioxidant properties. It has been shown to inhibit protein kinase C [Azzi et al.,
1997] and also to influence transcription by peroxisome proliferator-activated receptor-γ
(PPAR-γ) by acting as a ligand to the transcription factor [Pascale et al., 2006; Fang et al.,
2010]. Also, vitamin E can exist as one of eight stereoisomers. The naturally occurring
isomer is RRR whereas many commercial supplements are racemic at all chiral centres (all-
rac). None of these steroisomers is exactly equivalent to the naturally occurring RRR form
which may partially explain differences between supplements and diets rich in vitamin E
[Brigelius-Flohe´ and Traber, 1999].
Another often studied antioxidant is α-lipoic acid (Figure 1.10), or thioctic acid,
which is a cofactor for the E2 subunit of three mitochondrial enzyme complexes [Raddatz
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and Bisswanger, 1997; Biewenga et al., 1997]. It was found to be an antioxidant when it was
shown to prevent symptoms of vitamin C and E deficiency by Rosenberg and Culik [1959].
Its potential use as a therapeutic agent to treat diabetes has been considered for some
time [Gandhi et al., 1985] and more recently many papers have been published specifically
examining its effects on diabetic neuropathy. For example, Reljanovic et al. [1999] conducted
a two year placebo controlled study of the effect of α-lipoic acid on diabetic neuropathy.
They concluded that α-lipoic acid did have a beneficial effect on several attributes of nerve
conduction. Other studies by Coppey et al. [2001] in streptozotocin-induced diabetic rats
have shown that treatment with α-lipoic acid or hydroxyethyl starch deferoxamine can
significantly improve both nerve conduction velocity and preceding characteristics such as
a reduction in endoneurial blood flow.
Figure 1.9: The structures of the eight biologically active forms of Vitamin E
Figure 1.10: The structure of α-lipoic acid
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1.8.2 Aldose reductase inhibitors
Aldose reductase (AR), the first step in the polyol pathway, was an attractive pharmacologi-
cal target when considering the damage caused by excess polyol pathway flux. Soon after the
discovery of the involvement of AR in diabetic cataractogenesis researchers demonstrated
that AR inhibitors were capable of inhibiting cataract formation in diabetic rats [Dvornik
et al., 1973] and galactose-exposed rabbits [Kinoshita et al., 1968].
Early AR inhibitors developed for human use were toxic and had poor specificity—
they often inhibited other members of the aldo-keto reductase superfamily including alde-
hyde reductase isoforms. More recently drugs such as epalrestat have been marketed as a
treatment for diabetic neuropathy yet their efficacy remains below what has been demon-
strated in animal models since they are only partially effective in ameliorating symptoms
[Ramirez and Borja, 2008]. This may well be due to AR being implicated in many more
pathways than originally envisaged [Srivastava et al., 2005]. For example, AR may be more
involved with the reduction of a wide range of aldehydes generated from lipid peroxidation
than with the reduction of glucose. Inhibiting its activity may thus be increasing damage
from lipid peroxidation byproducts. Moreover, antioxidant administration alone is sufficient
to prevent cataractogenesis in rats, even though intra-lens polyol concentrations can be very
high (80–90 mM) [Srivastava et al., 2005]. Thus a possible solution to increase AR inhibitor
efficacy would be to administer AR inhibitors in combination with antioxidants.
1.8.3 Aminoguanidine
Aminoguanidine, also known as Pimagedine, is a small nucleophilic hydrazine derivative
which is able to react rapidly with dicarbonyl compounds and prevent the accumulation of
AGEs in the body. Aminoguanidine was noted to react with AGEs in vitro by Brownlee
et al. [1986] and by 1989, evidence had been published that aminoguanidine lowered AGE
concentrations in experimental diabetes [Nicholls and Mandel, 1989].
Based on this evidence, two clinical trials were established to investigate whether
aminoguanidine was effective in preventing overt nephropathy in diabetic patients. One
trial was conducted with type 1 and the other with type 2 diabetic patients (ACTION I and
II respectively). The outcome was not spectacular and the ACTION II trial was stopped in
1998 because of poor efficacy and safety concerns with side effects including abnormal liver
function tests and gastrointestinal disturbances [Freedman et al., 1999]. ACTION I was not
stopped but failed to deliver its clinical endpoint—a decrease in the time to the doubling of
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baseline serum creatinine—although there were some significant changes in lipid metabolism
and urinary protein output. These underwhelming results combined with other evidence of
toxicity (e.g. causing malignant tumours in rats [Oturai et al., 1996]) and off-target effects
(e.g. enzyme inhibition, reviewed by Thornalley [2003b]) means that aminoguanidine is not
likely to be used clinically.
1.8.4 Thiamine and Benfotiamine
The high cytosolic glucose concentrations prevalent in the diabetic state are damaging
through the pathways described above. Other pathways, such as the pentose phosphate
pathway (PPP) are capable of using this glucose and diverting it to less damaging metabo-
lites such as ribose-5-phosphate. The enzyme with most control over flux through the PPP
is transketolase which is dependent on the pyrophosphate form of the vitamin thiamine as
a cofactor. Thus it has been proposed that treatment with thiamine or derivatives such
as Benfotiamine could enhance activity of the PPP, thereby diverting glucose away from
damaging pathways. Thiamine as a therapy is discussed in more detail in the following
chapter, in particular also in Section 4.4.
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Chapter 2
Introduction to thiamine
Thiamine, or vitamin B1, is a water soluble vitamin which is essential in the pyrophosphate
form as a cofactor for key steps in carbohydrate metabolism. Like all vitamins, the human
body is unable to synthesise thiamine so it must be obtained in the diet where it can
be found in a wide variety of foods including whole grains, yeast, liver, pork and many
vegetables. Phosphate esters of thiamine in the diet are often hydrolysed in the gut lumen
by phosphatases to yield free thiamine which is subsequently transported from the lumen of
the gut into the blood stream where circulates freely. Thiamine is taken up into tissues via
dedicated transporters where it is pyrophosphorlyated to form the active cofactor, thiamine
pyrophosphate.
The concentration of thiamine in the body is maintained by a balance between
intestinal absorption, renal clearance and thiamine catabolism and degradation. Thiamine
is filtered at the glomerulus into the ultrafiltrate and is then actively re-absorbed in the
proximal tubules. It is this reabsorption that is crucial in maintaining a steady concentration
of the vitamin in the body.
2.1 Discovery and historical significance
Extreme thiamine deficiency in the diet gives rise to the disease beriberi (which translates
as “I cannot, I cannot” from the Sinhalese language from Sri Lanka) which was known
to antiquity—indeed, its symptoms were described by the Chinese physician Ch’ao-Yuan-
Fang Wu Ching in the 7th century AD. The disease has symptoms which include weight
loss, impaired tactile sensitivity (hypesthesia), oedema, vascular damage, weakened reflexes
(hyporeflexia) and in advanced cases, heart failure and death. Modern characterisation of
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the disease began in Japan where it was particularly prevalent due to the diet and known
locally as kakke´ (derived from two Chinese words meaning leg disease) [Carpenter, 2000].
The best description of the disease was published in 1804 by Tachibana Nan-kei. This
described not only the main symptoms as above but also seasonal variations and social
variations such as prevalence in the student population but not in the upper classes.
It was a Japanese naval doctor, Takaki Kanehiro, who first noted that the disease
affected naval officers less than naval seamen. The former consumed a varied diet including
meat and vegetables whilst the latter often consumed nothing but white rice for weeks at a
time. In 1882, he arranged an experiment on identically crewed Japanese battleships. One
crew was fed a more varied diet with meats, beans, barley and other ingredients whilst the
other was fed only white rice. Over the course of an identical voyage, the former ship had
only fourteen cases of beriberi with no fatalities where as the latter ship (with only rice in
the diet) had 161 cases of beriberi out of 376 crew with 25 fatalities. Despite Takaki’s work
on the causes of beriberi, the majority of Japanese navy doctors still believed that beriberi
was an infectious disease or caused by a toxin with the result that no program was put in
place to prevent the disease.
The first Western doctor to study the condition was Christiaan Eijkman, a Dutch
medical officer working in Java, who could induce polyneuritis gallinarum (a beriberi-like
disease) in chickens by feeding them only polished white rice and could cure it by feeding
them kitchen scraps (1893–1896). He observed a pathogenic degradation of the myelination
in both the chickens and in human beriberi patients. His successor, Gerrit Grijns, also
demonstrated that autoclaving food at 100–110℃ caused it to lose its “protective factor”
[Wuest, 1962]. Grijns was so convinced of this protective factor that he made the first
attempts to isolate it. However, it wasn’t until ten years later that a Polish chemist, Casimir
Funk, obtained a crystalline substance from rice polishings [Funk, 1912a; Carpenter, 2001].
He was convinced that he had isolated the vital ingredient in rice that prevented beriberi and
also that it was an amine. To this end, he coined the word “vitamine” meaning an amine
vital to life [Funk, 1912b]. As it turned out, Funk had not isolated thiamine but more
likely nicotinic acid. It was the Dutch chemists Barena C P Jansen and Willem F Donath
who, in 1926, first successfully isolated crystals of thiamine which they named “aneurin”
(for anti-neuritic vitamin). The structure provided by Jansen and Donath omitted the
crucial sulphur atom. Shortly after, the British Medical Research Council proposed the
identifier vitamin B1 for this anti-beriberi factor. By 1934, the structure of thiamine had
been correctly solved by R R Williams, an American chemist who gave the vitamin the name
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“thiamine” in recognition of this sulphur atom [Carpenter, 2000]. His laboratory followed
this feat with the first chemical synthesis of thiamine in 1936 (reviewed by Wuest [1962]).
The first commercial synthesis of thiamine took place in 1937. The cumulative outcome of
this research was that in the 1920s in Japan, a culture still very much dependent on white
rice as a staple food, beriberi accounted for 30% of all deaths yet by 1969, that figure had
dropped to 0.5% as a result of research into thiamine [Lonsdale, 2006].
2.2 Structure and structural analogues
Thiamine is a relatively stable compound comprising a thiazolium ring and a pyrimidine
ring linked by a methylene bridge (Figure 2.1). It is stable when exposed to heat in anhy-
drous form but is thermally-labile in foods, physiological systems and other non-anhydrous
conditions [Dwivedi and Arnold, 1973]. Thiamine has a molecular mass of 300.8 Da and
a full chemical name of 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-
methyl-1,3-thiazol-3-ium. It is prepared commercially as either the hydrochloride salt or
the slightly less soluble mononitrate salt for fortification in foods and for pharmaceutical
use [Expert Group On Vitamins and Minerals, 2000]. Synonyms for thiamine include thi-
amin, Aneurenin(e), Vitaneurin and other trade names [Expert Group On Vitamins and
Minerals, 2000]. The polar nature of thiamine makes it highly soluble in water. Dissolv-
ing thiamine hydrochloride at a concentration of 1% (w/v) in water naturally yields an
acidic solution (pH 3.13) in which the thiamine is stable at room temperature but not when
heated. When pH is increased beyond 5.5, thiamine becomes increasingly unstable although
the chemical half-life of thiamine at pH 7.0 and 25℃ is 47 weeks [Pachapurkar and Bell,
2005]. The biological half-life of thiamine is shorter than this due to catabolism, thiaminase,
thiamine oxidase and probably also peroxidase. Thiamine has a yeast-like thiazole odour
and a bitter taste.
The 2H proton of thiamine is very acidic (pK a = 18.0) and is capable of abstracting
to the solvent leading to the formation of the potent nucleophilic thiazolium ylid (Figure 2.2)
[Haake et al., 1971; Washabaugh and Jencks, 1989]. In the active site of thiamine-dependent
enzymes, this is exploited by lowering of the pK a by the active site of the enzyme (see Section
2.5 on page 39)
Thiamine degrades through hydroxide-catalysed thiazolium ring opening, leading to
the mercapto-olefinic derivative. This reaction has a half-life of 33 hours at pH 7.4 [Duclos
and Haake, 1974] and is reversible [Washabaugh et al., 1993] (Figure 2.3), a fact which is
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Figure 2.1: The structure of thiamine and thiamine phosphate esters.
Figure 2.2: The mechanism of thiamine ylid formation. Adapted with permission from
Washabaugh and Jencks [1989]
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exploited in the use of any of several lipophilic allithiamine derivatives which all have a ring-
opened structure that cyclises in vivo. Allithiamine is a lipid soluble derivative of thiamine
found naturally in garlic and discovered and characterised by Fujiwara et al. [1954a,b]. Ex-
amples of prodrugs derived from allithiamine include thiamine disulphide, thiamine propyl-
disulphide, isobutyrylthiamine disulphide (Sulbutiamine), thiamine tetrahydrofurfuryl disul-
phide (Fursultiamine or TTFD) and S -benzoylthiamine O-monophosphate (Benfotiamine)
(Figure 2.4). The structures of these compounds all have an open thiazolium ring which
re-closes in vivo after hydrolysis or reduction as appropriate. In the case of Benfotiamine,
the benzoyl-thioester linkage is hydrolysed by cellular and plasma non-specific esterases,
releasing benzoic acid. The resulting mercapto-olefinic formamide cyclises spontaneously to
form the thiazolium ring of thiamine monophosphate. Additionally, Benfotiamine can be hy-
drolysed by intestinal phosphatases to yield S -benzolythiamine. This is truly lipophilic and
can be detected in plasma after oral Benfotiamine dosing. S -benzolythiamine is hydrolysed
by esterases in tissues to yield thiamine (Figure 2.5) [Thornalley, 2005].
2.3 Metabolism of thiamine
Mammals are unable to synthesise thiamine and rely on exogenous sources of the vitamin.
Many bacteria, yeast and plants can synthesise thiamine monophosphate de novo by fusing
thiazole and pyrimidine moieties [Webb et al., 2007]; a process which was first elucidated in
yeast in 1960 [Camiener and Brown, 1960a,b]. These are synthesised separately and often
by quite diverse, species-specific mechanisms [Begley et al., 2008]. Research in this area is
still active and far from complete. In 2004, researchers managed to re-create the complete
thiazole synthesis system in a cell-free extract from E. coli [Leonardi and Roach, 2004] and
Kong et al. [2008] recently described a new gene in Arabidopsis thaliana which is similar to
the E. coli pyrimidine biosynthesis gene ThiC.
Once synthesised, thiamine cycles between one of four phosphorylation states in a
process summarised in Figure 2.6. Generally, in animals, thiamine is pyrophosphorylated
in one step to the active thiamine pyrophosphate (TPP). The majority of TPP will then
be bound by enzymes requiring it as a cofactor. Generally around 90% of cellular TPP
is contained within or associated with the mitochondria and used by the enzymes within
[Bettendorff et al., 1994b]. The remaining 10% is to be found in the cytosol where it
can be used as a cofactor for transketolase. Only 3–5% of cellular thiamine was found
bound to transketolase in rat brains [Bettendorff et al., 1994b]. TPP is capable of being
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Figure 2.3: The mechanisms of thiamine reversible hydrolysis and irreversible oxidation to
the highly fluorescent thiochrome. Adapted with permission from Washabaugh et al. [1993].
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Figure 2.5: The mechanism of Benfotiamine conversion to TMP and THM
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dephosphorylated in a stepwise manner via TMP back to the non-phosphorylated thiamine
(Figure 2.6).
A small amount of TPP is further phosphorylated from the cytosolic pool to form
thiamine triphosphate (TTP) in certain neurons [Makarchikov et al., 2003] in which it is a
cofactor for an enzyme involved in the unusual phosphorylation of histidine residues [Nghieˆm
et al., 2000] as well as playing a part in conduction of nerve impulses [Bettendorff et al.,
1994a].
2.4 Thiamine in the diet
Thiamine is widely available in the diet of higher organisms where it must be taken in
at regular intervals due to its water soluble nature and low overall body storage capacity.
Foods derived from whole grains of cereal crops provide the largest proportion of thiamine
in the UK diet amongst young people (38%, [Gregory and Lowe, 2000; Expert Group On
Vitamins and Minerals, 2000]) with vegetables, potatoes and savoury snacks accounting for
an additional 26%. The data for UK adult dietary composition of thiamine was compiled
by the Office for National Statistics in 2002 and a summary is given in Table 2.1. Most of
the thiamine is lost from whole grains in the production of white flour or polished rice so in
the UK, white flour must be fortified with thiamine to a level not less than an equivalent
of 0.24 mg per 100 g flour [Expert Group On Vitamins and Minerals, 2000]. Other potent
sources of thiamine in the diet include meat (particularly pork muscle), milk, legumes, fruit
and eggs.
Thiamine requirements in the diet are highly dependent on carbohydrate-based en-
ergy intake which in itself is also subject to variation based on age, body weight and phys-
ical activity as well as other factors such as climate or pathological conditions [Standing
Committee on the Scientific Evaluation of Dietary Reference Intakes, 1999; World Health
Organization’s Department of Nutrition for Health and Development, 1999; Expert Group
On Vitamins and Minerals, 2000]. Patients with cancer have high glycolytic fluxes and so
have increased need for thiamine but supplementation has drawbacks because the high doses
of thiamine given allow for fast production of the nucleotides needed for rapid cell division
via the transketolase-dependent reductive pentose phosphate pathway (see Section 2.6 on
page 41) [Boros et al., 1998]. Since requirements are relative to energy usage, the expression
of intake as a ratio to calories consumed is the preferred method. The recommended daily
dietary intake of thiamine in the UK is virtually stable throughout life rising from 0.3 for
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Figure 2.6: The metabolism of thiamine and its phosphate esters. Normal mammalian
reactions are drawn with black arrows. Reactions common to other classes of species
are drawn with grey arrows. References: thiaminase I [Fujita, 1954]; thiaminase II [Fu-
jita et al., 1954]; thiamine diphosphokinase [Leuthardt and Nielsen, 1952]; thiamine kinase
[Iwashima et al., 1972]; nucleoside triphosphatase [Brightwell and Tappel, 1968]; thiamine
phosphate kinase [Nishino, 1972]; thiamine diphosphate kinase [Itokawa and Cooper, 1968];
thiamine triphosphatase [Hashitani and Cooper, 1972]; thiamine phosphate diphosphorylase
[Camiener and Brown, 1960b]. Figure drawn with reference to the KEGG database available
at http:// www.genome.jp/ kegg/ [Kanehisa and Goto, 2000].
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infants to 0.4 mg 1000 kcal−1 for adults [Department of Health, 1991]. This translates to a
reference daily intake (RDI) of around 1 mg day−1 for a typical adult human. A slightly
higher rate of intake is recommended by the US authorities at 0.5 mg 1000 kcal−1 with an
increase to 0.9–1.0 mg 1000 kcal−1 for pregnant or breast-feeding ladies [National Research
Council, 1989].
2.5 Physiological role of thiamine
The majority of thiamine is active in the body as TPP, also known as cocarboxylase, which
is used as a cofactor by several enzymes. Three of these are multi-enzyme complexes in-
volved in the dehydrogenation of α-keto acids: the pyruvate dehydrogenase complex (PDH),
the α-ketoglutarate (2-oxoglutarate) dehydrogenase (α-KGDH) complex and the branched
chain α-ketoacid dehydrogenase complex. In addition to these complexes, two further en-
zymes require TPP as a cofactor: the pentose phosphate pathway enzyme transketolase and
2-hydroxyphytanoyl-CoA lyase which is a lysosomal enzyme involved in the catabolism of
phytanoic acid from chlorophyll [Foulon et al., 1999].
The three multi-enzyme complexes listed first are all large structures—larger than
a ribosome—and structurally very similar to each other. They each have three subunits
named E1, E2 and E3. It is the E1 subunit after which each complex is named and which
requires TPP as a cofactor. The E2 subunit uses two lipoic acid molecules bound to lysine
Type of food Percentage of dietary thiamine intake
Cereals and cereal products 34
Milk and milk products 6
Egg and egg dishes 1
Fat spreads 0
Meat and meat products 21
Fish and fish dishes 1
Vegetables (excluding potatoes) 15
Potatoes and savoury snacks 13
Fruit and nuts 3
Sugars, preserves and confectionery 1
Drinks 2
Miscellaneous 3
Average daily intake (mg) 1.77
Table 2.1: Thiamine composition of the diet from data on adults aged 19–64 years in the
United Kingdom as assessed in 1990–1991 [National Diet & Nutrition Survey, 2002].
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residues as cofactors (Figure 1.10 on page 26) whilst the E3 subunit uses a molecule of FAD.
All E1 subunits are multimeric, each with two α and two β domains [Ciszak et al., 2003].
In the case of the PDH complex, the E1 subunit initiates the reaction with the
TPP ylid attacking the electrophilic ketone of pyruvate. This results in an intermediate
β-alkoxide which decarboxylates yielding an enol which is deprotonated yielding a stable
intermediate bound covalently to the TPP. This undergoes reductive acetylation using the
lipoamide moieties on the E2 subunit, regenerating the TPP [Ciszak et al., 2003]. The E2
subunit then adds coenzyme A forming a molecule of acetyl-CoA before being regenerated
by the FAD contained in the E3 subunit.
A very similar reaction happens in the α-KGDH complex where the E1 subunit
performs the decarboxylation of α-ketoglutarate yielding a succinyl-TPP complex. This
complex is the precursor for the subsequent oxidation and transfer of coenzyme-A (performed
by the E2 and E3 subunits respectively) to yield succinyl-CoA, the final product [Tretter
and Adam-Vizi, 2005].
The third complex requiring TPP as a cofactor is that which decarboxylates the
α-ketoacids derived from the degradation of the branched chain amino acids leucine, valine
and isoleucine. In a manner similar to the other two complexes, the α-ketoacids are decar-
boxylated and activated products are formed: 3-methylbutanoyl-CoA, isobutyryl-CoA and
S -2-methylbutanoyl-CoA from each amino acid respectively. Each of these is then passed
ultimately into the citric acid cycle or biosynthetic pathways.
The reason why thiamine requirements are linked to dietary carbohydrate intake
is now clear: PDH is one of the main enzymes using TPP as a cofactor and pyruvate is
primarily derived from glucose metabolism. Hydrolysis of fatty acids yields acetyl-CoA
subunits directly without pyruvate involvement. However, in the brain, which relies heavily
on glucose (either exogenous or derived from gluconeogenic substrates during fasting) the
presence of TPP is more critical for energy release from metabolites. Of course, the fasting
brain relies more heavily overall on ketone bodies for energy but there is always some glucose
consumption since the mitochondria (used for ketone body conversion to acetyl-CoA and
subsequent oxidation by the citric acid cycle) are clustered in the cell bodies and are not
found along the axons where glycolysis is the primary energy source.
Transketolase is also dependent on TPP as a cofactor. This key enzyme in the
pentose phosphate pathway is discussed in more detail below.
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2.6 The pentose phosphate pathway
The pentose phosphate pathway (PPP) is a key metabolic pathway with two main roles
in the cell: it produces reduced NADPH and five carbon sugars, particularly ribose-based.
These two roles are spread across two branches of reactions, the oxidative reactions and the
non-oxidative reactions [Cabezas et al., 1999]. The PPP is also sometimes known as the
phosphogluconate pathway or the hexose monophosphate shunt.
The non-oxidative reactions are primarily used to re-arrange carbon frameworks and
convert five-carbon sugars to six-carbon sugars (or vice-versa) via a series of intermediates.
All reactions in the non-oxidative phase are completely reversible, indeed, they are driven
in “reverse” during the Calvin cycle as part of photosynthesis [Kruger and von Schaewen,
2003]. Importantly for this thesis, two reactions in the non-oxidative pathway are catalysed
by the TPP-dependent enzyme transketolase (Figure 2.7). The oxidative reactions are used
to generate reduced NADPH. They start with hexose sugar phosphates and convert them
to ribose-5-phosphate yielding two moles of reduced NADPH and one mole of CO2 for each
mole of sugar passed down the pathway. These pentoses can then be re-converted back
to hexoses by the non-oxidative branch if required. The overall reaction for the oxidative
pathway is:
Glc-6-phosphate + 2 NADP+ + H2O → Rib-5-phosphate + 2 NADPH + 2 H+
The overall reaction for the non-oxidative branch is:
6 Rib-5-phosphate ⇀↽ 5 Glc-6-phosphate
The first role of the PPP, as a producer of reduced NADPH in the cytosol, is
critical in maintaining cellular antioxidant capabilities since reduced NADPH is a substrate
for glutathione reductase, the enzyme which maintains the cellular glutathione pool in the
reduced state. It also has secondary implications since NADPH is also used in metabolic
processes including fatty acid synthesis and sterol synthesis: two molecules of NADPH are
oxidised for the addition of each acetyl unit to a growing fatty acid chain. This role of the
pathway producing NADPH is critical to cell survival, particularly in erythrocytes which
have an active PPP owing to their lack of oxidative metabolism. Additionally, the ribose
sugars produced by the pathway can be used as precursors for nucleotide and nucleic acid
biosynthesis.
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Figure 2.7: Schematic summary of the the pentose phosphate pathway. A: The oxidative
and non-oxidative reaction pathways. All reactions in the non-oxidative part are freely
reversible, as in the Calvin cycle. Single arrows are only used to indicate flux through the
pathway during NADPH synthesis. The number of carbons in each sugar is indicated by the
number of sides to the polygon. R5P: Ribose-5-phosphate; S7P: Sedoheptulose-7-phosphate;
F6P: Fructose-6-phosphate; G6P: Glucose-6-phosphate; X5P: Xylulose-5-phosphate; G3P:
Glyceraldehyde-3-phosphate; E4P: Erythrose-4-phosphate. B: The complete conversion of
6 riboses to 5 hexoses is shown. This is two sets of non-oxidative reactions from A in a
mirror-image arrangement.
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2.6.1 Control of the pentose phosphate pathway
The first oxidative reaction in the PPP, the conversion of glucose-6-phosphate (G-6-P) to 6-
phosphoglucono-δ-lactone, is essentially irreversible and provides the most control over flux
through this pathway. It is catalysed by the enzyme glucose-6-phosphate dehydrogenase.
Genetic defects in this enzyme can have serious consequences such as the disease favism
which is an intolerance to fava beans. Fava beans contain a molecule called divicine which
raises cellular H2O2 to fatal levels when G6P dehydrogenase is inactive.
The limiting factor for flux through the pathway is the availability of the oxidised
NADP+. The NADP+:NADPH ratio in the liver of a well fed rat is around 0.014 mean-
ing there is a vast excess of the reduced NADPH. This is considerably lower than the
NAD+:NADH ratio in the same tissue which is around 700. Thus, NADPH is only pro-
duced as fast as it is required. In the liver or adipose tissue this rate is higher than it would
be in muscle due to the high rate of lipogenesis and thus the high demand for NADPH. The
non-oxidative branch of the pathway is primarily controlled by substrate availability and
will flow readily in either direction.
This arrangement of oxidative and non-oxidative pathways allows for some interest-
ing biochemistry if the cellular need arises. It is possible for cells to use the pathway in
one of four ways dependent on the need for ribose-5-phosphate, NADPH and ATP. Firstly,
if a cell requires much more R-5-P than NADPH—perhaps a dividing cell synthesising
nucleotides—then G-6-P can be converted to fructose-6-phosphate and glyceraldehyde-3-
phosphate by normal glycolytic means. Then transketolase and transaldolase can convert
these to ribose-5-phosphate with the net result:
5 G-6-P + ATP −→ 6 R-5-P + ADP + H+
The second mode would be if the needs for NADPH and ribose-5-phosphate are
balanced. In this case, the oxidative pathway can be used on its own to produce two moles
of NADPH and one mole of ribose-5-phosphate for each mole of glucose-6-phosphate:
G-6-P + 2 NADP+ + H2O −→ R-5-P + 2 NADPH + 2 H+ + CO2
The third and fourth modes are similar in that the cell requires much more NADPH
than ribose-5-phosphate but they differ in whether the cell requires ATP or not. If the
cell does not require ATP, the glucose-6-phosphate can be completely oxidised by the PPP
yielding only NADPH. If the cell requires ATP, the ribose-5-phosphate can be returned to
glycolysis as pyruvate via the non-oxidative branch. This pyruvate can then be used to
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either generate ATP or as a precursor for biosynthetic pathways. Both the oxidative and
non-oxidative reactions are required here and the metabolites will move in a circular motion
(anticlockwise on Figure 2.7 A). The reaction for option three is:
G-6-P + 12 NADP+ + 7 H2O −→ 6 CO2 + 12 NADPH + 12 H+ + Pi
and for option four:
3 G-6-P + 6 NADP+ + 5 NAD+ + 5 Pi + 8 ADP −→
5 pyruvate + 3 CO2 + 6 NADPH + 5 NADH + 8 ATP + 2 H2O + 8 H+
These varied options make the PPP incredibly flexible and able to respond to cellular
needs in a way that other pathways are unable to. The fact that it provides an alternative
route for complete oxidation of glucose may be useful in the diabetic state, especially since
diabetes is a state associated with an increase in oxidative stress and the extra NADPH
generated by option three above may be useful. “Normal” oxidation of this glucose through
the citric acid cycle would primarily generate ATP or increase the mitochondrial membrane
potential, exacerbating the production of superoxide.
2.6.2 Transketolase
Transketolase (E.C. 2.2.1.1, TK) is a ubiquitous thiamine pyrophosphate-dependent en-
zyme found in all domains of life. It is a homodimer with each chain having a mass of
around 68 kDa in humans. There are two active sites within each TK homodimer, each
at the interface between the sub-units. Each active site requires one calcium ion and
one molecule of TPP as cofactors. It catalyses two reactions within the pentose phos-
phate pathway. These are the interconversion of the two pentose phosphates ribose-5-
phosphate and xylulose-5-phosphate with the seven-sugar sedoheptulose-7-phosphate and
the triosephosphate glyceraldehyde-3-phosphate along with the interconversion of the four-
carbon erythrose-4-phosphate and xylulose-5-phosphate with fructose-6-phosphate and gly-
ceraldehyde-3-phosphate:
R-5-P + X-5-P ⇀↽ S-7-P + GA3P
E-4-P + X-5-P ⇀↽ F-6-P + GA3P
The dependence of TK on TPP and a metal ion was originally demonstrated in yeast.
TPP can be removed from mammalian TK with relatively mild acidic conditions whilst the
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removal of TPP from yeast and E. coli TK requires alkaline conditions [Datta and Racker,
1961] after which the activity is completely ablated [Saitou et al., 1974]. Only after the
addition of TPP and a divalent metal ion is activity restored [Heinrich et al., 1972]. This
dependence on TPP has also been demonstrated by the presence of TPP in solved crystal
structures in yeast [Lindqvist et al., 1992; Nikkola et al., 1994]. The binding of TPP to
TK is a two-step process [Esakova et al., 2005; Kochetov and Izotova, 1973]. The first is
the binding of the TPP to the apo-enzyme in an fast and readily reversible step yielding a
catalytically inactive intermediate. This is followed by a second, slow step which includes
conformational changes in the apo-enzyme yielding the active holo-enzyme [Dalby et al.,
2007]. In addition, TK is prone to removal of the TPP moiety when any excess is removed
[Mitra et al., 1998]. This poses potential problems for the activity of TK in situations where
thiamine is deficient.
The mechanism of catalysis in TK is similar to that of PDH in that there is an
activated aldehyde being transferred to an acceptor which in the case of TK is an aldose
and in the case of PDH is the lipoamide. In both reactions it is the C2 atom of TPP which
ionises to yield the carbanion which attacks the carbonyl group of the substrate and forms
an activated glycoaldehyde. This then condenses with the new aldehyde to form a ketose
sugar which is released from the enzyme [Schenk et al., 1998].
2.7 Assay of thiamine
The clinical measurement of thiamine deficiency has traditionally been made by the use of an
indirect method using a suitable proxy: erythrocyte transketolase activity and saturation
with TPP. Erythrocytes are easily obtainable and transketolase activity in them is high
because of high ROS production and concomitantly high flux through the pentose phosphate
pathway. The assay involves measuring transketolase activity in fresh erythrocyte extract
followed by the addition of exogenous TPP and re-measurement of the activity. These values
can be used to determine the “thiamine effect”, or percentage of transketolase unsaturated
with TPP. A normal range for the thiamine effect in healthy human subjects is 0–15%,
in mildly thiamine deficient patients 15–25% and in severely thiamine deficient patients
>25% [Brady et al., 1995]. A urinary excretion rate for thiamine exceeding 0.20 µmol day−1
or 67µg day−1 is considered the threshold value for evidence of dietary sufficiency of the
vitamin [Finglas, 1993].
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For measurement of thiamine concentration in other biological samples, an array of
assay techniques have been used historically. These often involved measuring an indirect
response such as rate of growth of an organism. For example, rat growth rates were used
to study thiamine content of food before and after cooking [Aughey and Daniel, 1940].
Other techniques used involved assaying increased rates of alcohol production by fermenting
yeast or using bacteria such as Staphylococcus aureus. Such methods either involved large
amounts of cumbersome equipment or were subject to error due to thiamine biosynthesis
pathways present. Another factor was that both the pyrimidine and thiazole moieties are
active in many of these organisms [Niven and Smiley, 1943]. By 1943, a refinement of
these techniques was in use. It involved measuring the rate of production of polysaccharide
by Streptococcus salivarius when grown on a minimally defined agar medium [Niven and
Smiley, 1943]. Streptococcus salivarius is unable to use either cleavage product alone or
both combined as a substitute for thiamine.
These old techniques for assay of thiamine were vastly improved upon with the in-
troduction of the thiochrome method. Thiochrome is a highly fluorescent molecule which
can be synthesised easily by the alkaline oxidation of thiamine and its phosphate esters
and then readily detected (this is further covered in the Materials and Methods chapter,
particularly Figure 6.3 on page 89). This method was further refined when combined with
chromatography by Sander et al. [1991] when it completely replaced prior methods of de-
tection. Subsequent improvements led to increases in sensitivity and specificity along with
reduced analysis time [Fayol, 1997; Gerrits et al., 1997]. A thorough account of a modern
HPLC-based thiamine assay is given in Section 6.4 on page 89.
2.8 Thiamine transporters
There are two main proteins expressed in human cells that transport the physiologically
cationic thiamine across membranes. These are human thiamine transporters 1 and 2
(THTR-1 and THTR-2). Each of these is a member of the solute carrier family of pro-
teins, a fact represented in their gene names: SLC19A2 and SLC19A3 respectively. The
only other member of this family of proteins is reduced folate carrier 1 (RFC-1, gene name
SLC19A1 ) which transports the anionic folate across membranes. BLAST (Basic Local
Alignment Search Tool) analysis of the human genome suggests that there are no further
members of this family lying undiscovered [Ganapathy et al., 2004]. Homologues of these
transporters are evident in the genomes of other species such as D. melanogaster and C.
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elegans but the nature of the proteins in these organisms has not been studied [Ganapathy
et al., 2004]. Each member of the SLC19 gene family is expressed ubiquitously but generally
with higher levels in tissues such as kidney, intestine, liver and pancreas.
2.8.1 THTR-1
Human thiamine transpoter 1 (THTR-1) was the first identified member of the thiamine
transporter family. The coding region for the gene for THTR-1, SCL19A2, was cloned from
a human foetal brain cDNA library and the protein was determined to contain 497 amino
acid residues for a total molecular mass of 56 kDa and with a likely 12 transmembrane
helices [Diaz et al., 1999]. After the gene had been identified as a thiamine transporter and
cloned, Said reported on expression and promoter analysis of SLC19A2 in intestinal cells
[Reidling et al., 2002] and cellular and molecular aspects of thiamine uptake in cultured liver
cells [Said et al., 2002]. The initial work on the intestinal cells identified that the stomach,
duodenum and jejunum cells contained higher levels of SCL19A2 mRNA relative to β-actin
compared to the colon, cecum, rectum and ileum [Reidling et al., 2002] i.e. THTR-1 was
more abundant in the proximal end of the digestive tract than the distal end.
Thiamine transpoter research began during study of the disease thiamine-responsive
megaloblastic anaemia (TRMA, MIM (Mendelian Inheritance in Man): 249270, also known
as Rogers syndrome after Lon Rogers who discovered it in 1969 [Rogers et al., 1969]).
TRMA is an autosomal recessive disorder and mutations found clinically (D93H, S143F,
G172D and others including insertion mutations [Bergmann et al., 2009]) are associated
with impaired uptake of thiamine from the diet, thiamine deficiency, megaloblastic anaemia
(abnormally large erythrocytes), sensorineural deafness and non-type 1 diabetes mellitus
[Labay et al., 1999; Alzahrani et al., 2006]. Studies on some of these mutations have revealed
that they are associted with decreased activity of the transporter, not a failure of the
transporter to correctly express on the surface of cells [Balamurugan and Said, 2002]. TRMA
is treatable by daily oral administration of pharmacological doses of thiamine to the patient
(25–300 mg day−1 versus a normal RDI of around 1.5 mg day−1) [Oishi and Diaz, 2007].
Benzoyloxymethyl-thiamine, a lipophilic derivative of thiamine, has also been used in the
treatment of TRMA [Valerio et al., 1998]. In each case, treatment with thiamine maintains
health and corrects hyperglycaemia in pre-pubescent children but there is a chronic decline
in pancreatic function after puberty with a related requirement for insulin.
Neufeld et al. [1997] studied approximately 12 families from various ethnic groups
with TRMA and used the data to determine the location of the gene responsible by linkage
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analysis. They concluded that the locus of the gene responsible for TRMA was 1q23.2–
q23.3 but they did not identify the exact gene. The exact identity was found two years
later when several groups identified mutations in the genetic sequence and characterized the
protein responsible for TRMA as a thiamine transporter [Diaz et al., 1999; Dutta et al.,
1999; Fleming et al., 1999; Labay et al., 1999]. This new protein was named THTR-1 and
showed a 39% sequence homology to the reduced folate carrier gene, SLC19A1. As a result,
the gene for THTR-1 was named SLC19A2.
2.8.2 THTR-2
Human Thiamine Transporter 2 (THTR-2) was the second identified member of the thi-
amine transporter family. It is a transmembrane protein comprising 496 amino acids with
a molecular weight of 56 kDa. The protein undergoes no post-translational processing be-
fore reaching maturity with 12 transmembrane helices [Zeng et al., 2005]. The gene was
first reported in humans by Eudy et al. [2000] who recognised its significance as a human
homologue of a mouse gene which was potentially responsible for seizures in DBA/2J mice.
The gene was mapped to chromosome 2q37 (later refined to 2q36.3) and assigned the name
SLC19A3 as it fell in the same solute carrier family as THTR-1 and RFC-1. The functional
nature of the protein was first reported a year later by Rajgopal et al. [2001] who demon-
strated that it was a highly specific thiamine transporter that did not transport folate as
RFC-1 does.
THTR-2 has a high apparent structural homology with THTR-1. Both appear to
have the same membrane-spanning helix configuration, have a similar molecular mass and
share 53% amino acid sequence identity. THTR-2 appears to be expressed ubiquitously
[Eudy et al., 2000; Zeng et al., 2005] but is found at higher levels in certain tissues e.g.
placenta, liver and kidney along with discrete areas of the small intestine. Like THTR-1,
it is more abundant in the proximal half of the small intestine with some expression in the
more distal regions and colon [Said et al., 2004]. Tissues where THTR-2 is expressed are
often the same as those with higher than average levels of THTR-1. Despite their similar
localisation, there are differences in abundance between THTR-1 and THTR-2, often with
a lower abundance of THTR-2 than THTR-1 in a given tissue. For example, Ashokkumar
et al. [2006] have shown a level of THTR-1 mRNA several times higher than THTR-2 mRNA
in HEK-293 kidney cells. The more abundant mRNA for THTR-1 does not, however, mean
that it is the only protein critical for the uptake of thiamine. The importance of THTR-2
has recently been demonstrated in Japan by two brothers presenting with a Wernicke’s-
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like encephalopathy which responded to thiamine treatment. Wernicke’s encephalopathy is
characterised by impairment of short-term memory, ataxia, confusion and ophthalmopare-
sis. On investigation they were found to be compound heterozygotes for the K44E and
E320Q mutations in SLC19A3, not normally found in ethnically matched control patients
[Kono et al., 2009]. The authors proposed that the sub-cellular trafficking problems with
the mutated protein may explain the selective lesions seen in MRI scans of the brothers.
In addition, they speculated that the the up-regulation of THTR-1 in response to poor
activity of THTR-2 may be responsible for preventing any further symptoms of deficiency.
Furthermore, defects in THTR-2 are responsible for biotin-responsive basal ganglia disease
(BBGD), a genetic recessive disease that starts in childhood and presents as a subacute
encephalopathy, dysphagia and confusion. BBGD progresses to severe rigidity and dystonia
and eventual death if left untreated [Zeng et al., 2005]. High doses of biotin (Vitamin B7;
a cofactor for several critical carboxylases) are able to relieve symptoms within a few days
although the connection to thiamine transport remains unclear [Zeng et al., 2005].
THTR-2 has a marked polarity in its expression in in vitro intestinal models. It was
found by Said et al. [2004] to be expressed primarily on the apical membrane of polarised
intestinal Caco-2 cells with relatively little expression at the basolateral membrane. This
is in contrast to THTR-1 which was found to be expressed at both apical and basolateral
membranes in the same cell system, possibly with higher expression in the latter than the
former membrane. In the same study Said et al. [2004] analysed the relative contributions
of each transporter to the total carrier mediated thiamine transport in Caco-2 cells using
siRNA knockdown techniques. For each protein they were able to specifically knock down
expression and demonstrate a marked decrease in the uptake of thiamine. They concluded
that the two proteins together were responsible for the total carrier-mediated thiamine
uptake in this in vitro model. More recently, the role of THTR-2 in vivo has been further
investigated by the same group [Reidling et al., 2010]. They used an SLC19A3 deficient
mouse strain and demonstrated in both ex vivo cells and intestinal loops that thiamine
uptake was significantly reduced by between 70–80%. They hypothesise that the remainder
of uptake is attributable to an up-regulated THTR-1.
2.8.3 Mitochondrial thiamine pyrophosphate transporter
There is a third protein which is involved in thiamine transport. The gene found at
SLC25A19 was originally thought to encode a mitochondrial deoxyribonucleotide carrier
(DNC) [Dolce et al., 2001]. However, more recent studies by Lam et al. [2005] provided the
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first evidence that this was unlikely, followed soon after with the discovery by Lindhurst
et al. [2006] that SLC25A19 actually encodes a mitochondrial thiamine pyrophosphate
transporter. Lindhurst et al. [2006] demonstrated a decrease in mitochondrial thiamine
pyrophosphate concentrations in knockout mice along with normal mitochondrial levels of
ribo- and deoxyribonucleoside triphosphates—the originally proposed substrate of the DNC.
In addition, Kang and Samuels [2008] have provided bioinformatic, transgenic in vivo and
enzyme kinetic study evidence strongly in favour of SLC25A19 being a transporter of thi-
amine pyrophosphate.
Mutations in this protein cause Amish lethal microcephaly (MCPHA) which is
known to cause brain retardation and α-ketoglutaric aciduria. Knockout mice deficient
in SLC25A19 die by embryonic day 12 with a neural tube closure defect [Lindhurst et al.,
2006]. Beyond such observations, little is known about the role of SLC25A19 and its func-
tion in cellular thiamine metabolism.
2.8.4 Promoter elements of SLC19A2 and SLC19A3
Reidling et al. [2002] characterised the promoter elements of the THTR-1 gene necessary for
expression. By cloning the gene and selectively removing certain upstream sections of the
sequence, they identified several putative 5'-elements for regulation of the gene. Importantly,
the gene was found not to have a TATA box at the expected location but instead had a
CAAT box at position −305. The minimal promoter region between −356 and −36 was
analysed and putative regulatory elements including Nuclear Factor-1 (NF-1), Activator
Protein-1 (AP-1), Gut enriched Krupple-Like Factor-1 (GKLF) and Stimulating protein-1
(Sp1) were identified (Figure 2.8).
Figure 2.8: The sequence of the SLC19A2 minimal promoter region required for basal
activity. Boxes indicate putative promoter elements; red indicates transcription initiation
sites. The numbers are nucleotides relative to the A of the ATG start site as 1. Adapted
with permission from Reidling et al. [2002].
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Further work by the same laboratory [Reidling and Said, 2003] investigated the pro-
moter element in more detail using a variety of model systems including transgenic mouse
studies and cotransfection studies using Drosophila SL2 cells—a well established cell line
without any endogenous Sp1 activity [Courey and Tjian, 1988]. The transgenic mouse stud-
ies used full length and minimal promoter elements and showed that independent mutations
of the GKLF/Sp1, NF-1 or Sp1 cis elements led to a decrease in SLC19A2 promoter ac-
tivity. They also established that GKLF, NF-1 and Sp1 proteins all form complexes with
the DNA in the SLC19A2 promoter. Specifically with regard to Sp1, they showed that it
increases promoter activity in vitro. In the Drosophila SL2 cell studies, cells were simul-
taneously transfected with the SLC19A2 promoter and an Sp1 containing vector. These
studies showed a dose-dependent activation of both the minimal and full length promoter
by Sp1. Taken together, these results suggest a role for three of the four transcription
factors—GKLF, NF-1 and Sp1—being involved in the activation of SLC19A2 gene expres-
sion in vivo. This may in turn suggest that they are important in cellular regulation of
thiamine uptake and potentially whole-body thiamine homeostasis.
The role of 5'-promoter elements in the expression of SLC19A3 was researched
thoroughly by Nabokina and Said [2004] who used transiently transfected Caco-2 cells with
5'-deletion analysis conducted from a cloned 5'-regulatory region from the human SLC19A3
gene. The minimal promoter needed for transcription was found between positions −77 and
+55 bp and contained a number of putative promoter binding elements including sites for
Sp1 (GC boxes at positions −48/−55 and −15/−12 bp) and NF-1. These elements were
discovered by, and further investigated with, mutational analysis. Mutating all sites except
the more distal (−48/−55 bp) GC box had no effect on basal transcription. Mutation of the
distal GC box markedly decreased basal transcription. Supershift analysis showed that both
Sp1 and the related Sp3 are capable of binding to this GC box which suggests a role for both
these transcription factors and this GC box in modulating basal expression of SLC19A3.
2.8.5 Characteristics of thiamine transport
Thiamine transport has been studied in several different models representing different tis-
sues. The HepG2 cell line has been used to model the liver [Said et al., 2002], jejunal
basolateral membrane vesicles have been isolated and studied [Dudeja et al., 2003] and the
HEK-293 cell line has been used to model certain aspects of kidney uptake [Ashokkumar
et al., 2006]. More recently, a similar study was published on thiamine uptake in pancreatic
β-cells [Mee et al., 2009]. Each of these studies are concordant on several points.
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1) The uptake of thiamine is both temperature and energy dependent but indepen-
dent of Na+ or other metal cations such as Li+ or K+. Uptake is slower at temperatures
lower than 37℃ and is inhibited markedly by pre-incubation of cells with inhibitors of
metabolism such as 2,4-dinitrophenol, sodium azide, p-chloromercuriphenyl sulphonate and
iodoacetate, each at 1 mM. This suggests that there is an active transport process involved
which is independent of sodium translocation across the membrane.
2) The uptake is dependent on a pH gradient across the cell membrane. There is a
much higher uptake rate with an alkaline or neutral buffer around cells than with an acidic
buffer. That is, there must be an outwardly facing pH gradient i.e. pHin < pHout.
3) The uptake is saturable as a function of concentration with apparent K m values
in both the nanomolar and low micromolar range. This again suggests a form of active
transport. The K m values are dependent on tissue type but as an example, thiamine
uptake in HEK-293 cells has an apparent K m at 70.0±18.4 nM and another at 2.66±0.18 µM
[Ashokkumar et al., 2006]. Said et al. [2004] determined that the K m for THTR-2-mediated
thiamine uptake was 27.1±7.6 nM in Caco-2 cells. Likewise, Dutta et al. [1999] determined
an apparent K m of 2.5±0.6 µM for thiamine uptake by THTR-1 alone. These two results
taken with the work by Ashokkumar et al. [2006] suggest that multiple transporters with
different affinities for thiamine work togather to provide overall thiamine transport capacity.
4) Thiamine transport is subject to competition and inhibition by other small
molecules. The transport of [3H]thiamine is cis-inhibited and trans-stimulated by unlabelled
thiamine and structural analogues such as oxythiamine and amprolium but not by struc-
turally unrelated organic cations such as tetraethylammonium and N -methylnicotinamide.
Also, uptake of thiamine is competitively inhibited by amiloride in a dose-dependent manner
with an apparent K i of 0.6 mM in HEK-293 cells.
Collectively, these observations suggest that the thiamine is taken up by at least two
carriers which are specific to thiamine and are thiamine-proton antiports. It is thus likely
that each contributes to the total capacity for thiamine transport which would explain
the multiple apparent K m values observed. THTR-1 appears to be the more dominant
transporter with the higher flux in liver cells [Said et al., 2002] and HEK-293 cells (between
four and ten times the flux of THTR-2 [Ashokkumar et al., 2006]). It is worth noting
that exposure of cells to high concentrations of thiamine leads to lower levels of transporter
expression and protein abundance [Mee et al., 2009], possibly as a result of negative feedback.
An alternate explanation would be the ability of thiamine to break open into an acyclic,
unionised form and diffuse across the membrane at high concentrations.
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2.8.6 Cellular trafficking of THTR-1 and THTR-2
Work on cellular trafficking of THTR-1 and THTR-2 was carried out and published between
2003 and 2006 [Subramanian et al., 2003, 2006]. In each case, a series of experiments
was performed in duodenal epithelial cells involving successively truncated forms of the
relevant target protein with enhanced green fluorescent protein (EGFP) coupled to the
carboxy-terminus. Imaging of the cells after each transfection gave subcellular localisation
information and allowed a certain amount of mechanistic determination to be made about
sub-cellular movement of the transporters.
The full length THTR-1-EGFP-fused protein was actively expressed on the surface of
the cell. When EGFP-fused truncations were studied it emerged that THTR-1 needed amino
acids 19–29 in the amino-terminus and integrity of the transmembrane backbone polypeptide
for surface expression (Figure 2.9). Removal of the carboxy-terminal region did not affect
the localisation of the transporter to the surface. Notably, truncations within a region
where thiamine responsive megaloblastic anaemia (TRMA) mutations are commonly found
resulted in intracellular retention of the protein which may explain some of the aetiology of
that disease. Confocal imaging of THTR-1 trafficking revealed that microtubules, but not
microfilaments, are essential for its intracellular movement [Subramanian et al., 2003].
THTR-2, unlike THTR-1, appears to be expressed almost exclusively on the apical
membrane of polarised cells [Boulware et al., 2003; Subramanian et al., 2006]. This was
demonstrated in both Caco-2 cells and MDCK cells as models of the intestine and the kidney
respectively. Subramanian et al. [2006] showed that around 90% of fluorescence observed
from the full-length THTR-2-GFP fusion protein was seen at the apical membrane with only
around 10% seen at the basolateral membrane (Figure 2.10). It is common for many nutrient
transporters to be dependent on sequences within their carboxy-termini for correct polarised
trafficking yet this was not the case with THTR-2. Despite its carboxy-terminus domain
being quite dissimilar to that of THTR-1 and a potential source of difference between the two
proteins, THTR-2-GFP fusion proteins with truncations from the carboxy-terminus region
were still polarised and inserted in the membrane in the same way as the full-length protein.
In a similar manner to THTR-1, modifications to the amino-terminus and the polypeptide
backbone prevented correct movement from the intracellular membrane structures to the
cell surface [Subramanian et al., 2006]. It is thus likely that THTR-1 and THTR-2 belong to
a growing family of proteins more heavily reliant on transmembrane polypeptide sequences
to direct their trafficking [Kundu et al., 1996; Lin et al., 1998; Dunbar et al., 2000].
Direct imaging of THTR-2-containing vesicles showed a rapid bi-directional traf-
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ficking process to and from the cell surface. This movement of THTR-2-containing vesicles
was faster than the movement of THTR-1 containing vesicles (average velocity of 2.3±0.1
versus 1.71±0.13 µm s−1 respectively). The movement can again be disrupted by inhibitors
of microtubule, but not microfilament, formation as was found with THTR-1. Microtubular
structures within MDCK cells are polarised with a minus end at the apical face and a plus
end at the basolateral face. Movement along the microtubules is conducted by dyneins (to
the minus end) and kinesins (to the plus end). The apical localisation of THTR-2 sug-
gests a role for dyneins in this process but further work is needed to characterise this fully
[Subramanian et al., 2006].
Figure 2.9: THTR-1 localisation. A: Left to right: Full length THTR-1-EGFP fusion
product in HuTu-80 duodenal epithelium cells (green); FM4-64—a lipophilic styryl dye
specific to the plasma membrane (red); Overlay of both plasma membrane and THTR-1-
EGFP confirming localisation of full length protein. B: Left to right: Truncated THTR-
1-EGFP demonstrating intracellular location; FM4-64 plasma membrane marker; overlay.
Adapted with permission from Subramanian et al. [2003].
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Figure 2.10: THTR-2 localisation. A: The targeting of THTR-2-GFP and GFP alone in
single MDCK cells in lateral (xy, left) and axial (xz, right) sections. B: The targeting
of THTR-2-GFP and GFP alone in single Caco-2 cells in lateral (xy, left) and axial (xz,
right) sections. C: The cumulative population measurements of axial polarity of THTR-2
expression, compared with known apical (p75) and basolateral (V1aR) markers. Reproduced
with permission from [Subramanian et al., 2006].
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Chapter 3
Introduction to glycosylation
and Sp1
Glycosylation is the process by which carbohydrate moieties, or glycans, are added to pro-
teins forming glycoconjugate products. These moieties are added by either a co-translational
or post-translational process and can range in size from a single monosaccharide unit to
large multimeric complexes comprising many monosaccharides. The GlcNAc-β-Asn linkage
in ovalbumin was the first glycosylation linkage described [Johansen et al., 1961] and since
then the field has expanded dramatically to include a wide range of linkages and chemistries
(reviewed by Spiro [2002]).
Glycans can be attached to proteins in one of several manners. An N -glycan, or
N -Asn-linked oligosaccharide, as the name suggests is joined by a β-glycosylamine link-
age to the nitrogen in the residual group of asparagine residues. In particular, the linkage
of N -acetylglucosamine (GlcNAc) monosaccharides to this residue is the most widely dis-
tributed of all glycosylations and forms the basis of many large and complex polysaccharide
moieties [Spiro, 1973]. O-glycans are linked through an active hydroxyl group in much the
same manner as phosphorylations, however their variety is much wider than that of phos-
phorylation. They are found on every species of hydroxyl containing amino acid residue:
serine, threonine, tyrosine and the non-standard amino acids hydroxyproline and hydroxy-
lysine. They are also found in a wide variety of anomeric configurations, both α- and
β-forms, and with a wide variety of carbohydrate moieties (Figure 3.1). Most O-linked
glycans are based around a molecule of N -acetylgalactosamine (GalNAc) linked to a serine
or threonine residue. This core is then extended into a variety of structure sub-classes. Due
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to this abundance, the term O-glycan is commonly used in the literature to refer specif-
ically to O-GalNAc-based glycans. Of course, other O-linked glycans exist and these are
usually referred to by specific names, e.g. O-GlcNAc. Other major classes of glycocon-
jugates also exist such as C-mannosyl linkages where an α-mannosyl residue is bound to
C2 of tryptophan through a carbon-carbon bond [de Beer et al., 1995], phosphoglycosyl
bonds where a carbohydrate is attached to a protein via a phosphodiester linkage [Haynes,
1998] and glycosylphosphatidylinositol (GPI) anchors in which mannose residues are used
with phosphoethanolamine and phosphatidylinositol to link proteins to a phospholipid mem-
brane. These other classes of structures are beyond the scope of this thesis and will not be
discussed further.
Figure 3.1: Schematic representation of known types of O-Linked sugar-peptide bonds. Hyp
is hydroxyproline; Hyl is hydroxylysine; GlcNAc is N -acetylglucosamine; Gal is galactose;
Ara is arabinose; Glc is glucose; FucNAc is N -acetylfucosamine; Xyl is xylose; Man is
mannose; GalNAc is N -acetylgalactosamine; Pse is pseudaminic acid; DiAcTridH is 2,4,-
diacetamido-2,4,6-trideoxyhexose. Adapted with permission from Spiro [2002].
3.1 The O-GlcNAc modification
It was the prevailing dogma for much of the last century that glycosylation occurred exclu-
sively on proteins that were either actively excreted from the cell or were destined to be
transported to the cell surface. By the mid 1980s this view was considered to be incom-
plete and is likely only to be true today for classical N -type glycans and O-glycans. Both
of these classes of glycan are dependent on glycosyltransferases with active sites contained
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within the ER or Golgi apparatus [Varki et al., 1999]. It is now evident that other types of
glycosylation exist. Proteins that are not excreted but remain in the nuclear or cytoplasmic
compartments can be glycosylated by a number of smaller modifications which are dynam-
ically added and removed post-translationally. A key example of this type of modification
is the addition of N -acetylglucosamine monosaccharide units via an O-linked β-linkage to
serine or threonine residues within polypeptides (Figure 3.2). This modification is known as
O-GlcNAc. It was first characterised systematically in 1983 in studies using radiolabelled
UDP-galactose and highly purified bovine galactosyltransferases which were used to tag
the O-GlcNAc residues [Torres and Hart, 1984]. These early studies were also the first to
conclusively demonstrate the location of O-GlcNAc in intracellular locations, rather than
the traditional extracellular realm of glycosylations where it is notably absent. O-GlcNAc
presence is widespread throughout multicellular eukaryotes having been seen in virtually all
studied systems [Comer and Hart, 2000]. In systems where it is present, it is essential and
its ablation is fatal, for example in mouse embryonic stem cells [Shafi et al., 2000].
Figure 3.2: The structure of O-Linked N -acetylglucosamine. O-GlcNAc transferase (OGT)
dynamically attaches N -acetylglucosamine to serine or threonine residues and O-GlcNAcase
removes the modification. The peptide shown represents a typical attachment site, however
there is no well defined consensus sequence. Adapted from Varki et al. [1999].
3.2 Control of O-GlcNAc cycling
The amount of O-GlcNAc present on serine and threonine residues in a protein, its “O-
GlcNAcylation” status, is rapidly and dynamically altered by a pair of enzymes in a man-
ner that is highly analogous to phosphorylation and dephosphorylation by kinases and
phosphatases. These enzymes are O-GlcNAc transferase (OGT; uridine diphospho-N -
acetylglucosamine:polypeptide β-N -acetylglucosaminyltransferase), which adds N -acetyl-
glucosamine units, and O-GlcNAcase which removes them. Since glycosylation and phos-
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phorylation can both potentially occur on the same amino acid residues, there exists a
complex dynamic interplay between the two modifications, frequently with multiple sites of
phosphorylation or glycosylation on the same protein, often on the same residues [Comer
and Hart, 2000]. Indeed, the treatment of cells with agents which promote phosphoryla-
tion, like okadaic acid—a phosphatase inhibitor, reduce O-GlcNAcylation whilst inhibition
of kinases leads to increased levels of O-GlcNAc [Griffith and Schmitz, 1999]. Unlike phos-
phorylation where there are many known pairs of kinases and phosphatases, the single pair
of enzymes involved in O-GlcNAc cycling suggests that changes to the rate of addition or
removal of the O-GlcNAc will have wide-reaching effects over the entire cell, rather than
specific effects on small sections of metabolism as with phosphorylation [Varki et al., 1999].
3.2.1 O-GlcNAc transferase
O-GlcNAc transferase (OGT; E.C. 2.4.1.-) catalyses the addition of N -acetylglucosamine to
serine or threonine residues within proteins using the activated precursor uridine diphosphate-
N -acetylglucosamine (UDP-GlcNAc) forming a β-glycosidic link. Its gene is found at Xq13
in humans [Shafi et al., 2000], it was cloned for the first time in 1997 and is highly evo-
lutionarily conserved [Kreppel et al., 1997]. The enzyme, as purified from rat liver, is a
heterotrimer comprising two 110 kDa α subunits and one 78 kDa β subunit [Haltiwanger
et al., 1992]. It is the α subunit which contains the active site. Each N-terminus of the
α-subunits contains at least 11.5 tetratricopeptide repeats—a structural motif made of 34
amino acid residues—[Blatch and La¨ssle, 1999; Kreppel et al., 1997] which facilitate the for-
mation of large complexes, not only containing the α and β-subunits but also other proteins
which can modify the activity and target specificity of the complex [Comer and Hart, 2000].
OGT activity is critically dependent on the abundance of its substrate UDP-GlcNAc.
UDP-GlcNAc occupies a unique central position in cellular metabolism with many key path-
ways combining to produce the molecule (Figure 3.3). It is because of this central position
and dependence on UDP-GlcNAc concentration that OGT is so exquisitely sensitive to the
metabolic status of the cell. In addition to the central position of UDP-GlcNAc in cellu-
lar metabolism, OGT is capable of being O-GlcNAcylated itself as well as phosphorylated
on tyrosine residues (which appears to activate the enzyme) [Kreppel et al., 1997]. It is
inhibited by UDP, in a potent negative feedback loop, and is sensitive to a range of UDP-
GlcNAc/UDP ratios which span the entire physiological range of nucleotide sugars. These
factors combine to add a further level of complexity to the regulation of the enzyme and
O-GlcNAcylation itself.
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3.2.2 O-GlcNAcase
A purified enzyme fraction which could catalytically remove O-GlcNAc from proteins was
isolated from rat spleen cytosol in by [Dong and Hart, 1994]. The enzyme activity was
specific to O-GlcNAc and was not affected by the presence of O-GalNAc, either as an
inhibitor or as a substrate. The enzyme was shown to have two subunits: a 54 kDa α subunit
and a 51 kDa β subunit. The apparent mass of the catalytically active enzyme indicates that
the molecule is an αβ heterodimer. The enzyme was first referred to as hexosaminidase C
and was observed to have a neutral pH dependence, as opposed to the acidic dependence of
the more extensively studied lysosomal hexosaminidases A and B [Varki et al., 1999]. More
recently, researchers studying the cytosolic hyaluronidase MGEA5 (meningioma expressed
antigen 5) deduced that this enzyme shared the same sequence as the enzyme with the
O-GlcNAcase activity and that the two proteins were splice variants [Comtesse et al., 2001].
Thus it is common in the literature for the protein to be referred to as O-GlcNAcase or
MGEA5. The term bifunctional protein NCOAT (nuclear cytoplasmic O-GlcNAcase and
acetyltransferase) is now also commonly used since the protein has multiple catalytic roles
including the acetylation of lysine residues in histone tails.
The nature of the regulation of O-GlcNAcase is not fully understood. It appears to
be found in protein complexes which often include OGT itself, particularly in the case of
transcription complexes. O-GlcNAcase also interacts with a large number of other proteins
within the cell but little detail is understood. What is known is that its activity is tightly
regulated in order to prevent futile cycling of O-GlcNAcylation within these complexes.
Figure 3.3: UDP-GlcNAc precursors. UDP-GlcNAc biosynthesis is crucially dependent on
many diverse areas of cellular metabolism. This unique position means that as a substrate
for OGT, it is sensitive to changes in many of these metabolic pathways. Adapted from
Varki et al. [1999].
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3.3 Functions of O-GlcNAc
The role of the O-GlcNAc modification is dependent on its exact location and the function of
the protein to which it is attached, much as is the case for phosphorylation. Understanding
of the role of the O-GlcNAc modification began to accelerate once researchers could reliably
detect the modification in situ. Early research was impeded because O-GlcNAc is partic-
ularly labile and was frequently lost during ionisation procedures used during mass spec-
trometery. Early strategies to combat this problem included direct chemical derivatisation
of O-GlcNAc [Vocadlo et al., 2003] and enzyme-linked derivatisation with a ketone-biotin
tag [Khidekel et al., 2003, 2004]. These techniques were complemented by the development
of a specific antibody against the O-GlcNAc modification which showed the true extent of
modification on cellular proteins. Figure 3.4 illustrates O-GlcNAcylation in an extract from
HeLa cells.
Figure 3.4: An extract from HeLaS3 cells were immunopurified using an O-GlcNAc specific
antibody. The resultant protein mix was separated using 2D gels and then silver-stained.
Large numbers of individual proteins can be seen to be O-GlcNAcylated. Reproduced from
Wells et al. [2001]
There are several known systems in which O-GlcNAc plays a part, some of which
are more relevant to this thesis than others. O-GlcNAc is known to be important in regu-
lating protein trafficking. For example, in neurons, O-GlcNAcylation of synapsin appears to
prevent the release of neurotransmitter-containing vesicles from the cytoskeleton, thereby
delaying or preventing neurotransmission [Cole and Hart, 1999]. Research on the role of
O-GlcNAc on synapsins began in 1991 [Lu¨thi et al., 1991] and is still an active area of
research today with recent papers being published on the potential role of O-GlcNAc in
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synaptic plasticity in the hippocampus e.g. [Tallent et al., 2009]. As an aside to this, O-
GlcNAc has also been implicated in the pathogenesis of several neurodegenerative diseases.
The locus for the OGT gene, Xq13, has been linked to Parkinson’s dystonia [Graeber et al.,
1992] and the O-GlcNAcase locus, 10q24.1 has been linked to late onset Alzheimer’s disease.
Direct inhibition of O-GlcNAcase appears to block tau phosphorylation in vivo [Yuzwa et al.,
2008] and tau O-GlcNAcylation itself appears to be important in development of aggregated
tau bundles [Gong et al., 2006].
Protein turnover is also affected by O-GlcNAcylation. Several core parts of the
26S proteasome are O-GlcNAcylated which appears to inhibit ATPase activity of the pro-
teasome, thereby lowering proteolytic capacity e.g. [Zhang et al., 2007]. Also, there is a
definite link between O-GlcNAc and ubiquitination itself; the two processes aren’t com-
pletely antagonistic but ubiquitination appears to be modulated by O-GlcNAcylation with
E1, the ubiquitin activating enzyme, being O-GlcNAcylated [Guinez et al., 2008]. Reduced
glycosylation of the transcription factor Sp1 has been shown to be associated with increased
proteasome susceptibility [Han and Kudlow, 1997].
Perhaps most importantly, O-GlcNAc modification is heavily involved with the regu-
lation of transcription and translation. The direct O-GlcNAcylation of several transcription
factors is important to modify their function. Such modified transcription factors include
NF-κB, p53, c-Myc, CREB and Sp1 [Zachara and Hart, 2004]. In addition, basal transcrip-
tion factors such as the eukaryotic initiation factor 4A1, parts of the ribosome and RNA
polymerase II are modified [Zachara and Hart, 2004; Jackson and Tjian, 1989]. This opens
up a massive potential for cellular regulation by O-GlcNAcylation.
3.4 O-GlcNAc in diabetes
O-GlcNAc levels are intrinsically linked to the availability of UDP-GlcNAc which in turn is
dependent on the availability of glucose. Flux through the hexosamine biosynthesis pathway
(HBP) which produces the UDP-GlcNAc normally accounts for 2–5% of the total glycolytic
flux. Under conditions of elevated glucose or glycolytic inhibition (for example, increased
free fatty acid metabolism inhibits pyruvate oxidation [Hawkins et al., 1997]) higher absolute
fluxes pass through the HBP leading to elevated UDP-GlcNAc levels and higher rates of
O-GlcNAcylation. This provides a link between elevated O-GlcNAc levels with diabetes, in
which glucose levels are inherently unstable and hyperglycaemia is common, and increased
flux through the HBP which has long been implicated in hyperglycaemic toxicity [Brownlee,
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2001]. There is much evidence that hyperglycaemia is responsible for increased flux through
the HBP in a wide variety of systems. Pang et al. [2004] report how HBP flux is increased in
neonatal rat cardiomyocytes in hyperglycaemia and Rajamani and Essop [2010] also report
that hyperglycaemia induces the HBP leading to apoptosis in the myocardium. Pantaleon
et al. [2010] ascribe the toxic effects of hyperglycaemia on early mouse embryos to increased
flux through the HBP and James et al. [2002] propose that hyperglycaemia causing increased
flux through the HBP is responsible for determining transcription of NF-κB-dependent genes
in mesangial cells.
The ultimate effect of increased flux through the HBP is increased O-GlcNAcylation.
A multitude of studies have been published which attempt to link increased O-GlcNAcylation
with the complications of diabetes. Teo et al. [2010] reviewed studies demonstrating that in-
creased HBP flux in adipocytes leads to an impairment in insulin-dependent glucose uptake
i.e. insulin resistance. Further studies increased the HBP flux by a variety of means including
glucosamine infusion (bypassing the flux-controlling GFAT at the start of the HBP pathway,
[Virkama¨ki et al., 1997; Rossetti et al., 1995]), GFAT transgenic mice [Hebert et al., 1996;
Hazel et al., 2004] and OGT transgenic mice [McClain et al., 2002]. In each case, levels of
O-GlcNAc increased and insulin resistance was observed. In addition, McClain et al. [2002]
found deoxynorleucine, an inhibitor of GFAT, prevented this observed insulin resistance,
confirming that it is the combination of OGT and UDP-GlcNAc that is important. Work
conducted by Fu¨lo¨p et al. [2007] on the myocardium in Zucker diabetic fatty (ZDF) rats
showed elevated cellular UDP-GlcNAc and concomitant O-GlcNAcylation. However, there
was no change in OGT expression suggesting that it is increased flux through the HBP that
is crucial in this model. The myocardium was observed to exhibit several characteristics
typical of type 2 diabetic cardiomyopathy including delayed calcium sequestration and im-
paired mechanical relaxation. More recently, research with kidney sections from patients
suffering from diabetic nephropathy by Degrell et al. [2009] has shown that the number of
nuclei which stain positive for O-GlcNAc in diabetic glomeruli is significantly higher than
for control kidneys.
In summary, it is now clear that hyperglycaemia, hyperlipidaemia and insulin can all
affect O-GlcNAcylation and that the dysregulation of this important means of modification
of cellular transcription is likely to be a key culprit in the aetiology of diabetic complications
[Hart et al., 2007; Dias and Hart, 2007].
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3.5 The Sp family of transcription factors
The Sp family of transcription factors constitutes half of a major group of transcription
factors called the Sp/KLF family (KLF: Kru¨ppel-like factor, so named because of its ho-
mology to the Drosophila protein Kru¨ppel). There have been eight members of the Sp
family discovered to date. The first, Sp1, was characterised in 1987 after an earlier discov-
ery [Dynan and Tjian, 1983; Kadonaga et al., 1987, 1988] whilst more recently discovered
members of the family have been numbered incrementally. The name Sp originally referred
to the purification scheme for the protein which included Sephacryl and phosphocellulose
columns. However, more recently other expansions have been attached to the abbreviation
including “specificity protein” and “stimulating protein”. Each member of the family con-
tains three highly conserved Cys2His2 zinc-finger domains for binding specific sequences of
DNA known as GC boxes (consensus sequence 5'–GGGGCGGGG–3') or GT boxes (con-
sensus sequence 5'–GGTGTGGGGG–3') [Letovsky and Dynan, 1989; Philipsen and Suske,
1999]. Not all members of the Sp family have been studied equally; Sp1 and Sp3 have
been more thoroughly studied compared to other members of the family. Sp2 appears to be
expressed ubiquitously but there is little data on specific tissue expression levels [Kingsley
and Winoto, 1992]. Sp4 is found only in the developing testes and the brain, Sp7 is involved
in osteoblast differentiation [Nakashima et al., 2002] and the expression characteristics of
the other members of the family have yet to be investigated thoroughly [Waby et al., 2008].
3.5.1 Sp1 transcription factor
As a key ubiquitous transcription factor, Sp1 expression is essential for life: Sp1 null mice die
around embryonic day 11 after a period of retarded development [Marin et al., 1997]. Sp1
has a molecular mass of around 81 kDa and shares structural similarity with other members
of the Sp family (Figure 3.5). Both Sp1 and Sp3 have been shown to be bifunctional
as transcriptional regulators. Whether they activate or repress transcription of a particular
gene depends on the cell type and the promoter although the mechanisms behind this process
are poorly understood. As an example, Sp1 has been shown to repress transcription of the
human adenine nucleotide translocase-2 (ANT2) promoter [Zaid et al., 2001] yet it promotes
transcription of the thiamine transporters THTR-1 and THTR-2 [Reidling and Said, 2003;
Nabokina and Said, 2004]. The situation isn’t clear even when a gene has been determined
as “activated” or “repressed” by Sp1 since the influence of other factors can change the
activity of Sp1 in a given situation; the presence of platelet-activating factor prevents the
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repression of MMP-9 expression by Sp1 in human corneal epithelial cells [Taheri and Bazan,
2007].
Sp1 is capable of synergistic activation where a promoter element contains multiple
Sp1 binding sites. Sp1 appears to achieve this through a direct protein-protein interaction
which loops the intervening DNA, something that Sp3 is incapable of [Mastrangelo et al.,
1991; Su et al., 1991]. Sp1 also appears to play a key role in regulating the methylation
pattern of genes by maintaining methylation-free CpG islands for many promoter elements,
mainly house-keeping genes. Sp1 exerts transcriptional control over a large number of genes
spread over virtually the entire genome but with strong emphasis on genes involved in the
synthesis and metabolism of nucleotides along with cell cycle-related genes. Importantly for
this thesis, the promoter elements for the thiamine transporters contain Sp1 binding sites.
Figure 3.5: Structure of the Sp family from Sp1 to Sp4. This figure shows the structure of
the lower part of the Sp family with key domains highlighted. The two activator domains
are each capable of stimulating transcription when bound to DNA through a DNA-binding
zinc-finger domain. The serine and threonine rich regions are involved with most post-
translational modification, especially phosphorylation and glycosylation. The buttonhead
domain is in a highly charged region of the protein and is used for synergistic activation by
sterol-regulatory element-binding proteins. [Li et al., 2004; Solomon et al., 2008].
Notably, the promoter elements for genes regulated by Sp1 are often missing the
TATA box for binding TATA-binding protein (TBP) and recruitment of the associated
TBP-associated factors (TAFs) [Kadonaga et al., 1987]. Instead, Sp1 is capable of binding
to transcription factor TFIID via TATA binding protein associated factors TAFII130 and
TAFII55 before recruiting the RNA polymerase RNAPolII directly [Gill et al., 1994; Solomon
et al., 2008]. It has been estimated by Letovsky and Dynan that there are between 5000
and 10 000 copies of Sp1 within a mammalian cell which corresponds to an intranuclear
concentration of between 1.25–2.5× 10−7 M [Letovsky and Dynan, 1989].
3.5.2 Sp1 post-translational modifications
The fact that Sp1 is capable of being O-GlcNAcylated was first demonstrated by Jackson
and Tjian [1988] who noted that Sp1 could be purified using its affinity for wheat germ
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agglutinin. We now know that members of the Sp family can accept a wide range of post-
translational modifications with residues spread throughout their structures that can accept
phosphorylation, O-GlcNAcylation, acetylation, ubiquitination and SUMOylation (small
ubiquitin-like modifier). Sp1 is capable of being glycosylated on at least eight different
residues with sites scattered throughout the structure. Some are located in the serine
and threonine rich regions highlighted in Figure 3.5 but others are located in regions such
as the zinc finger domains. Despite being thought of as a basal transcription factor, the
large number of post-translational modifications that the Sp1 can accept means that it is a
perfect candidate for modulating gene expression in response to hormonal and other factors
(reviewed by Solomon et al. [2008]).
Before discussing modifications in detail, one important factor which should be
reiterated is that serine and threonine residues are potential targets for both glycosylation
and phosphorylation. This conflict is not hypothetical but very real. A common conclusion
in the Sp1 field is that this competition is key and that both phosphorylation and O-
GlcNAcylation occur on the same residues at different times (reviewed by Wells et al. [2001]).
Modifications to Sp1 appear to alter its function in several ways. Often, a modi-
fication will alter the sub-cellular location of the transcription factor, thereby altering its
transcriptional activities. Alternatively, the modifications either promote or inhibit protein-
protein interactions with varied consequences. In many cases, these modifications are driven
by an external factor such as insulin. These will be discussed in turn below.
3.5.3 Translocation of Sp1 to the nucleus
Like many transcription factors, Sp1 can be found both in the nucleus, where it can be
active, and the cytosol, where it is transcriptionally inactive. Its location appears to be
determined by its phosphorylation and glycosylation status. Studies in liver cells have
shown that insulin treatment leads to O-GlcNAcylation of Sp1 followed by a translocation
to the nucleus within 30 minutes. By 240 minutes, O-GlcNAcylated Sp1 in the nucleus
had diminished to negligible levels. Meanwhile, phosphorylated Sp1 levels increased in the
nucleus during the same time period. The researchers concluded that O-GlcNAcylation is
critical for nuclear translocation followed by phosphorylation (often on the same residues)
for activation of its transcription factor functions [Majumdar et al., 2004, 2006]. Other
studies such as work on rat lymphoma cells by Dauphinee et al. [2005] have also linked
O-GlcNAcylation of Sp1 with nuclear translocation. This potential mode of action is shown
in Figure 3.6A.
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3.5.4 Insulin and Sp1
Insulin not only appears to affect short term glycosylation of Sp1; it also modulates long-
term Sp1 abundance. Studies on insulin deprivation in H-411E hepatocyte cells by Pan
et al. [2001] showed a drop in Sp1 concentration. Furthermode, low basal levels of liver
Sp1 were markedly increased upon administration of insulin in the streptozotocin-induced
diabetic rat [Pan et al., 2001]. Paradoxically, glucagon also has a similar effect on Sp1
concentrations. Glucagon would normally be expected to be an antagonist to the actions of
insulin but in the same H-411E hepatocyte system, glucagon treatment led to an increase
in Sp1 steady-state concentrations although this appears to be through a cAMP dependent
pathway [Keembiyehetty et al., 2002]. Additionally, Walgren et al. [2003] demonstrated that
hyperglycaemia and insulin are both capable of increasing the glycosylation of Sp1 with each
re-enforcing the actions of the other.
This means that insulin not only affects the short-term glycosylation status of Sp1
(and thus its subcellular location and activity) but also its long-term abundance in the cell.
This appears to be where the actions of insulin and glucagon differ because only insulin,
and not glucagon, is capable of altering the glycosylation status of Sp1 [Keembiyehetty
Figure 3.6: The roles of O-GlcNAcylation of Sp1. The conflicting roles of Sp1 O-
GlcNAcylation are shown in this figure adapted from O¨zcan et al. [2010]. A: O-
GlcNAcylation of Sp1 has been shown to promote nuclear translocation and activation
of transcription [Majumdar et al., 2004, 2006]. B: Sp1 O-GlcNAcylation can also lead
to repression of transcription by recruitment of the co-repressor protein mSin3A by OGT
[Yang et al., 2002]. C: Other studies have shown that modification of Sp1 by O-GlcNAc can
disrupt its interaction with TAF110, thereby repressing transcription. [Roos et al., 1997]
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et al., 2002]. In summary, the action of insulin on Sp1 appears to increase long-term Sp1
levels and also short-term O-GlcNAcylation which leads to nuclear translocation of Sp1 and
subsequent activation of transcription.
3.5.5 Other effects of Sp1 glycosylation
The nuclear translocation of Sp1 by glycosylation is in contrast to other functions of
O-GlcNAcylation of Sp1. Whereas translocation to the nucleus would appear to increase
transcription, Yang et al. [2002] have shown that OGT recruitment to Sp1 in the nucleus
can glycosylate Sp1 and simultaneously recruit the corepressor mSin3A which represses
transcription (Figure 3.6B).
O-GlcNAc has also been implicated in the susceptibility of Sp1 to proteolytic degra-
dation. Han and Kudlow [1997] artificially altered the glycosylation status of many proteins
in normal rat kidney (NRK) cells and MDA-468 breast cancer cells with 5 mM glucosamine.
This bypassed the enzyme with most control over flux into the hexosamine biosynthesis
pathway and led to hyperglycosylated Sp1. Complementarily, they used glucose starvation
coupled with cAMP stimulation of the same cells to induce a hypoglycosylated state with
nearly all Sp1 being non-glycosylated. After this depletion of glycosylation, Sp1 became
very susceptible to proteolytic degradation by the proteasome. Additional work by Kud-
low’s group [Roos et al., 1997] has shown that O-GlcNAcylation of Sp1 blocks its ability to
interact with TAF110 which represses its transcriptional activation abilities (Figure 3.6C).
Kang et al. [2003] used 2-deoxyglucose, a non-metabolizable glucose analogue which
mimics glucose starvation. In this system they showed that despite mimicking a low glu-
cose environment in the cells, Sp1 was counter-intuitively hyper -glycosylated yet its Sp1-
dependent gene expression was lower. The Sp1 field is full of controversey similar to this
and in a recently published review on glycosylation of transcription factors, O¨zcan et al.
[2010] highlight how little we fully understand about how the glycosylation of Sp1 affects its
activity. The exact result of glycosylation in any given circumstance appears to be difficult
to predict and empirical data needs to be sought for any given situation. In addition to
these complex observations, little work has been done on the sites of glycosylation. It may
be that the effects are very much site-dependent, something not seen in studies to date.
3.5.6 Sp1 phosphorylation
A large number of studies have been performed on the effects of phosphorylation on Sp1.
The consensus opinion is that phosphorylation leads to a higher affinity of Sp1 for DNA—
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and with it more active transcription of the target gene—whilst dephosphorylation leads to
a decreased affinity for DNA and decreased transcription. Often the phosphorylation sites
occur within the zinc finger domains which has lead to suggestion that the phosphorylation
is altering the structure of the zinc finger and increasing its affinity for the DNA [Waby
et al., 2008].
Recent work by Chuang et al. [2008] has shown that the phosphorylation of Sp1
appears to be important for its stability during mitosis. This is contrary to much evidence
which says that overall, phosphorylation of Sp1 appears to target it for proteolytic degra-
dation, specifically phosphorylation on serine 7 with proteolytic processing being regulated
by phosphorylation on serine 59 [Spengler et al., 2008]. In contrast, Vicart et al. [2006]
suggest that it is dephosphorylation of Sp1 that is important for its stability and activity
during transcription of genes involved in cell division. It is clear from the controversy in the
literature that the understanding of the function of phosphorylation on Sp1 is incomplete.
3.5.7 Sp1 and the thiamine transporter genes
Analysis of the promoter elements of each member of the SLC19Ax family, which includes
the thiamine transporters, has demonstrated that each contains at least one GC box which
binds Sp1 and other members of the Sp family. In each case, analysis showed that the
presence of Sp1 was essential for basal transcription of the gene with an almost complete
ablation of promoter activity following introduction of GC-box sequence oligonucleotides to
compete for the available Sp1 (SLC19A1 : 3 GC boxes [Tolner et al., 1999]; SLC19A2 : 1 GC
box [Reidling and Said, 2003]; SLC19A3 : 2 GC boxes [Nabokina and Said, 2004]). Likewise,
the basal expression of each of the genes for THTR-1 and THTR-2 could be diminished by
mutating the GC-box sequence in each promoter element [Reidling and Said, 2003; Nabokina
and Said, 2004]. Studies in the Sp-deficient Drosophila SL2 cell line showed that either Sp1
or Sp3 could activate SLC19A3 transcription in a dose-dependent manner [Nabokina and
Said, 2004]. Therefore it remains unclear which protein is required in vivo as either may
perform the activation. None of these studies investigated the effects of glycosylation of Sp1
on the efficiency of induction of transcription.
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Chapter 4
Project-specific background
4.1 Thiamine deficiency in diabetes
Chronic thiamine deficiency is associated with the classical diseases beri-beri [Tanphaichitr
et al., 1970] and Wernicke-Korsakoff syndrome (which comprises Wernicke’s encephalopathy
and Korsakoff’s associated psychosis) [Butterworth, 2003; Pannunzio et al., 2000]. These
are only observed in patients who have a severe, chronic deficiency of thiamine which could
be due to a diet lacking the vitamin (i.e. malnutrition), chronic alcoholism (the most
common reason for presentation with severe thiamine deficiency in the developed world)
or increased clearance of thaimine in renal dialysis or HIV/AIDS (reviewed by Thornalley
[2005]). Thiamine deficiency is conventionally assessed by means of the thiamine effect,
or percentage unsaturation of transketolase with its cofactor TPP (Section 2.7). None of
the likely reasons for a severe thiamine deficiency are are associated with diabetes mellitus
but a mild thiamine deficiency may well be present in the diseased state. This has been
considered for a long time [Janes and Brady, 1948] but only recently has more detailed study
been undertaken.
The evidence for a mild thiamine deficiency in diabetic patients has mounted since
the 1960s from a series of small observation trials. A Norwegian study conducted by Haugen
[1964] demonstrated a 27% decrease in whole blood thiamine in 21 type 1 diabetes patients
but no decrease in 12 type 2 diabetes patients. A Japanese survey of thiamine status in 7
type 1 and 39 type 2 moderately well controlled diabetic patients was conducted [Saito et al.,
1987]. It concluded that 79% of diabetic patients had an erythrocyte TK activity below the
normal minimum and 76% had a plasma thiamine concentration lower than the normal min-
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imum. An Israeli study of 100 type 2 diabetic patients with a mean HbA1 of 9.2% showed
that erythrocyte TK activity was below the normal minimum in 18% of patients [Havivi
et al., 1991]. In addition, a small study conducted by Valerio et al. [1999] in Italy examined
the thiamine status of 10 type 1 diabetic patients and found that plasma thiamine concen-
tration was 34% lower than normal controls and could be normalised in a placebo-controlled
trial with 50 mg day−1 of the thiamine derivative benzoxymethyl-thiamine. Furthermore, a
study in Hungary conducted by Jermendy [2006] investigated erythrocyte transketolase ac-
tivity in seventy five diabetic patients (13 type 1 and 62 type 2 with a mean HbA1c of
9.6%) and showed that the thiamine effect was significantly higher in diabetic patients that
controls (14%±1% versus 8%±2%). Five of the patients were treated for seven days with
320 mg Benfotiamine daily and a significant decrease in their thiamine effect was observed
(10%±3% versus 2%±2%) [Jermendy, 2006] suggesting therapy with thiamine derivatives
may be beneficial.
Most recently, our laboratory studied the thiamine status of 26 type 1 and 48 type 2
diabetic patients with and without microalbuminuria in the Colchester region along with 20
normal healthy control volunteers [Thornalley et al., 2007]. We found that the plasma thi-
amine concentration, as measured by HPLC, was decreased 76% in type 1 diabetic patients
and 75% in type 2 diabetic patients (median concentrations (95% confidence intervals):
normal volunteers 64.1 nM (58.5–69.7 nM), type 1 diabetic patients 15.3 nM (11.5–19.1 nM;
p < 0.001) and type 2 diabetic patients 16.3 nM (13.0–19.6 nM; p < 0.001); Figure 4.1). This
decrease in plasma thiamine concentration was linked to a marked increase in renal clear-
ance and fractional excretion of thiamine in the diabetic state. Renal clearance rates were
increased 24-fold in type 1 diabetes and 16-fold in type 2 diabetes (median clearance rates
were 3.7, 86.5 and 59.8 mL min−1 in control, type 1 and type 2 diabetic patients respectively)
and fractional excretion was increased 25-fold in type 1 diabetic patients and 15-fold in type
2 diabetic patients (median fractional excretion was 2.8%, 71.2% and 41.6% in control, type
1 and type 2 diabetic patients respectively). There was no evidence of a nutritional defi-
ciency of thiamine as judged by urinary thiamine in the normal range (> 0.20 µmol day−1
[Finglas, 1993]). Rather, plasma thiamine concentration negatively correlated with both
renal clearance and fractional excretion of thiamine suggesting that the plasma thiamine
deficiency was linked to renal mis-handling of filtered thiamine i.e. a substantial decline
in tubular re-uptake of thiamine in diabetes. Additionally, plasma thiamine concentration
and urinary excretion of thiamine negatively correlated with the concentration of soluble
vascular cell adhesion molecule 1 (sVCAM-1), a marker of vascular dysfunction.
71
Interestingly the same study revealed why clinical thiamine deficiency in diabetes
has gone unreported: erythrocyte TK activity, the primary clinical measure of thiamine
deficiency [Haas, 1988], was not significantly different between control patients and diabetic
patients, that is all patient values were below 15%. Further investigation showed that the
plasma deficiency was masked by increased abundance of THTR-1 and the TMP-transporter
RFC-1 in erythrocyte membranes which maintained intracellular thiamine concentrations
despite the low plasma abundance. These transporters are likely up-regulated in erythrocyte
precursors in reponse to the low thiamine concentration in plasma. In confirmation, direct
analysis of intra-erythrocyte thiamine concentrations by HPLC showed no difference between
diabetic patients and control volunteers, confirming that the higher abundance of transporter
protein was masking plasma thiamine deficiency.
Figure 4.1: Diabetic thiamine deficiency. This frequency distribution shows that diabetic
patients have marked plasma thiamine deficiency. Data in the inset represent median values
for 20, 26 and 48 patients for control, type 1 and type 2 diabetes respectively. Adapted with
permssion from Thornalley et al. [2007].
A small study in Australia published by Vindedzis et al. [2008] surveyed the thiamine
intake status of 113 diabetic patients with both type 1 and 2 diabetes. They found that
only 15.7% of patients not taking thiamine supplements had a low level of intra-erythrocyte
thiamine. Vindedzis et al. [2008] concluded that supplementation with thiamine at ap-
proximately three times the recommended daily intake rate (>4 mg daily in Australia) was
significantly correlated with normal erythrocyte thiamine levels but that adequate thiamine
intake within the normal dietary range was not.
72
4.2 Thiamine and biochemical dysfunction in vitro
The effects of hyperglycaemia on human erythrocytes was studied by Thornalley et al. [2001].
They noted that supplementation with thiamine alleviated some of the hyperglycaemia-
induced biochemical dysfunction. Specifically, incubation of the cells with 50–500µM thi-
amine led to an increase in the activity of transketolase, a decrease in the concentration
of the triosephosphate pool, a decreased rate of formation and concentration of methylgly-
oxal and increases in the concentrations of two pentose phosphate pathway intermediates,
sedoheptulose-7-phosphate and ribose-5-phosphate. This effect was explained by the stim-
ulation of the pentose phosphate pathway and a concomitant increase in activity of the
non-oxidative branch of the PPP by thiamine in a manner as described above (Section 4.4
and Figure 4.2).
Other studies exposed bovine aortal endothelial cells to hyperglycaemic conditions
and researchers noted an increase in membrane-localised PKC activity along with activation
of poly (ADP-ribose) polymerase [Du et al., 2003], increases in intracellular UDP-GlcNAc
and AGE concentration and activation of NF-κB, a transcription factor sensitive to oxida-
tive damage. Each of these pathways of damage was blocked by the addition of 50–100 µM
Benfotiamine (S -benzoylthiamine O-monophosphate) to the culture conditions [Hammes
et al., 2003; Mabley et al., 2004]. Further work in bovine aortal endothelial cells has demon-
strated that thiamine can prevent hyperglycaemia-induced delay in replication [Selva et al.,
1996] and increase in von Willebrand factor [Ascher et al., 2001].
Work by Porta’s group on bovine retinal pericytes and human umbilical vein en-
dothelial cells (HUVECs) in vitro has shown that both thiamine and Benfotiamine act
to prevent hyperglycaemia-induced decreases in replication, increases in apoptosis and in-
creases in AGE accumulation [Beltramo et al., 2004; Selva et al., 1996]. In addition, in
human retinal pericytes, both treatments prevented apoptosis induced by hyperglycaemia-
conditioned extracellular matrix [Beltramo et al., 2009], corrected the increase in matrix
metalloproteinase-2 (MMP-2) caused by hyperglycaemia and also increased the expression
of tissue inhibitor of metalloproteinase-1 (TIMP-1) [Tarallo et al., 2010]. In HUVECs,
thiamine and Benfotiamine both ameliorate the hyperglycaemia-induced activation of the
polyol pathway by mediating an increase in transketolase activity and a decrease in aldose
reductase mRNA and expression [Berrone et al., 2006].
73
4.3 Thiamine intervention therapy in vivo
In 2003, Babaei-Jadidi et al. [2003] published the results of a study of both thiamine and
Benfotiamine supplements at both a low and high concentration (7 or 70 mg kg−1 day−1)
given to streptozotocin-induced diabetic rats receiving low-dose insulin to moderate the
diabetes for six months. They demonstrated that both thiamine and Benfotiamine were
capable of preventing the onset of diabetic nephropathy as judged by the prevention of
microalbuminuria. Thiamine and Benfotiamine were also effective in lowering the accumu-
lation of AGEs in renal glomeruli, retina, sciatic nerve, urine and plasma [Karachalias et al.,
2010a]. This result was achieved without affecting plasma glucose concentration or glycated
haemoglobin. Benfotiamine also prevented hyperfiltration in diabetic animals relative to
control diabetic animals. Both thiamine and Benfotiamine also corrected increased renal
clearance of thiamine, glucosuria and increased diuresis. Whilst investigating the mode
of action, they noted that both thiamine and Benfotiamine supplementation increased the
plasma thiamine concentration in all tested groups which subsequently increased transke-
tolase activity; transketolase abundance was only increased in the 70 mg kg−1 day−1 group.
This diverted triosephosphates to ribose-5-phosphate and led to a decrease in PKC activity,
a decrease in AGEs and a decrease in oxidative stress as measured by plasma thiol con-
centration. A plasma thiamine deficiency of 50–70% was also noted in the unsupplemented
diabetic rats relative to the normal control rats: plasma thiamine concentration was 50–70%
lower in diabetic rats.
Hammes et al. [2003] investigated the effects Benfotiamine on the development of
retinopathy in Wistar rats as judged by the increase in formation of retinal acellular capil-
laries. High dose supplementation at 80 mg kg−1 day−1 was sufficient to prevent significant
increase in the number of capillaries compared to control animals.
Further studies in streptozotocin-induced diabetic Wistar rats have investigated
the progression of neuropathy as judged by decreased nerve conduction velocity (NCV).
Therapy with high dose thiamine and Benfotiamine (70 and 100 mg kg−1 day−1 respectively)
prevented the decrease in NCV along with preventing accumulation of AGEs [Stracke et al.,
2001]. Diabetic neuropathy has also been studied in humans. Diabetic patients (n = 24)
received Benfotiamine at 80 mg day−1, pyridoxine at 180 mg day−1 and cyanocobalamin at
0.5 mg day−1 for two weeks followed by a ten week period at half dosages showed a significant
increase in NCV relative to placebo [Stracke et al., 1996]. Of course, the results in this study
may not be specific to Benfotiamine.
Thiamine and Benfotiamine supplements have also been evaluated for their effect
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against cardiomyopathy [Ceylan-Isik et al., 2006; Kohda et al., 2008]. Thiamine treatment
prevented decline in glycaemic control of streptozocin-induced diabetic rats in a manner
linked to residual β-cell function [Karachalias et al., 2010b]. Thiamine reduced plasma
glucose and leptin concentration in drug na¨ıve type 2 diabetic patients [Gonza´lez-Ortiz
et al., 2010]. Also, the Hoorn study linked low dietary thiamine to progression of patients
to impaired glucose tolerance (IGT) and type 2 diabetes [Bakker et al., 1998]. Thus there
may be beneficial effects of thiamine therapy in the prevention of loss of glycaemic control
in IGT and early stage type 2 diabetes.
4.4 Mode of action for thiamine therapy
There are several theories that attempt to explain the link between hyperglycaemia and
diabetic complications. As previously discussed, these include increased flux through the
polyol pathway, increased production of AGEs, activation of protein kinase C and activation
of the hexosamine biosynthesis pathway. All of these pathways are likely to be linked through
an overproduction of superoxide by the mitochondria. The common feature behind each of
these theories is the accumulation of intracellular glucose in endothelial cells, mesangial
cells and podocytes which have high expression of the glucose transporter GLUT1 [Heilig
et al., 1995; Coward et al., 2005]. This high intracellular glucose concentration then leads
to an increase in glycolytic intermediates and in particular a build-up of triosephosphates.
These accumulating glycolytic intermediates are the driving force behind each of the theories
explaining dysfunction.
Thiamine therapy uses a novel approach to potentially address this increase in inter-
mediate accumulation. By increasing the activity of the cytosolic enzyme TK, it boosts flux
through the reductive pentose phosphate pathway. The reductive PPP allows an alternative
route for diversion of these intermediates and thus increasing its activity diverts potentially
damaging glycolytic intermediates such as glyceraldehyde-3-phosphate into relatively low
reactivity metabolic products such as ribose-5-phosphate (Figure 4.2). It is through this
pathway that thiamine therapy is proposed to act.
4.5 The HK-2 cell line
The HK-2 cell line is used in this project as an in vitro model of the human proximal
tubule epithelium. It was produced by Ryan et al. [1994] from a primary culture grown
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from normal human adult male renal cortex. The culture was exposed to a recombinant
retrovirus containing the human papilloma virus (HPV 16) E6 and E7 genes. This method
of transduction has been shown to immortalise many diverse types of epithelial cells without
changing their function (e.g. [Halbert et al., 1991; Hawley-Nelson et al., 1989]). The E6 and
E7 gene products bind to DNA regulation proteins and promote cell proliferation without
causing deviation from normal controls on growth such as cell-cell adhesion and anchorage
dependency. This means that cells immortalised in this manner are more like the original
cells than many highly transformed cell lines.
Ryan et al. verified the identity of their stably transfected cell line by comparison to
primary cultures of the same cells. Adenylate cyclase activity in response to parathormone
and antidiuretic hormone was measured—proximal tubules respond with an increase in
adenylate cyclase activity to parathormone but not to antidiuretic hormone. α-methyl
glucopyranoside cell uptake (a marker of glucose transport) was assessed in the presence of
sodium chloride and phlorizin (uptake is sodium dependent and inhibited by phlorizin) and
found to be similar to primary cultures of proximal tubule epithelium cells.
Figure 4.2: Schematic showing the hypothesis behind high-dose thiamine therapy and alle-
viation of symptoms of hyperglycaemia.
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Chapter 5
Aims and hypotheses
Previous research by this group has shown that diabetic patients have a marked decrease in
plasma thiamine concentration and a concomitant increase in renal clearance of the vitamin
[Thornalley et al., 2007]. It is the primary aim of this project to identify and attempt to
characterise the mechanism behind this plasma thiamine deficiency. It is the hypothesis
of this thesis that it is this increased renal clearance which is responsible for the reduced
plasma thiamine concentration.
To examine the increased renal clearance of thiamine, the project will follow several
in vitro strategies. Firstly, the location of the thiamine transporters THTR-1 and THTR-2
in the human kidney will be determined. These are responsible for the salvage of filtered
thiamine and are thus of crucial importance. No prior work has demonstrated the location of
these transporters in human kidney sections. Work studing the MDCK canine cell line and
rabbit proximal tubules suggests that the transporters are located in the proximal tubule
[Mahajan and Acara, 1994]. The high degree of similarity between all mammalian systems
suggests that the location will be similar in humans but this will be verified with normal hu-
man kidney samples. Formalin-fixed and paraffin-embedded human kidney sections will be
stained using immunohistochemistry and antibodies against human THTR-1 and THTR-2
to demonstrate the location of the transporters.
The mechanism behind the increased renal clearance will also be investigated. The
working hypothesis is that the increased renal clearance is due to decreased uptake of thi-
amine from the glomerular ultrafiltrate. This hypothesis is consistent with known facts.
Thiamine, as a small molecule, is filtered through the glomerular basement membrane and
into the ultrafiltrate. Once in the proximal tubule, it is only the activity of transporter
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proteins which maintains plasma levels of key metabolites that are filtered by the glomeruli.
Thus two scenarios are possible; either thiamine is more prone to filtration in the diabetic
state or its re-uptake into the plasma is impaired. If the first scenario were true and filtration
were increased at the glomerulus, it would stand to reason that this would be concomitant
with an increase in GFR since there is no active excretion of thiamine (or any other small
metabolite) in the glomerulus. Despite the increase in GFR often seen in diabetes patients,
this does not account for the increased excretion so the second scenario has been adopted
as a working hypothesis i.e. that there is a failure in re-uptake of the vitamin. This work
will be conducted in both an immortalised proximal tubule epithelial cell (PTEC) model
cell line and in primary PTECs from a normal human kidney.
The proposed mechanism behind the expected decrease in re-uptake of thiamine
is based upon the transcription factor Sp1 and the products of the hexosamine biosyn-
thesis pathway. In the diabetic state, an excess of available glucose drives a higher flux
through many pathways, including the HBP ([Brownlee, 2001] and Section 3.4). Increased
flux through the HBP leads to increased concentrations of UDP-N -acetylglucosamine, the
precursor for enzymatic glycosylation. This in turn leads to elevated levels of O-GlcNAc
on cellular proteins (Section 3.4). One such protein which is likely to be glycosylated to
a higher extent in the diabetic state is the transcription factor Sp1 which is one of the
factors responsible for the initiation of transcription of the thiamine transporters THTR-1
and THTR-2. It is the hypothesis of this thesis that the increased levels of glycosylation of
Sp1 lead to a decrease in the expression of the thiamine transporters with a concomitant
decrease in thiamine re-uptake in the kidney. Sp1 glycosylation is known to be important
for the transcription of many genes but has not been demonstrated for the thiamine trans-
porters. This hypothesis will be investigated by assessing mRNA and protein abundance
of proteins involved in O-GlcNAcylation as well as assessing the glycosylation status of the
Sp1 transcription factor. Hexosamine pathway product concentrations will also be assayed
in low and high glucose concentrations. The hypothesis is summarised in Figure 5.1.
A secondary, and complementary, aim of this thesis is to investigate the pharmaco-
logical effect of thiamine on microalbuminuria in 40 type 2 diabetes patients in a double-blind
placebo-controlled trial. Type 2 diabetes patients have a 75% decreased plasma thiamine
concentration and a 16-fold increase in renal clearance rates of thiamine compared to normal
controls [Thornalley et al., 2007]. It will be determined if an oral pharmacalogical inter-
vention can restore plasma thiamine concentration to normal. The study will continue by
assessing the effect of thiamine intervention on the rate of urinary albumin excretion.
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Figure 5.1: Project hypothesis overview. This encapsulates the mechanistic theory behind
why we believe plasma thiamine concentrations are decreased in the diabetic state.
79
Chapter 6
Materials and methods
6.1 Materials
6.1.1 Cells and tissues
The human renal proximal tubule epithelial HK-2 cell line [Ryan et al., 1994] was obtained
from ATCC (Manassas, VA, USA). Human kidney proximal tubule epithelial cells (PTECs)
were isolated from a 25 year old female human kidney donated for transplantation but found
to be unsuitable and used for renal research with consent. This study was approved by the
Coventry National Health Service Regional Ethics Committee (NHS-REC): applicant Dr
Daniel Zehnder.
6.1.2 Cell culture reagents
HK-2 cells and human PTECs in primary culture were cultured in a 1:1 mixture of Dul-
becco’s modified Eagle medium (DMEM) and Ham’s F-12 nutrient supplement prepared
in-house without thiamine or glucose (Biological Sciences, University of Warwick). Trypsin-
ethylenediaminetetraacetic acid (EDTA) solution (0.25% trypsin w/v and 0.02% EDTA w/v
in Hank’s balanced salt solution, 0.22 µm sterile-filtered) was purchased from Sigma-Aldrich
(Poole, UK). Foetal bovine serum (FBS) was from Biosera (Ringmer, UK).
l-Glucosamine (99%), β-d-glucose (tissue-culture grade), Lucifer yellow carbohy-
drazide (CH), dipotassium salt, penicillin-streptomycin solution (10 000 units mL−1 peni-
cillin and 10 mg mL−1 streptomycin), sodium carbonate (≥99.0%) and thiamine hydrochlo-
ride were purchased from Sigma-Aldrich. 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES), sodium salt was from Fisher Scientific (Loughborough, UK).
80
6.1.3 Enzymes, substrates, cofactors and inhibitors
Type II collagenase (EC 3.4.24.3, 125 units mg−1 from Clostridium histolyticum) was pur-
chased from Worthington Biochemical Corporation (Lakewood, NJ, USA). Triosephosphate
isomerase (EC 5.3.1.1, Type III-S, ≥4000 units per mg protein) and α-glycerophosphate
dehydrogenase (EC 1.1.1.8, 100–300 units per mg protein) were both purified from rabbit
muscle and supplied as an ammonium sulphate suspension from Sigma-Aldrich. SensiMix
SYBR green Low-Rox Kit for quantitative polymerase chain reaction (qPCR), Biomix Red
PCR mix and BioScript reverse transcriptase (a Moloney murine leukaemia virus reverse
transcriptase modified to have low RNAse H activity, thereby increasing yields) were pur-
chased from Bioline (London, UK). Peroxidase and glucose oxidase (PGO) caplets each
containing glucose oxidase (EC 1.1.3.4, 500 units from Aspergilus niger), peroxidase (EC
1.11.1.7, 100 purpurogallin units from horseradish) and buffer salts were purchased from
Sigma-Aldrich.
d-Ribose-5-phosphate, disodium salt (98–100%), o-dianisidine dihydrochloride, thi-
amine pyrophosphate hydrochloride and β-nicotinamide adenine dinucleotide, reduced form
(β-NADH, 98%) were from Sigma-Aldrich. Protease inhibitor cocktail in DMSO for mam-
malian cell and tissue extracts and containing 4-(2-aminoethyl)benzenesulfonyl fluoride
(AEBSF) hydrochloride, aprotinin, bestatin hydrochloride, [N -(trans-epoxysuccinyl)-l-leu-
cine 4-guanidinobutylamide] (E-64), leupeptin hemisulphate salt and pepstatin A was also
from Sigma-Aldrich. RiboSafe RNAse inhibitor (a proprietary recombinant protein which
competitively inhibits RNAses A, B and C) was purchased from Bioline.
6.1.4 Antibodies
Mouse monoclonal horseradish peroxidase (HRP)-conjugated antibodies to β-actin (mAb-
cam 8226, ab20272), mouse monoclonal antibodies to peptide sequence GQVEEYDLD-
DDINSRVEMKPK, residues 249–269 of human aquaporin 1 (Aqp-1; ab9566), rabbit poly-
clonal antibodies to human lamin A (ab26300) and specificity protein 1 (Sp1; ab13370),
and goat polyclonal antibody to human O-linked N -acetylglucosamine transferase (OGT;
ab59135) were purchased from Abcam (Cambridge, UK). Mouse polyclonal antibodies to
uromodulin (UMOD; B01P) were purchased from Abnova (Taipei City, Taiwan).
Rabbit polyclonal antibodies to human thiamine transporter 1 (THTR-1; THTR11-
A and THTR12-A) and human thiamine transporter 2 (THTR-2; THTR22-A) were pur-
chased from Alpha Diagnostic International (San Antonio, TX, USA). Mouse monoclonal
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antibodies to human THTR-1 (5B10) were purchased from Abnova. Rabbit polyclonal an-
tibodies to THTR-1 (HPA016599) were purchased from Sigma-Aldrich. Goat polyclonal
antibodies to THTR-1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA).
Mouse monoclonal antibodies to O-GlcNAc residues (HGAC85, ab2735) were from
Abcam. Mouse monoclonal antibodies to O-GlcNAc (MAb CTD 110.6) were purchased as
part of an analytical kit from Pierce (Thermo Scientific, Rockford, IL, USA). Anti-mouse,
-rabbit and -goat HRP-conjugated secondary antibodies were purchased from Abcam.
6.1.5 Analytical and preparative kits
Bradford assay dye reagent and the detergent compatible (DC) protein assay kit were
purchased from BioRad (Hemel Hempstead, UK). Liquid chromatography solid anion ex-
change (LC-SAX) solid phase extraction (SPE) cartridges (quaternary amine bonded to
silica with a chloride counter-ion, 500 mg per 3 mL cartridge) were from Supelco (Sigma-
Aldrich). RNeasy Mini Kits for RNA preparation were purchased from Qiagen (Crawley,
UK). Enzyme-linked immunosorbent assay (ELISA) kits for soluble vascular cell adhesion
molecule 1 (sVCAM-1) were purchased from R&D Systems (Abingdon, UK).
6.1.6 Chromatographic materials
Methanol, acetonitrile, isopropanol (IPA), tetrahydrofuran and 35% ammonia solution (all
HPLC-grade) were purchased from Fisher Scientific. Formic acid (≥96.0%) and trifluo-
roacetic acid (TFA, spectrophotometric grade 99+%) were purchased from Sigma-Aldrich.
Anion exchange HPLC was performed with an HEMA-IEC Bio-Q column (200 mm
× 4.6 mm, 10 µm particle size) with a guard column made of the same material from All-
tech (Carnforth, UK). Reversed phase HPLC was performed with a C18 X-Bridge column
(150 mm × 3 mm, 3.5 µm particle size) with guard columns of the same material from Waters
(Milford, MA, USA).
6.1.7 Immunohistochemistry materials
Moist chambers for maintaining high humidity around slides were from Raymond Lamb
(Thermo Scientific). Xylene, isopropanol, formaldehyde solution (37% w/v), EDTA and
citric acid, trisodium salt (all analytical grade) were purchased from Fisher Scientific. Water-
repellent peroxidase anti-peroxidase (PAP) pens and phosphate-buffered saline (PBS)-Tween
82
rinsing solution (10 mM sodium phosphate at pH 7.4 plus 0.01% Tween-20) were purchased
from A Menarini Diagnostics (Florence, Italy). Buffers A and C for antigen retrieval (propi-
etary mixes at pH 6.0 and 4.5 respectively) were purchased from PickCell Laboratories
BV (Amsterdam, The Netherlands). Distyrene and plasticiser in xylene (DPX) moun-
tant, Mayer’s haematoxylin solution and hydrogen peroxide solution (3% w/w) were pur-
chased from Sigma-Aldrich. Vectastain Universal Quick Kit and Avidin/Biotin blocking
kit were purchased from Vector Laboratories (Peterborough, England). LiquidDAB (3,3'-
diaminobenzidine) reagent was purchased from BioGenex (San Ramon, CA, USA).
6.1.8 Analytical standards
Uridine 5'-diphosphoglucose (UDP-Glc, ≥98% disodium salt from Saccharomyces cerevisiae),
uridine 5'-diphospho-N -acetylglucosamine (UDP-GlcNAc, ≥98%, sodium salt), guanosine
5'-diphospho-d-mannose (GDP-Man, ∼98% from Saccharomyces cerevisiae) and thiamine
monophosphate hydrochloride dihydrate were purchased from Sigma-Aldrich. Chloroethyl-
thiamine was synthesised in-house by a colleague (see Section 6.4.3.1).
6.1.9 Other reagents and consumables
For western blotting, β-mercaptoethanol, ammonium persulphate (ACS reagent grade),
N,N,N ',N '-tetramethylethylenediamine (TEMED; ≥99% electrophoresis grade), Tween 20,
bovine serum albumin (BSA, initial fractionation by heat shock; fraction V: minimum 98%),
3',3'',5',5''-tetrabromophenolsulfophthalein sodium salt (bromophenol blue, electrophoresis
grade), glycerol (molecular biology grade) and hydrochloric acid (25% w/w solution, an-
alytical grade) were purchased from Sigma-Aldrich. Coomassie Brilliant Blue G250 (ana-
lytical grade) was purchased from Fluka (Poole, UK). Acrylamide:bis-acrylamide solution
(30% w/v, 37.5:1, Ultrapure grade) was purchased from National Diagnostics (Hessle, UK).
Sodium dodecyl sulphate (SDS; electrophoresis grade), acetic acid (glacial), tris(hydroxy-
methyl)aminomethane base, EDTA, glycine, methanol and sodium chloride (all analyti-
cal grade) were all purchased from Fisher Scientific. Instant dried skimmed milk pow-
der was purchased from Tesco (Cheshunt, UK). Polyvinylidene fluoride (PVDF) membrane
(Hybond-P) and X-ray film (Hyperfilm) were purchased from GE Healthcare (Little Chal-
font, UK). Filter paper, grade 1, was purchased from Whatman (Little Chalfont, UK).
Enhanced chemiluminescence (ECL) reagent kit was purchased from Pierce. Molecular
mass ladder (10–250 kDa, #SM1811) was purchased from Fermentas (York, UK).
For other solutions, calcium chloride, ethanol (molecular biology grade), l-glutamine
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solution (200 mM, tissue culture grade), magnesium sulphate heptahydrate, perchloric acid
solution (60% w/v), potassium chloride, potassium ferricyanide (K3Fe(CN)6, >99%), tri-
chloroacetic acid (TCA, ≥99.5%) and Triton X-100 were purchased from Sigma-Aldrich.
Orthophosphoric acid (85%+), disodium hydrogen phosphate, sodium dihydrogen phos-
phate, potassium dihydrogen phosphate (anhydrous), dipotassium hydrogen phosphate tri-
hydrate, sodium hydroxide (98+%), potassium hydroxide and sodium acetate salt (all an-
alytical grade) were purchased from Fisher Scientific. Tritiated thiamine (10 Ci mmol−1,
1 mCi mL−1, 50 µCi aliquot) was purchased from American Radiolabeled Chemicals (St.
Louis, MO, USA). Percoll (15–30 nm colloidal silica particles coated with polyvinylpyrroli-
done (PVP), 23% w/w in water) for density centrifugation was purchased from Fluka. Ul-
tima Gold scintillation fluid was purchased from Perkin Elmer (Seer Green, UK).
Primers were ordered from the Invitrogen custom primer service (Paisley, UK) in
lyophilised form. Nuclease-free water was purchased from Qiagen. Oligo d(T)18 primers
(270 ng µL−1 in water), deoxyribonucleotide triphosphate (dNTP) mixes (lithium salts,
100 mM each) and agarose powder (electrophoresis grade) were purchased from Bioline.
Ethidium bromide solution (10 mg mL−1 in water, for molecular biology) was purchased
from Sigma-Aldrich.
UV transparent microplates and microspin filters (0.22 µm pore size, cellulose) were
purchased from Corning Life Sciences (Amsterdam, The Netherlands). HPLC vials, inserts
and caps were purchased from Chromacol (Welwyn Garden City, England). All other gen-
eral laboratory consumables and sundries not individually detailed (including test tubes,
glass slides, cover slips and tissue culture plastic-ware) came from either Greiner Bio-One
(Stonehouse, England) or Fisher Scientific.
6.1.10 Instrumentation
All water used for assays had a resistivity ≥18.2 MΩ cm at 25℃ and a total organic car-
bon content ≤2 µg L−1 (filtered by an Advantage A10 Milli-Q system (Watford, UK)). Ab-
sorbance and fluorescence-based microplate assays were performed using a Fluostar Optima
microplate reader (BMG Labtech, Aylesbury, England). All HPLC was performed on an
UltiMate 3000 series HPLC system from Dionex (Camberley, UK) comprising a four-channel
degasser, binary pumps with high pressure gradient mixing and low pressure solvent selectors
for each pump, thermostatic split-loop autosampler, thermostatic column compartment with
two 6-port switching valves, photodiode array and fluorescence detector. RNA quantitation
and quality control was performed using an ND 1000 spectrophotometer from NanoDrop
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(Wilmington, DE, USA). Ultracentrifugation was performed in a CS150GXL micro ultra-
centrifuge made by Hitachi Koki (Tokyo, Japan) with an S55-A rotor and polycarbonate
tubes from Sorvall (Loughborough, UK). Gels were imaged on a ChemiGenius2 transillu-
minator and imaging system from Syngene (Cambridge, England). Real-time qPCR was
performed with a 7500 Fast Real-Time PCR System from Applied Biosystems (Warrington,
UK). Immunohistochemistry slides were digitized using a Mirax Midi slide scanner from
Carl Zeiss (Jena, Germany).
Other laboratory equipment included a chilled microcentrifuge from Hettich (Tut-
tlingen, Germany), a large chilled centrifuge from Sorvall, electrophoresis equipment and
power supplies from Amersham Biosciences, (Little Chalfont, UK), a Vibra-cell sonicator
(75 W) from Sonics & Materials (Newtown, CT, USA), a 2100 Retriever antigen retrieval
unit from Prestige Medical (Blackburn, UK), an ImageScanner transparent film scanner
from Amersham Biosciences and a Uvikon UV/visible spectrophotometer from NorthStar
Scientific (Potton, UK). A stainless steel sieve (212 µm aperature) was purchased from Fisher
Scientific.
6.1.11 Software
HPLC chromatogram integration was performed using Chromeleon software v6.80 SP2
(Dionex). Statistical tests were performed in either SPSS v18 (IBM, Chicago, IL, USA)
or GraphPad Prism v5 (GraphPad Software, La Jolla, CA, USA). qPCR analysis was
performed with Sequence Detection System (SDS) software v2.0.1 (Applied Biosystems).
Scanned slides were viewed and cropped using Mirax Viewer v1.12.22 (Carl Zeiss). Primers
were designed using the Primer 3 software based at the National Center for Biotechnology
Information (NCBI) website (www.ncbi.nlm.nih.gov/nuccore). X-ray film image scanning
was performed using LabScan software (Amersham Biosciences). Densitometry was per-
formed using ImageJ (rsbweb.nih.gov/ij). Figures for this thesis were prepared using Gnu-
meric v1.9.14 (www.gnome.org/gnumeric) and Inkscape v0.47 (www.inkscape.org). Chemi-
cal structures were drawn with Chemsketch v10 (ACD/Labs, Toronto, Canada). This thesis
was typeset using LATEX 2ε typesetting software (www.latex-project.org).
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6.2 Cell culture methods
HK-2 cell line PTECs and freshly isolated human PTECs were both cultured in the same
manner in a 37℃ incubator with a 5% CO2 95% air water-saturated atmosphere. The
medium used was DMEM/F-12 supplemented with 2.5% FBS, 1% penicillin/streptomycin
solution (final concentrations 100 U mL−1 penicillin and 100 µg mL−1 streptomycin), 20 mM
NaHCO3, 15 mM HEPES at pH 7.4. Media were supplemented with glucose and thiamine to
achieve final concentrations of 5 mM or 26 mM glucose and 4 nM or 4µM thiamine. Samples
of medium were assayed to test final glucose and thiamine concentrations.
Cells were cultured in sterile polystyrene culture vessels with no additional coating
necessary for cell adhesion. Cells were passaged when at around 80–90% confluence and
were never allowed to reach confluence unless monolayer formation was required for the ex-
periment. Passaging was achieved by aspirating culture medium and adding approximately
1 mL per 25 cm2 0.25% trypsin-EDTA to each flask. The flasks were returned to a 37℃ in-
cubator for 3–5 min until the cells had detached. The activity of the trypsin was neutralised
by adding culture medium including FBS to the flask and the cells were then diluted to the
target concentration in new flasks.
Immortalised cells were revived from liquid nitrogen storage every three months to
ensure that cells did not drift genetically over long periods of time. After removal from
cold storage, cells were grown exponentially for a minimum of two weeks to allow them to
become accustomed to the new 5 mM glucose, 4 nM thiamine medium before use.
For experimental procedures, four different combinations of glucose and thiamine
concentration were used. These were: (i) 5 mM glucose and 4 nM thiamine (−G−T), (ii)
5 mM glucose and 4 µM thiamine (−G+T), (iii) 26 mM glucose and 4 nM thiamine (+G−T)
and (iv) 26 mM glucose and 4 µM thiamine (+G+T). Cells were routinely cultured in −G−T
medium and were seeded into the four experimental media simultaneously from the same
stock for the duration of an experimental incubation. HK-2 cell passage number was un-
known; primary cells were used at passage number 4 or earlier.
6.3 Proximal tubule epithelial cell extraction
There has been much work performed since the 1950s on isolating cellular fractions from
kidneys. Early work used magnetic particles of iron oxide which lodged in glomeruli during
perfusion and were subsequently used to separate glomeruli using magnetic attraction [Cook
and Pickering, 1958]. This method was not chosen because of the potential for oxidative
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damage caused by the iron particles. Other methods advocate differential sieving or other
mechanical means [Weiland et al., 2007; Obatomi and Bach, 1996; Luhe et al., 2003; Rudolfs
K. Zalups, 1996] or enzymatic techniques [Elliget and Trump, 1991; Frye and Patrick, 2002;
Terryn et al., 2007]. The enzymes chosen for digestion can vary quite widely with most
people using collagenase and others using additives such as BSA or secondary enzymes
including dispase (a bacillus-derived matrix metalloproteinase which cleaves fibronectin and
collagen IV and to a lesser extent collagen I but not collagen V or laminin). More elaborate
methods include using antibodies to a unique epitope on the cell of interest followed by a
secondary antibody conjugated with a magnetic particle. Separation can thus be achieved
using a powerful magnet [van Beijnum et al., 2008] in a manner similar to Cook and Pickering
[1958]. Several enzymatic techniques included the use of density gradient centrifugation
[Pen˜aranda et al., 1996; Pietruck et al., 2006, 2003; Weinberg et al., 1987; Zager and Foerder,
1992; Zager et al., 1993]. The method presented herein represents a combination of published
methods refined to work well on rat PTECs and then adapted for human PTECs.
The donor human kidney was kept on ice between removal and arrival at our labo-
ratory (less than 24 hours). Sections of cortex from the decapsulated kidney were used for
PTEC isolation. Approximately 1–1.5 cm3 of cortex tissue was cut up finely using a scalpel
in a Petri dish on ice. The diced cortex was transferred to a large beaker and collagenase
solution added (100 mL 0.1% type II collagenase in PBS with 5 mM CaCl2). The beaker
was covered and incubated and digested for 40 min at 37℃ in a shaking water bath at 180
revolutions per minute. After incubation the partially digested material was poured over a
stainless steel sieve (212 µm aperature size). The material collected on the sieve contained
undigested cortex and was retained for use later. The material collected below the sieve
contained the tubule fragments and was sedimented by centrifugation (2 min, 30× g, 4℃).
After sedimentation, the supernatant was discarded and the pellet of cellular material re-
suspended in ice-cold DMEM/F12 medium supplemented with 1% penicillin/streptomycin,
20 mM NaHCO3, 15 mM HEPES at pH 7.4, 5 mM glucose and 4 nM thiamine in the absence
of FBS. The resuspended tubule fragments were sedimented once more by centrifugation
(2 min, 30× g, 4℃). The wash was repeated a total of three times for each digest to remove
cellular debris.
The washed tubule fragments were then separated by density-gradient centrifugation
in a self-forming 31% Percoll gradient with a final osmolarity of 300 mOsmolar made up with
sodium chloride and water. The mixture of Percoll, sodium chloride, water and cellular di-
gest fragments was homogeneous before centrifuguation. By centrifuging (30 min, 30 000× g,
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4℃ with gentle acceleration (3/10) and no braking) a density gradient was formed and the
fragments separated into three discrete fractions (Figure 6.1), of which the lower comprised
the bulk of the proximal tubule fragments.
Figure 6.1: Cells from a human kidney digest separated in Percoll. Fractions 1, 2 and 3
were universally visible. Fraction 3 contained the majority of proximal tubule fragments.
All similar fractions from multiple separations were pooled and topped up to 50 mL
with ice-cold medium before collecting the cellular material by centrifugation (5 min, 130× g,
4℃). The supernatant was discarded to remove the Percoll. Each fraction was resuspended
in 37℃ DMEM/F-12 medium as described above and further supplemented with 2.5% FBS
before seeding at an estimated confluence of 10–20% in tissue culture flasks.
To further increase the yield of the extraction procedure, the material previously
collected on top of the stainless steel sieve was pooled and re-digested with collagenase. All
further steps were identical to the procedure described above. Figure 6.2 shows an example
of a confluent monolayer of these cells under light microscopy. The identity of the cells was
confirmed by immunohistochemistry.
Figure 6.2: Microscopic image of a monolayer of human PTECs in primary culture
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6.4 Thiamine assay
6.4.1 Principle of assay
The assay of thiamine is based on the alkaline oxidation of thiamine and its phosphate es-
ters to highly fluorescent thiochrome and thiochrome phosphate esters respectively (Figure
6.3)—a technique first described by [Jansen, 1936]. Modern methods such as the one de-
scribed herein separate the fluorescent thiochromes using reverse phase HPLC. A pre-column
derivatisation technique using sodium hydroxide (15% w/v) and potassium hexacyanofer-
rate (K3Fe(CN)6—1% w/v) was used. Due to instability once mixed, reagents were mixed
freshly at a ratio of 4:1 before an aliquot of the combined reagent was mixed with the sam-
ple. The derivatisation formed the thiochromes which were separated by HPLC and their
presence detected by their strong fluorescence.
CH3NH2
N
N
CH3
N+
S OR
K3[Fe(CN)6]
NaOH
N
CH3
N
N
CH3
N
S OR
Thiamine or phosphate ester Thiochrome or phosphate ester
Figure 6.3: The alkaline oxidation of thiamine and its phosphate esters to the respective
thiochrome by sodium hydroxide and potassium ferricyanide. R represents either H for
thiamine, phosphate for thiamine monophosphate or pyrophosphate for thiamine pyrophos-
phate.
6.4.2 Chromatographic conditions
A Waters XBridge C18 reverse phase column as described above was chosen because high
concentrations of sodium hydroxide were used for derivatisation and it has increased resis-
tance to high pH relative to traditional silica-based C18 columns. The column was 150 mm
× 3 mm with a 3.5 µm particle size and the HPLC system used was the Dionex UltiMate
3000 series system described above (see Section 6.1.10).
The mobile phases used were 10 mM KH2PO4 pH 8.4 in water for solvent A, 10 mM
KH2PO4 pH 8.4 in 50% methanol for solvent B, water for rinsing in solvent line C and 30%
IPA with 0.1% TFA in solvent line D for column cleaning.
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The column was equilibrated with 95% A and 5% B (i.e. 2.5% methanol). Separation
was carried out over 20 min from injection by raising the mobile phase linearly from 5% B
to 100% B. Fluorimetric detection was carried out using an excitation wavelength of 365 nm
and an emission wavelength of 439 nm.
After each injection, the column was cleaned by flushing with 10 column volumes of
water followed by 10 column volumes of 30% IPA + 0.1% TFA before re-rinsing the column
using 10 column volumes of water followed by 8 min re-equilibration with 95% A and 5% B
at 1 mL min−1.
6.4.3 Assay standardization
The assay was standardized by use of chloroethylthiamine as an internal standard. Chloro-
ethylthiamine is not naturally occurring and exhibits a great structural similarity with
thiamine and its derivatives which means that it derivatises under the same conditions yet
can be chromatographically resolved. By integrating the peak area for the internal standard
and the peak area for the analyte it is possible to express the analyte as a percentage of the
internal standard and deduce the amount present by reference to a standard curve.
6.4.3.1 Chloroethylthiamine synthesis
Chloroethylthiamine was prepared in-house by a colleague by nucleophilic substitution of
the hydroxyl group on the 5'-(2-hydroxyethyl) group on the thiazolium ring with chloride.
This is facilitated by the sulphonylchlorination (-SOCl) of the hydroxyl group by thionyl
chloride which is then susceptible to nucleophilic attack by chloride ions (Figure 6.4).
Thiamine chloride (1 g, 3 mmol), was added to 20 mL of thionylchloride and refluxed
for three hours at 80–85℃. The excess thionylchloride was then removed by distillation at
85–90℃ and the residual solid washed with diethyl ether (5 mL × 2). The remaining solid
was purified by recrystallisation from ethanol (5 mL), filtered under aspiration and dried
under a vacuum. The product was characterized by mass spectrometry and 1H and 13C
NMR spectroscopy.
6.4.4 Calibration of stock solutions
Stock solutions of thiamine (THM), thiamine monophosphate (TMP) and thiamine py-
rophosphate (TPP) were calibrated spectrophotometrically prior to use as standards. Each
analyte was dissolved in 10 mM H3PO4 at pH 2.15 and kept on ice. The standards were
90
diluted in 10 mM H3PO4 at pH 2.15 and readings of absorbance at λmax 247 nm were made,
ensuring readings lay between 0.5 and 1 absorbance units by adjusting the dilution factor.
The concentration of each solution was calculated with reference to Table 6.1. The cali-
brated stock solutions were kept at −80℃ and diluted in 10 mM sodium acetate, pH 4.5 to
make working solutions of 100µM which were kept at −80℃ or −20℃ for short term use.
Analyte λmax at pH 2.15 (nm) ε (M−1 cm−1)
THM 247 [Dawson et al., 1986] 14 200 [Dawson et al., 1986]
TMP 247 [Al Ali, 2006] 15 300 [Al Ali, 2006]
TPP 247 [Dawson et al., 1986] 13 000 [Dawson et al., 1986]
Table 6.1: Absorbance characteristics of thiamine assay standards
6.4.5 Preparation of standard curves
Standard curves for assay calibration were prepared in the range of 0.1–2.5 pmol of each
analyte for analysis of cell extracts or plasma (the low standard curve) and in the range
of 1–20 pmol for analysis of urine (the high standard curve). Each standard on the low
curve contained 2.5 pmol CET as an internal standard (IS) and each standard on the high
curve contained 20 pmol CET. A working stock of 0.1 µM and 0.01 µM or 1.0 µM and 0.1 µM
thiamine metabolites was prepared by dilution into 10 mM sodium acetate buffer (pH 4.5)
CH3NH2
N
N
CH3
N+
S OH
Cl
OS
CH3NH2
N
N
CH3
N+
S O
CH3NH2
N
N
CH3
N+
S Cl
SOCl2
(- Cl-)
Cl- -(SOCl-)
Thiamine
Chloroethylthiamine
Figure 6.4: The reaction scheme for the synthesis of the internal standard, chloroethylthi-
amine
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from the calibrated stock solutions prepared above. All preparation was carried out on ice to
prevent sample degradation. Reagent volumes used for standard preparation are presented
in Tables 6.2 and 6.3. For each standard tube, internal standard was combined with 20%
TCA (w/v) dissolved in 0.9% sodium chloride (w/v). The thiamine metabolite mix was
added to each tube and the volume made up to 40 µL with water. 10 µL of 2 M sodium
acetate was added to each tube to neutralise the TCA and return the pH to approximately
4.5 (volumes determined empirically).
Each tube was mixed thoroughly by vortexing and the contents filtered through a
cellulose spin filter (0.22 µm pore size, 10 min, 4000× g, 4℃). 40 µL of each filtrate was
then dispensed into HPLC vials prior to analysis. Samples were not stored for longer than
48 hours at 4℃ before analysis.
6.4.6 Preparation of samples
Plasma samples (50 µL) were deproteinised with 20% TCA in 0.9% saline (20µL) and
2.5 pmol internal standard was added (5 µL, 0.5 µM). The samples were mixed and placed
on ice (10 min) to allow complete precipitation before sedimentation of the precipitate by
centrifugation (10 min, 20 000× g, 4℃). The supernatants (50 µL) were removed and the pH
adjusted to 4.5 by addition of 2 M sodium acetate (8.5 µL—volume determined empirically).
Samples were spin-filtered (0.22 µm pore size) and 40 µL was used for thiamine analysis.
Urine samples were diluted 10-fold in water before analysis. Dilute urine samples
(25 µL) were deproteinised with 20% TCA in 0.9% saline (10µL) and 20 pmol internal stan-
dard was added (10µL, 2 µM). The samples were mixed and placed on ice (10 min) to allow
complete precipitation before sedimentation of the precipitate by centrifugation (10 min,
20 000× g, 4℃). The supernatants (44µL) were removed and the pH adjusted to 4.5 by
addition of 2 M sodium acetate (10 µL—volume determined empirically). Sample were spin-
filtered (0.22 µm pore size) and 40 µL was used for thiamine analysis.
Cell samples were collected by trypsinisation from a T-75 flask near confluence. Cells
were washed twice in successive steps in ice-cold PBS in order to ensure complete removal of
thiamine present in the growth medium. The cells were resuspended in lysis buffer (200 µL,
10 mM sodium acetate pH 4.5 with 0.02% Triton X-100) at an approximate density of
8× 105 cells in 50 µL—a density previously determined to be suitable for thiamine analysis.
The samples were kept on ice at all times so that the low pH and the low temperature
ensured analyte stability.
The samples were sonicated on ice (10 seconds, 75 W) and transferred to ice-cold
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microcentrifuge tubes before sedimenting membranes by centrifugation (30 min, 20 000× g,
4℃). The cytosolic supernatant was used for thiamine analysis and protein concentration
determination (BioRad DC protein assay). For thiamine analysis, the supernatants (50 µL)
were deproteinised with 20% TCA in 0.9% saline (10 µL) and 2.5 pmol internal standard was
added (5 µL, 0.5 µM). The samples were mixed and placed on ice (10 min) to allow complete
precipitation before sedimentation of the precipitate by centrifugation (10 min, 20 000× g,
4℃). The supernatants (60 µL) were removed and the pH adjusted to 4.5 by addition of 2 M
sodium acetate (8 µL—volume determined empirically). Sample were spin-filtered (0.22 µm
pore size) and 40µL was used for thiamine analysis.
6.4.7 Chromatography of samples
After preparation, samples were stored in a 4℃ autosampler immediately prior to analysis.
The autosampler needle drew 40 µL 15% NaOH and 10 µL 1% K3Fe(CN)6 and dispensed
them into a clean vial. The derivatising agent was mixed by 3 repeats of drawing and
dispensing in the vial. 10µL was drawn from the derivitising agent solution and dispensed
into the 40µL of sample. The sample was mixed thoroughly by 3 repeats of drawing and
dispensing. 25 µL of the derivatised sample was drawn up and injected onto the column
already equilibrated with 95% A and 5% B (see Section 6.4.2 for details of the mobile
phase). The gradient described in Table 6.4 was run to first separate the analytes, then
displace the phosphate salts before cleaning and re-equilibrating the column.
The fluorescence chromatogram obtained was integrated using the Chromeleon soft-
ware and concentrations of thiamine metabolites determined by reference of the thiochrome
peak area ratio (analyte/internal standard) to the standard curve. An example chro-
matogram is given in Figure 6.5. Example standard curves are given in Figures 6.6 (THM),
6.7 (TMP) and 6.8 (TPP).
6.4.8 Assay validation
Intra- and inter-batch coefficients of variance (CV) were determined by repeated measures of
1 pmol standards containing all three analytes. 12 identical replicates were run consecutively
to determine the intra-batch CV. 12 replicates made separately and analysed with separate
standard curves were used to determine the inter-batch CV. The results are given in Table
6.5.
Thiochrome half life was determined by a colleague [Al Ali, 2006] by manually
derivatising a standard sample and then injecting aliquots at regular intervals and moni-
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Time
(min)
A (10 mM
KH2PO4
pH 8.4 in
water)
B (10 mM
KH2PO4 pH
8.4 in 50%
methanol)
C
(Water)
D (30%
IPA +
0.1%
TFA)
Flow
(mL min−1)
0 95 5 0 0 0.5
20 0 100 0 0 0.5
20.01 0 0 100 0 0.5
22 0 0 100 0 1.0
31 0 0 100 0 1.0
31.6 0 0 0 100 0.4
44 0 0 0 100 0.4
44.01 0 0 100 0 0.4
46 0 0 100 0 0.4
48 0 0 100 0 1.0
55 0 0 100 0 1.0
55.01 95 5 0 0 1.0
70 95 5 0 0 1.0
70.5 95 5 0 0 0.5
Table 6.4: Thiamine assay mobile phase gradient
Figure 6.5: Thiamine assay example chromatogram. This is a chromatogram obtained for
a 1 pmol standard for THM, TMP and TPP. The internal standard has 2.5 pmol present as
for all samples and standards.
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Figure 6.6: Example standard curve for thiamine analysis. This is a typical standard curve
in the range of 0.25 to 2.5 pmol.
Figure 6.7: Example standard curve for thiamine monophosphate analysis. This is a typical
standard curve in the range of 0.25 to 2.5 pmol.
Analyte Intra-batch CV (%) Inter-batch CV (%)
THM 1.1 3.2
TMP 2.4 3.0
TPP 2.0 3.7
Table 6.5: Thiamine assay intra- and inter-batch CVs (n = 12)
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toring fluorescence. The results in Table 6.6 show that the fluorescence is stable for the
duration of the assay. It also underlines the necessity to derivatise each sample individ-
ually prior to analysis, especially considering that complete oxidation is achieved within
15 seconds [Wielders and Mink, 1983].
Analyte t1/2 (hours) t5% (hours) t5% (min)
THM 3.4 0.25 15
TMP 4.3 0.32 19
TPP 5.0 0.37 22
IS 3.4 0.25 15
Table 6.6: Thiochrome half lives after derivatisation
To confirm that analytes did not interconvert during sample preparation or derivati-
sation, 2 pmol standards were prepared which contained only one analyte. These were anal-
ysed sequentially separated by blank samples to test for carryover from one to the next.
No carryover was observed indicated by blank chromatograms with no observable peaks.
Results in Figure 6.9 show that only TPP has a small peak for TMP (3.6% the size of the
TPP peak) and no other analytes are present as contaminants. This small TMP peak may
be present as a contaminant in the commercially available TPP (repeated assays with fresh
TPP gave the same chromatograpy) or it may be due to degradation of TPP to TMP during
sample handling. Fresh plasma spiked with known amounts of THM, TMP or TPP show a
Figure 6.8: Example standard curve for thiamine pyrophosphate analysis. This is a typical
standard curve in the range of 0.25 to 2.5 pmol.
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similar pattern with recoveries of the analytes between 96–103%.
Figure 6.9: Thiamine assay single analyte analysis. In each case, 2 pmol analyte were
assayed, n = 3
Limits of detection (LOD) for analytes were determined according to the definition of
the Environmental Protection Agency (defined in 40 CFR §136, [EPA, 2010]). A low 0.5 pmol
standard was assayed 10 times and the LOD determined from LOD = t(n−1,1−α=0.99) × S
where t(n−1,1−α=0.99) is the Student’s t value appropriate for a 99% confidence level and a
standard deviation estimate with n−1 degrees of freedom and S is the standard deviation of
the replicate analyses. LODs are given in Table 6.7. If the protocol for the HPLC machine
were to be modified for maximum injection of analyte and not optimised for speed, the
limits of detection could be lowered to 40% of their current values. This sensitivity was not
required for any analysis so the assay was optimised for speed.
Analyte LOD (fmol)
THM 32
TMP 6.7
TPP 94
Table 6.7: Thiamine assay limits of detection. n = 10
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6.5 Hexosamine pathway intermediate assay
6.5.1 Aim and principle
This assay was designed to separate by HPLC and quantify hexosamine biosynthesis path-
way intermediates by UV absorbance. Specifically, the assay quantified levels of uridine
diphosphate-N -acetylglucosamine (UDP-GlcNAc) and uridine diphosphate-glucose (UDP-
Glc). Samples were initially prepared by anion exchange solid phase extraction before sep-
aration on an anion exchange HPLC column. Guanosine 5'-diphospho-d-mannose (GDP-
mannose) was chosen as an internal standard due to its low abundance in human cells and
tissues.
This method was based on the work initially validated by Robinson et al. [1995] who
adapted an original assay developed in 1985 [Wice et al., 1985]. This method was improved
herein by eliminating the need for ozone-depleting solvents and reducing spurious peaks
present on the chromatogram by adding solid phase extraction based on previous work by
Span et al. [2001]. Other methods (e.g. capillary zone electrophoresis [Lehmann et al.,
2000]) have been published to determine the concentration of these metabolites but HPLC
was chosen due to equipment availability and prior experience with the technique.
6.5.2 Standard preparation
Authentic standards for the assay were calibrated and used to prepare standard curves for
sample quantitation. Both UDP-Glc and UDP-GlcNAc were prepared in 10 mM KH2PO4
at pH 7.0 before spectrophotometric calibration at 262 nm (ε262 =10 000 M−1 cm−1 at pH
7.0 [Dawson et al., 1986]). For standard use, a mixture of UDP-Glc and UDP-GlcNAc was
prepared with both analytes at a concentration of 150 µM. Standards were prepared as
described in Table 6.8. Each of the standards was subjected to solid phase extraction in a
manner identical to that of the samples.
6.5.3 Sample preparation
Cells were grown in each test medium for five days. Cultured cells close to confluence
from one T-175 tissue culture flask (∼7.5× 106 cells) were removed by trypsinisisation
and sedimented by centrifugation (5 min, 125× g, 4℃) for each sample. The supernatant
was discarded and the cell pellet washed by resuspension in ice-cold PBS followed by
re-sedimentation. Ice-cold lysis buffer comprising 100 mM KCl, 1 mM EDTA and 50 mM
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KH2PO4 at pH 7.5 (1 mL) was added to each cell pellet. All steps from this point forward
were performed on ice.
The cells in the pellet were lysed by sonication (10 s, 75 W) and the membranes
clarified from the lysate by centrifugation (30 min, 20 000× g, 4℃). The membrane pellet
was discarded and the supernatant collected. 50µL of the supernatant was reserved for
protein assay and 700 µL was used for the remaining assay steps.
Each 700µL supernatant aliquot was mixed with 700 µL 1.2 M perchloric acid to
precipitate protein and 10 µL 1 mM GDP-mannose (10 nmol) added as an internal standard.
The samples were mixed by brief vortexing and allowed to stand on ice for 10 min to allow
complete precipitation. The protein precipitate was sedimented by centrifugation (10 min,
13 500× g, 4℃) and the supernatant reserved (approximately 1.3 mL supernatant was re-
covered in each case). 10 times the volume of each supernatant of KH2PO4 at pH 2.5 was
added to each supernatant before beginning solid phase extraction.
6.5.4 Solid phase extraction
The solid phase extraction (SPE) used Supelclean LC-SAX anion exchange cartridges (3 mL
capacity, 500 mg packing material each). A vacuum manifold was used to speed up sample
permeation through the packing material but for optimal binding of analytes to the sub-
strate, the flow rate was never allowed to exceed 5 mL min−1. Prior to use the columns were
conditioned by applying the following to each cartridge in turn, in each case leaving 0.5–
1 mm of solvent on top of the frit after each application: 2 mL methanol, 2 mL water, 2 mL
10 mM KH2PO4 at pH 2.5. After conditioning, the samples were loaded onto and drawn
through the SPE cartridges. The cartridges were washed with 5 × 1 mL 10 mM KH2PO4 at
pH 2.5 followed by 2.5 mL 50 mM KH2PO4 at pH 2.5 and finally 0.5 mL 150 mM KH2PO4
Standard
(nmol)
1 mM
GDP-mannose
(µL)
150 µM standard
mix (µL)
10 mM KH2PO4 at
pH 2.5 (mL)
1 10 6.67 12.98
5 10 33.33 12.96
10 10 66.67 12.92
20 10 133.3 12.86
35 10 233.3 12.76
50 10 333.3 12.66
Table 6.8: Standard curve preparation details for the hexosamine pathway metabolite assay.
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at pH 7.5. All eluates were discarded. The compounds of interest were eluted using 2 ×
0.75 mL 150 mM KH2PO4 at pH 7.5. The tubes were left to run dry and the entire volume
of eluate was collected. The samples were spin-filtered (0.22 µm pore size, 10 min, 4000× g,
4℃) and transferred to HPLC vials ready for injection. Samples were stored at 4℃ prior
to analysis.
6.5.5 HPLC conditions
The HPLC column used was a 200x4.6 mm HEMA-IEC Bio-Q anion exchange column with
a 10 µm particle size. The mobile phases were 15 mM ammonium formate, pH 3.8 (A) and
1 M ammonium formate, pH 4.5 (B). Water and 30% IPA were used for rinsing salt from the
system and cleaning the column after sample runs. The column was held in a thermostatic
column oven at 25℃. The mobile phase increased from 0% to 50% B over 25 min using a
concave gradient (slope 8 in the Chromeleon software) and is shown in Figure 6.10. The
mobile phase was held at 50% B for 2.5 min before returning to 100% A for equilibration
(7.5 min). The flow rate was 2 mL min−1 and detection was by UV absorbance at 262 nm.
The autosampler was thermostatically controlled at 4℃ and the injection volume was 100µL.
The needle was washed before every injection using water. The column was washed with
100% B prior to 30% IPA in water. An example chromatogram is given in Figure 6.11.
Example standard curves generated using the peak area ratio of the analyte peak/internal
standard peak are given in Figures 6.12 and 6.13. Analyte recoveries after SPE are given in
Table 6.9.
Analyte Recovery (%)
UDP-Glc 90.1%
UDP-GlcNAc 86.4%
GDP-Man 75.4%
Table 6.9: Hexosamine pathway analyte recovery percentages after solid phase extraction.
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Figure 6.10: Hexosamine pathway intermediate assay mobile phase gradient
Figure 6.11: Hexosamine pathway intermediate assay example chromatogram. This chro-
matogram shows peaks for UDP-Glucose and UDP-N -acetylglucosamine (5 nmol each) as
well as the internal standard, GDP-mannose (10 nmol).
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Figure 6.12: Example standard curve for UDP-glucose analysis. This is a typical standard
curve in the range of 1 to 50 nmol.
Figure 6.13: Example standard curve for UDP-N -acetylglucosamine analysis. This is a
typical standard curve in the range of 1 to 50 nmol.
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6.6 Real-time quantitative PCR
6.6.1 Principle of assay
Real-time quantitative PCR (qPCR) was used for assaying the relative copy numbers of
mRNA transcripts in cells and tissues. Briefly, the cellular RNA was extracted and reverse-
transcribed to yield cDNA. The cDNA was then amplified in a normal PCR reaction whilst
the amplification was quantified at every cycle by measuring the fluorescence of the reaction
as it prodeeded. The fluorescence was generated using the SYBR green dye which is highly
fluorescent when bound to double-stranded, but not single-stranded, DNA (i.e. the amplifi-
cation product). This technique was chosen above other chemistries such as TaqMan (which
relies on cleavage of a dual-labelled probe during amplification to separate free fluorophore
from the quencher) due to its ease of use and price.
6.6.2 Primer design
Good quality primers were designed for the qPCR in a manner similar to other PCR re-
actions. Criteria for choosing a good primer were that the primer should be between 18
to 22 base pairs in length, have a target melting temperature of around 60℃, have a GC
content of 40–60%. The presence of a GC clamp at the 3' was advantageous. Primer design
attempted to avoid potential secondary structure formation, excessive repeats, and runs of
more than four bases of a kind to avoid mis-priming.
In addition to following the good primer design principles above, the following princi-
ples specific to qPCR were also applied. Amplicon lengths were designed to be short(around
100 base pairs) to allow for quick amplification. If it was possible, primers were designed to
span an exon-exon junction or so that the amplicon bridged an intron completely i.e. for
the product to pass an exon-exon junction in the cDNA. This was to enforce an additional
element of quality control on the assay. If cDNA had been prepared from a total RNA
extract which had not been treated with DNAse enzymes, there may have been genomic
DNA present which would have provided an additional template for the primers. A primer
which bridged an exon-intron junction was not likely to prime on genomic DNA whilst an
amplicon that spanned an entire intron would produce a longer product than expected, often
not amplifying completely in the time available.
Following the criteria above, the following technique was used to generate primers
for qPCR. The gene of interest was retrieved from the NCBI nucleotide database available
online at www.ncbi.nlm.nih.gov/nuccore. The correct mRNA sequence was selected from the
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database results. By using an mRNA sequence, the database was pre-annotated with exon-
exon junctions which made primer design quicker and more efficient. Using the accession
number for the chosen mRNA sequence, the NCBI Primer-Blast tool was used to generate
primers (www.ncbi.nlm.nih.gov/tools/primer-blast). Primer-Blast is based on the Primer3
software for generation of primers [Rozen and Skaletsky, 2000]. The subsequent basic local
alignment search tool (BLAST) step compared the primers with the Refseq RNA database.
This step determined the specificity of the primers by seeing if they were likely to mis-prime
on alternate targets.
Of the possible primers returned by the NCBI Primer-Blast tool, one or two pairs
were chosen based on their specificity to the target sequence, their exon-exon junction span-
ning characteristics, their Tm, their amplicon length and their GC%. All primer sequences
used are presented in Table B.1 in Appendix B. The process for testing primers once pur-
chased is described below.
6.6.3 RNA extraction
Cellular RNA should be of high quality for accurate quantitation by qPCR. Cellular RNA
is not stable and the extraction of RNA was carefully carried out to avoid problems with
RNAse degradation of the samples. RNAses are exceptionally stable and active enzymes
that do not generally require cofactors for their function. To avoid degradation of RNA,
all samples were snap-frozen in a dry ice and ethanol bath before storage at −80℃ prior to
extraction—a temperature at which RNAses are inactive. The only other alternative would
have been to immediately denature all protein in the samples, an approach not as practical
as snap-freezing.
RNA extraction was carried out using the microspin-based Qiagen RNeasy Mini Kit
following the protocol provided by the manufacturer. Briefly, the sample was lysed com-
pletely by addition of a buffer containing both a high concentration of guanidine-thiocyanate,
a chaotropic agent, and β-mercaptoethanol to reduce di-sulphide bridges; a technique first
used in 1979 [Chirgwin et al., 1979]. Cellular samples were lysed by pipetting up and down
whilst tissue samples such as kidney were lysed by brief sonication. Ethanol was added ac-
cording to the supplied protocol to allow for required binding conditions for the silica-based
spin-column. The sample was passed through the spin-column and total RNA was bound
with high efficiency, provided that the column was not overloaded. The sample was washed
with a series of buffers, each containing high concentrations of ethanol before eluting the
concentrated and purified RNA using 30–50µL water.
106
6.6.3.1 RNA quality control
The RNA was analysed spectrophotometrically to provide information on quality and con-
centration. This was performed using a NanoDrop 1000 spectrophotometer using 1.5 µL
of RNA per sample. The A260 reading was used to determine concentration of the RNA
given that a value for A260 of 1 is equal to an RNA concentration of 44µg RNA mL−1. The
ratio between the A260 and A280 values was used to determine RNA quality with respect to
contaminants that absorb in the UV spectrum such as protein. Pure RNA would give an
expected A260/A280 ratio of between 1.9–2.1.
In addition to spectrophotometric analysis, spot samples of RNA were separated
on a 2% agarose gel with ethidium bromide. Two peaks for the 28S rRNA and 18S RNA
were clearly visible and appeared in the approximate ratio of 2:1. Smearing of these bands
indicated unwanted RNAse activity and a likely degradation of all RNA in the sample. Any
samples with degraded RNA were discarded and replaced with freshly derived samples.
6.6.4 Reverse transcription
After extraction of total RNA, reverse transcription was used to generate cDNA. 5µg tem-
plate RNA and 0.5 µg oligo-dT primers were added to an RNAse-free tube. Nuclease-free
water was added to a final volume of 12µL. The samples were heated to 70℃ for 5 min
before chilling on ice. Subsequently, 1 µL 10 mM dNTP mix, 4 µL 5× reaction buffer (pro-
vided with the BioScript enzyme), and 0.5 µL RNAse inhibitor were added to each sample.
The samples were mixed by pipetting before 1 µL BioScript enzyme was added. The reverse
transcriptase was thoroughly mixed into the sample by pipetting and the samples were in-
cubated at 40℃ for 60 min. The reaction was stopped by heating to 70℃ for 10 min followed
by chilling on ice. The cDNA was stored at −20℃ without repeated freeze-thawing.
6.6.5 Testing of primers
Primers were ordered lyophilised and were reconstituted on arrival in water to a concentra-
tion of 100 µM. Pairs of primers were then diluted together to a working solution of 5 µM of
each primer in water. Before use, primers were tested to ensure that they amplified a spe-
cific product of the correct mass. Reaction tubes for each primer containing 1 µL template
cDNA from the reverse transcription step, 1µL primer mix at 5 µM in water, 8 µL water
and 10µL BioMix Red mix including DNA polymerase, dNTPs, buffers, salts and loading
dye. The reaction tube was thoroughly mixed and cycled through the conditions shown in
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Figure 6.14 in a PCR thermocycler.
Figure 6.14: BioMix Red PCR cycling conditions
The reaction products were separated on a 2% agarose gel. This gel was prepared by
dissolving 2% w/v agarose in tris-acetate-EDTA (TAE) buffer (final concentrations 20 mM
tris base, 10 mM acetic acid and 1 mM EDTA.Na2, pH 8.0) by careful heating in a microwave
oven. Ethidium bromide was added from a 10 mg mL−1 stock to a final concentration of
0.5 µg mL−1 and the gel allowed to set before submerging in TAE buffer. 15µL of each 20 µL
PCR product was transferred to a well on the gel and a voltage of between 90–110 V was
applied to the gel for 1–2 hours to separate the reaction products. The gel was said to be
finished once the dye front had moved approximately 5 cm from the loading wells. The gel
was viewed and photographed in a UV transilluminator (see Figure 6.15). Any primer pair
which did not amplify with a single clean product was substituted for an alternative pair of
primers for the same product. An additional technique to test primer quality not employed
here would be to digest each product with a known restriction enzyme and to re-run the
products on a second gel. The size ratio would indicate if the sequence of the amplified
section is likely correct.
Figure 6.15: Primer quality control example gel image. Each lane represents a PCR reaction
product. All lanes have produced a single product at the correct mass (as determined
by including a molecular mass ladder on the gel) except lane 5 which has not amplified
adequately.
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6.6.6 Assay controls
All qPCR assays were thoroughly controlled to ensure reliability of the quantitative results.
Water blank qPCR amplifications were performed in which the template was substituted
for water and “RT−” amplifications were performed in which the template was prepared
using a reverse transcription step with water substituting for the reverse transcriptase. Am-
plification in the water blank would indicate contamination of the experiment by exogenous
material whilst amplification in the RT− blank is usually due to amplification from the
genomic DNA present in the sample.
Example traces for a properly conducted experiment are shown in Figure 6.16. In
cases where the water blank amplified at all, it did so very late (usually past 35 cycles).
The gap between the amplification of the target and the RT− control indicated the relative
abundance of genomic DNA to cRNA. For example, amplification 7 cycles later represents
1/27 or 0.7% of the target being present in the form of genomic DNA. Amplification 9 cycles
later would represent 0.2%. At this stage, other errors become more significant and the
effect of the genomic DNA can be ignored. It is not possible to perform a water blank
amplification for every well so it was assumed that if the water blank on a plate did not
amplify then the quality of the plate preparation was such that the rest of the plate was
also free of contamination.
Figure 6.16: qPCR example control amplifications for THTR-1. This is an example of a
properly conducted experiment. The RT+ sample crosses the threshold first at around 21
cycles. The RT− sample crosses much later at around 31 cycles meaning that it has an
abundance of approximately 1/210 or 1/1000 of the RT+ sample. The water blank does not
cross the threshold indicating that there has been no contamination of the well.
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In addition to these controls, a melt curve was prepared at least onece for each primer
pair and target. This was achieved using the PCR machine to increase the temperature of
the sample in small steps from a relatively low temperature (e.g. 65℃) to a relatively
high temperature (e.g. 90℃) over a range that incorporated the melting temperature of
each product. The fluorescence decreased gradually as the products melted. By plotting
the first order differential of the fluorescence against temperature, peaks were derived that
corresponded to products. Figure 6.17 is an example plot containing two peaks. The good
qPCR reaction has only one sharp peak corresponding to a single product and the bad qPCR
reaction contains a split peak indicating the presence of primer dimers or other artefacts of
amplification. Reactions with poor peak shape had their primers re-designed.
Figure 6.17: qPCR example product melt curves. The green curve represents a good quality
PCR reaction with a single product. The red curve represents the product obtained from a
RT− control which is of poor quality with two discernible peaks.
6.6.7 Primer efficiency
Since only relative levels of expression were required it was not necessary to construct a
standard curve of the type required for absolute quantitation. The traditional comparative
Ct method or the ∆∆Ct method is an approximation method that assumes that each PCR
reaction is a perfect doubling. The ∆Ct between reference gene and target gene is calculated
for both the control condition and the test condition. The difference between these ∆Ct
values is the ∆∆Ct. The fold-change in expression of the gene of interest relative to the
110
reference gene is then given by 2∆∆Ct . I used a more accurate method for quantitation de-
scribed by Pfaﬄ [2001] which used pre-determined efficiencies for PCR reactions to produce
higher quality results.
Detemining efficiencies for the Pfaffel method was achieved by constructing a stan-
dard curve based on serial dilutions of template DNA over several orders of magnitude. A
typical curve extended from 10 to 0.01 ng RNA. The samples was amplified following the
cycling conditions to be used for the assay and the Ct values were determined for each
concentration. The Ct values were plotted against the logarithm of the amount of RNA
(ng) and a straight line was fitted to the data. Figure 6.18 shows a typical standard curve
obtained. The efficiency was determined according to Equation 6.1 where m is the gradient
of the efficiency plot. Convention varies but I used a value of 1 to mean a perfectly efficient
reaction with a doubling of product every cycle. Efficiencies should be between 0.9 and 1.1
for properly functioning primers. Efficiencies that were outside this range were often due to
off-target amplification or poor annealing and were solved by re-designing primers.
Figure 6.18: Example primer efficiency determination curve. This example curve was ob-
tained for primers for the gene TXNIP. The gradient of the line can be used to determine
efficiency using Equation 6.1.
Efficiency = 10
-1/m − 1 (6.1)
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Once primer efficiency had been determined, the ratio of relative expression levels
of the genes of interest in treated versus control conditions was determined according to
Equation 6.2, assuming β-actin as the loading control [Pfaﬄ, 2001].
Ratio =
(1 + Efficiencyβ-actin)∆Ctβ-actin(control−treated)
(1 + Efficiencytarget)∆Cttarget(control−treated)
(6.2)
6.6.8 Design of experiments
Each primer pair was thoroughly tested prior to analysis of samples to determine efficiency
and specificity by the methods described above. An RT− control was used with a typical
template to determine whether the genomic DNA present would amplify at a similar rate to
cDNA species. No cDNA species were sufficiently rare to amplify near the genomic DNA so
further RT− controls for each primer pair were not performed to save space on plates. The
loading control chosen for each experiment was β-actin, a commonly used house-keeping
gene. Using a single reference gene is potentially problematic if its expression varies with
experimental conditions. It would be beneficial to use multiple genes (e.g. GAPDH, 5S
RNA) simultaneously to ensure that the normalisation is correct and appropriate.
Experiments were designed to fit onto the minimum number of plates possible. A
given biological replicate was assayed for all genes of interest on one 96-well plate with three
technical replicates for each gene.
6.6.9 Sample analysis
After plate layout design, the plates were constructed and run on a real-time cycler. To
simplify preparation of the plates, a concentrated SYBR green-containing master mix was
purchased (SensiMix SYBR Low-Rox kit). This master mix contained a hot-start Taq
polymerase which was modified to cause complete inactivation before exposure to a high
temperature (95℃ for 10 min), thereby minimising primer-dimer formation and non-specific
amplification which could potentially be caused during sample set-up and handling.
Each well contained a final volume of 20µL comprising 1µL primer solution at 5 µM
for each primer in water, 1 µL template DNA, 8 µL water and 10 µL 2x SYBR green reaction
master mix. To minimise pipetting errors, the primer solution and the SYBR green solution
were combined into a single solution (11µL well−1) and the template DNA was diluted with
water to allow a pipetting volume of 9µL well−1.
After dispensing reagents, the plates were sealed with transparent plate seals and
mixed by vortexing. The plates were centrifuged briefly to sediment droplets of liquid
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in the wells and to eliminate frothing and bubbling caused by mixing. The plates were
transferred to the real-time cycler immediately if possible or stored at 4℃ for a maximum
of 24 hours before analysis. Each plate was cycled according to Figure 6.19 and fluorescence
measured each cycle during the extension phase. Fluorescence of the passive dye ROX was
also recorded each cycle and used by the machine to normalise signal fluorescence. Not all
plates were subjected to a dissociation stage since these are time-consuming. Instead, each
primer pair was tested thoroughly beforehand to ensure that the products were of a known
quality.
Figure 6.19: qPCR cycling conditions with SensiMix SYBR green reagents
6.6.10 Interpretation and analysis of amplification data
Analysis was undertaken only after all plates in an experimental set had been amplified. All
plates that formed part of one experiment were analysed together with the same analysis
conditions such as baseline and threshold values. The threshold is the fluorescence level,
past which a target is considered amplified; the baseline is the period at the start of the
cycling when there is little or no fluorescence. This was chosen to start after the initial
fluorescence reading had stabilised and stop before fluorescence due to amplification was
noticeable. It was crucial that the machine-generated values for thresholds be discarded as
they could lead to varying Ct values due to inter-plate variation. An example amplification
plot is given in Figure 6.20 to demonstrate choice of these values.
Relative gene expression was determined using the Pfaﬄ equation above and the
pre-determined primer efficiencies. Statistical analysis was performed on relative gene ex-
pression before normalisation. Finally, relative gene expression was normalised to the control
condition (5 mM glucose and 4 nM thiamine; −G−T).
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Figure 6.20: qPCR example sample amplification showing two genes in triplicate with
threshold and baseline values shown. The y-axis uses a logarithmic scale which means
that exponential amplification follows a straight line. Thus a threshold value of 0.2 has
been chosen since this lies within the exponential portion of amplification for both genes.
The baseline was adjusted from the common value of 3–15 to 3–12 so as to avoid the very
early amplification of gene 1.
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6.7 Immunohistochemistry
The immunohistochemistry studies were based on the Avidin-Biotin Complex (ABC) method
which uses the oxidation of 3,3'-diaminobenzidine (DAB) by a peroxidase linked antibody
to yield a brown stain. Nuclei were counterstained blue using Mayer’s haematoxylin.
Tissue was embedded in paraffin wax and 2–3 µm sections were cut using a micro-
tome and laid on the surface of water at 39℃ to remove creases. The sections were floated
onto silane-coated slides and dried in an oven at 60℃, a temperature just below the melting
point of the wax. Cut sections were stored at room temperature in the dark before use.
Before use, the paraffin sections were de-waxed by soaking in xylene for 5 min prior
to sequential transfer through baths of 100% isopropanol, 90% isopropanol and distilled
water for 5 min each. The dewaxed sections were subjected to antigen retrieval to break
some of the formalin crosslinks at either pH 4.5 (“Buffer C”), pH 6.0 (“Buffer A”) or pH 7.8
(4.13 mM tris base, 1.71 mM EDTA, 1.24 mM citric acid, pH 7.8 with sodium hydroxide)
in a bench-top antigen retrieval unit for 20 min. pH 7.8 was found to be optimal in all
cases. Following antigen retrieval, sections were delineated on the surface of the slides with
a hydrophobic PAP pen before being washed twice in PBS-tween wash buffer at pH 7.4 for
5 min each. The slides were soaked in a 1.5% w/w H2O2 solution in PBS-tween to quench
endogenous peroxidase activity. The slides were washed twice more for 5 min in PBS-tween.
Normal blocking serum (3 drops—150 µL) diluted in PBS (Vectastain Universal
Quick Kit) was added to each slide and left to incubate for 20 min at room temperature
before being drained off. To block the high endogenous levels of biotin in the kidney sections,
an avidin-biotin blocking kit was used. The slides were incubated for 15 min in avidin-D
solution and PBS-tween was used to rinse the slides prior to the addition of biotin solution
and a further 15 min incubation. The slides were finally rinsed with PBS-tween (2 × 5 min).
The primary antibody was diluted to an empirically pre-determined concentration
(between 1:50 to 1:750; 20–1.3 µg mL−1) in PBS-tween and 200µL was applied to each slide
before an overnight incubation at 4℃. The slides were subsequently washed with PBS-
tween (2 × 5 min) prior to incubation with the biotinylated secondary antibody (Vectastain
Universal Quick Kit) for 30 min at room temperature.
Following the secondary antibody step, the slides were washed in PBS-tween (2
× 5 min) before incubation with the streptavidin-peroxidase complex in PBS (Vectastain
Universal Quick Kit) for 30 min at room temperature. The slides were washed in PBS-tween
(2 × 5 min) prior to the addition of the peroxidase substrate (DAB) which was left to react
for 7 min at room temperature. The sections were sequentially briefly rinsed in distilled
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water (to prevent DAB precipitation) and PBS-tween. Mayer’s haematoxylin solution was
added to the slides for counterstaining (60 seconds, room temperature). The slides were
rinsed in distilled water prior to being allowed to “blue up” in the alkali PBS-tween wash
buffer for 2–3 min.
The stained slides were thoroughly dehydrated by passing them through baths of
distilled water, 90% isopropanol, 100% isopropanol and xylene before mounting in DPX
mountant. The DPX was allowed to harden under a coverslip and the slides observed by
light microscopy.
For immunohistochemical analysis of cells, glass slides were irradiated in a UV-
crosslinker for 2 hours to sterilise them. Sterile slides were transferred to a class II hood
and a 1 mL drop of medium containing cells was placed on each slide. The drop spread over
around one-half to two-thirds the surface of the slide with a final cell confluence between
5–20%. Each slide was returned within a sterile container to a humidified 37℃ incubator
with a 5% CO2, 95% air atmosphere. Cells adhered to the slides within a few hours and
were left to culture until harvested.
On the day of cell fixation, slides were placed in a slide rack and rinsed three times
in PBS to remove traces of medium. Slides were then transferred to a solution of 4%
formaldehyde in PBS and left overnight at room temperature to fix. Slides were rinsed free
of formaldehyde in water and left to air-dry. Slides were stored at room temperature in the
dark before use. Antigen retrieval and subsequent steps were used in a manner identical to
tissue paraffin-embedded tissue sections.
Negative control slides were prepared by replacing the primary antibody with PBS
during the overnight incubation step.
6.8 Immunoblotting
Individual protein abundance levels were quantified by immunoblotting with subsequent
chemiluminescent detection.
Protein samples were harvested or prepared by other procedures described herein
before mixing 1:1 with 2× loading buffer (1.25 mL 1 M tris.HCl pH 6.8, 3 mL glycerol, 1 g
SDS, 1 mL 10 mM EDTA, 500 µL β-mercaptoethanol, 10 mg bromophenol blue, q.s. to 10 mL
with water). After mixing, the protein was denatured at 95℃ for 10 min. SDS-PAGE gels
were prepared to the specifications in Table 6.10. Gel density was chosen empirically based
on the molecular mass of the proteins of interest. Gels were mounted into a gel-running tank
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and anode and cathode buffer was added (24.7 mM tris base—3 g L−1, 192 mM glycine—
14.4 g L−1 and 3.46 mM SDS—1 g L−1). Samples were loaded into the wells (at a maximum
volume of 20µL well−1) and then stacked at 80 V for 40 min. The gels were run at 110–130 V
until the dye front had almost migrated to the base of the gel.
The separated proteins were transferred to polyvinylidene fluoride (PVDF) mem-
brane using a semi-dry method. In detail, eight pieces of Whatman number 1 filter paper
were cut to the same size as the gel and soaked in transfer buffer (38.6 mM glycine—2.9 g L−1,
23.1 mM tris base—2.8 g L−1 and 20% v/v methanol in water). One piece of PVDF mem-
brane was cut the same size as the gel and first soaked in 100% methanol before soaking in
transfer buffer. The gel was removed from the cassette and soaked briefly in ice-cold transfer
buffer. The transfer unit carbon electrodes were wetted with transfer buffer and then the
following were built up from bottom to top: positive electrode, four sheets of Whatman
number 1 filter paper, the PVDF membrane, the gel, four more pieces of filter paper and
then the negative electrode. The stack was rolled gently with a glass rod to remove air bub-
bles before starting transfer. The proteins were transferred from gel to membrane by setting
up a current of 120–150 mA through the stack at up to 12 V for 90–150 min depending on
gel size.
After transfer, the membrane was removed from the stack and blocked overnight
at 4℃ in 2% BSA or 5% non-fat milk powder in tris buffered saline with tween (TBS-T:
0.8% NaCl w/v, 20 mM tris.HCl, pH 7.5—2.42 g L−1 and Tween 20 0.1% v/v). Validation
studies were completed to ascertain experimental conditions such as the choice of blocking
agent, primary and secondary antibody concentrations and incubation time. After blocking,
the membrane was incubated in primary antibody solution prepared in blocking agent in
TBS-T using the pre-determined concentration and time. The membrane was removed from
the primary antibody solution and rinsed several times in TBS-T before incubation in an
animal-specific horseradish peroxidase-linked secondary antibody solution. The membrane
was rinsed thoroughly in TBS-T several times. Finally, the membrane was covered evenly
with freshly mixed enhanced chemiluminescence (ECL) solution, left to stand for one minute
and then sandwiched between two layers of cling film and exposed to X-ray film until bands
appeared. Exposed films were developed, fixed and rinsed in water before drying. Bands
were quantified by scanning the film using an Amersham Biosciences ImageScanner and
densitometry was performed using ImageJ software.
If necessary, the membranes were then stripped of antibody by rinsing for one hour
at room temperature in stripping buffer (6.25 mL tris.HCl pH 6.8, 2 g SDS and 714µL
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β-mercaptoethanol per 100 mL). After stripping, the membrane was washed in TBS-T,
re-blocked and re-probed with a second antibody.
6.8.1 Enrichment of membrane proteins
For immunoblot analysis of membrane proteins, an enriched membrane-containing fraction
was prepared using a method adapted from Bahia et al. [2003] before separation by elec-
trophoresis. Cells under culture were washed twice with ice-cold PBS. A cell pellet was
harvested by scraping cells from a tissue culture flask and then sedimenting them by cen-
trifugation in PBS (5 min, 125× g, 4℃). The supernatant was discarded and the cells
were disrupted by sonication in lysis buffer(50 mM tris-HCl, pH 7.4 at 4℃, 50 mM EDTA
and protease inhibitor cocktail) for 10 seconds on ice. The membranes were collected by
centrifugation (30 min, 20 000× g, 4℃) and were resuspended by brief sonication in resus-
pension buffer (50 mM tris-HCl, pH 7.4 at 4℃, 3 mM MgCl2 and 2% SDS) before analysis
by immunoblotting.
6.9 Enzyme-linked immunosorbent assay
sVCAM-1 analysis was carried out using a sandwich ELISA kit. Plasma samples were diluted
20-fold and 100µL added to the wells of a 96-well microplate according to instructions from
the manufacturer. The secondary enzyme-linked antibody was added to the well (100µL)
and the plate sealed and allowed to incubate for 90 min at room temperature. Each well
was aspirated and washed with wash buffer (4× 100 µL) before colour reagent (100 µL) was
added to each well. The hydrogen peroxide and the chromogen (tetramethylbenzidine) in
the colour regent are catalysed by the peroxidase for 20 min in the dark at room temperature
to yield a blue colour. The reaction is stopped by the addition of stop solution (2 N H2SO4,
50 µL) which yields a yellow colour. The plate was read within 30 min at 450 nm with
reference wavelength correction at 540 nm.
For each plate, standards were added to the plate in the range 6.25–200 ng mL−1.
A standard curve was constructed and sVCAM-1 concentrations deduced with reference to
the curve.
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6.10 Transketolase activity assay
The activity of transketolase was measured by an enzymatic kinetic method originally de-
veloped by Smeets et al. [1971] which couples the formation of glyceraldehyde-3-phosphate
(G3P) from ribose-5-phosphate (R5P) and xylulose-5-phosphate (X5P) to the oxidation
of NADH using triose phosphate isomerase (TPI) and glycero-3-phosphate dehydrogenase
(GDH). The method was further improved by Tate and Nixon [Tate and Nixon, 1987] who
modified the concentrations of the linking enzymes to reduce the lag inherent to the assay.
The version of the assay used for this work is based on the work of Chamberlain et al. [1996]
which involved further optimisations for a stable reaction mixture.
R-5-P + X-5-P Transketolase−−−−−−−−→ Sedoheptulose-7-phosphate + G3P
G3P TIM−−−→ DHAP
DHAP + NADH + H+ GDH−−−→ Glycerophosphate + NAD+
Approximately 1× 106 cells were trypsinised and washed thoroughly in ice-cold PBS
to remove traces of medium and trypsin before sonication for 10 s in 100µL 10 mM sodium
phosphate buffer and 1% protease inhibitor cocktail. The membranes were sedimented by
centrifugation (30 min, 20 000× g, 4℃) and the cytosolic supernatant assayed for transke-
tolase activity. The sample to be analysed was incubated with the assay cocktail and the
reduction in absorbance at 340 nM due to removed NADH was monitored.
6.10.1 Calibration standard curve
An NADH standard curve for calibration of the assay was prepared in the range of 0–6 nmol
NADH per microplate well (Table 6.11). An example standard curve is given in Figure 6.21.
6.10.2 Preparation of assay cocktail
A 10 mL assay cocktail sufficient for 50 assays was prepared by mixing the following (final
concentrations are listed in parentheses): 5 mL 500 mM tris-HCl, pH 7.8 (250 mM); 1 mL
148 mM ribose-5-phosphate (14.8 mM); 253 µL 10 mM NADH (253 µM); triose phosphate
isomerase (185 U ml−1); glycerol-3-phosphate dehydrogenase (6 U ml−1) and water to a final
volume of 10 mL.
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Amount of
NADH
(nmol)
500 mM
Tris-HCl pH
7.8 (µL)
100 µM
NADH (µL)
Water (µL) Total
volume (µL)
0 115 0 115 230
1 115 10 105 230
2 115 20 95 230
3 115 30 85 230
4 115 40 75 230
5 115 50 65 230
6 115 60 55 230
Table 6.11: Transketolase assay NADH standards preparation volumes
Figure 6.21: Example standard curve for NADH typically observed during a transketolase
assay. The range is from 0–6 nmol well−1 in a total volume of 230µL.
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6.10.3 Analysis of samples
Two wells in a 96-well microplate were used for analysis of each replicate of each sample.
Both wells had 200 µL assay cocktail added and then one had 10 µL water added to it to
assay native transketolase activity whilst the other had 10 µL 8 mM thiamine pyrophosphate
added to it to saturate the transketolase and measure the “thiamine effect”—or percentage
unsaturated transketolase. The wells were mixed thoroughly by pipetting and 10 µL 5-
fold diluted cell lysate was added to each well before mixing again. The absorbance was
monitored at 340 nm every 2 min for 3 hours at 37℃ with regular orbital shaking prior to
each read cycle in a microplate reader. The order of addition proved critical with samples
giving spurious and poorly reproducible results when added in other orders.
The A340 was plotted against time for each sample and the linear portion of the plot
(Figure 6.22) was used for determination of the gradient of the data. The time-frame for
the linear portion was chosen so that for all samples analysed, the curve was linear within
that range. The rate of decrease of NADH was quantified using the standard curve and
was converted into transketolase activity normalised to protein concentration. Data were
expressed as units of transketolase activity per mg protein.
Figure 6.22: Example transketolase assay reaction curve. This typical curve shows the initial
accelerating decrease in absorbance with a central linear section and a terminal plateau. The
linear section was used for analysis of rate of reaction
The thiamine effect is the percentage unsaturation of transketolase with thiamine
pyrophosphate and is determined using Equation 6.3 where ∆A340 TPP− is the change in
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absorbance for the sample incubated without thiamine pyrophosphate (i.e. apoenzyme not
active) and ∆A340 TPP+ is the change in absorbance for the sample incubated with thiamine
pyrophosphate (i.e. apoenzyme has been saturated with cofactor and is now active).
Thiamine effect (%) =
∆A340 TPP− −∆A340 TPP+
∆A340 TPP+ × 100 (6.3)
6.11 Thiamine transport studies
Tritiated thiamine can be used as a tracer to follow the movement of thiamine introduced
to cells. Two sets of experiments were performed using tritiated thiamine. The first was
a simple uptake or release experiment. For uptake, the cells were exposed to tritiated
thiamine for a set time and the amount taken up quantified. For release, the cells were pre-
loaded with tritiated thiamine then release was measured during a subsequent timed release
period. In both cases, transport rates relative to amount of protein can be determined. The
second measured in situ transport across the membrane by culturing the cells on a semi-
permeable support. By introduction of the labelled compound on one side of the membrane,
its movement to the other side over a period of time could be measured.
6.11.1 Tritiated thiamine uptake study
The simple uptake experiment was performed using the HK-2 cell line. Cells were seeded
in advance in 6-well plates and cultured for five days in one of four conditions: 5 mM
glucose and 4 nM thiamine (−G−T), 5 mM glucose and 4 µM thiamine (−G+T), 26 mM
glucose and 4 nM thiamine (+G−T) or 26 mM glucose and 4µM thiamine (+G+T). At the
commencement of the study, each well was washed three times with 2 mL Krebs-Ringer
solution at 37℃. Krebs-Ringer solution contained 133 mM NaCl, 4.93 mM KCl, 1.23 mM
MgSO4, 0.85 mM CaCl2, 5 mM glucose, 5 mM glutamine and 20 mM HEPES at pH 7.4
at 37℃ and 4℃. After rinsing, each well had 1 mL 15 nM 3H thiamine solution added
in Krebs-Ringer solution. The fluid was evenly dispersed over the cells and the plates
were incubated at 37℃ for 10 min. After incubation, the plates were removed from the
37℃ heating chamber and placed on a bed of ice. The supernatant containing the bulk
of the 3H thiamine was discarded. The cells were washed three times with 2 mL ice-cold
Krebs-Ringer solution to remove extracellular thiamine. The cells were lysed by addition
of 1 mL 1 M NaOH. The lysates were transferred to microcentrifuge tubes and the lysate
was clarified by centrifugation (2 min, 1000× g, 21℃). 0.5 mL clarified cell lysate was mixed
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thoroughly with 4 mL scintillation fluid. Each sample was counted for 5 min in a scintillation
counter. A portion of the remaining cell lysate was used to determine protein concentration
using the Bradford assay.
Having determined the radioactivity present in the scintillation tube, it was possible
to determine the total radioactivity present in the cells in the well. A blank value for the
radioactivity was determined from an uptake experiment with only non-radioactive thiamine
and subsequently subtracted from each of the results. By combining knowledge of the
specific activity of the thiamine, radioactivity in the cells and protein present in the well it
was possible to determine an uptake rate in fmol 10 min−1 mg protein−1.
6.11.2 Tritiated thiamine release study
Proximal tubule cells will, in vivo, transport thiamine from the proximal tubule lumen to
the vasculature. This means that they both take up and release thiamine. Thus, in addition
to studying uptake rate of tritiated thiamine, the release rate from cells pre-loaded with 3H
thiamine was also studied. HK-2 cells were prepared in 6-well plates in the four conditions
described above. All cells were pre-cultured for 5 days before experimentation. On the day
of the experiment, the cells were rinsed free of medium using 3x2 mL Krebs-Ringer solution
at 37℃. The cells were then pre-loaded with 3H thiamine for 5 hours by incubating cells
with 1 mL DMEM/F-12 medium containing either 5 mM or 26 mM glucose as relevant and
15 nM 3H thiamine. The cells were placed at 37℃ in a 5% CO2 humidified incubator for
duration of the incubation. After the uptake period had elapsed, the cells were processed as
quickly as possible. The incubation medium was discarded and the cells were rinsed with
2x2 mL Krebs-Ringer solution at 37℃, taking care to aspirate fully after each addition. Only
two wash steps were used since the original thiamine concentration was only 15 nM and two
rinses would be sufficient to lower that to effectively 0 nM whilst minimising the time when
the cells are releasing thiamine in an unmeasured manner. After rinsing, each well had
1 mL Krebs-Ringer solution added at 37℃ and the plates were returned to a 37℃ heating
chamber for 10 min. After this time had elapsed, the plates were chilled on ice and the
1 mL supernatant collected. The cells were rinsed three times with 2 mL ice-cold Krebs-
Ringer buffer and the cells were lysed in 1 mL 1 M NaOH. The lysates were collected in
micro-centrifuge tubes and clarified by centrifugation (2 min, 1000× g, 21℃). 0.8 mL lysate
supernatant or 0.75 mL 3H thiamine release supernatant was mixed with 4 mL scintillation
fluid and mixed thoroughly. Each sample was counted for 5 min in a scintillation counter.
The Bradford assay was used to determine protein concentration.
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The scintillation results and the protein analysis were used to determine the amount
of intracellular thiamine and the amount of thiamine released from the cells into the super-
natant over 10 min.
6.11.3 Transwell inserts
Transwell inserts allow monolayers of cells to grow with access to both apical and basal
chambers. A schematic is shown in Figure 6.23. The microporous membrane in the inserts
used was made from polycarbonate and had 0.4 µm pores at a density of 1× 108 pores cm−2.
The inserts fitted into the wells of a 12-well microplate and had a total area of 1.12 cm2
each. Cells were seeded onto the inserts at 30–50% confluence.
Figure 6.23: Schematic of a Transwell insert
6.11.4 Lucifer yellow permeability
The confluence and integrity of epithelial monolayers grown on Transwell inserts was deter-
mined using trans-epithelial transport rates of Lucifer yellow dye. Confluent and undamaged
monolayers normally allow only low levels of Lucifer yellow to pass via the paracellular route.
Damaged monolayers allow much higher transport rates. The methods for this type of assay
are well established for use in the 21-day old Caco-2 monolayer system—a human colon car-
cinoma cell line—as a model for gut epithelial transport [Lindhardt and Bechgaard, 2003;
Hubatsch et al., 2007; Konsoula and Barile, 2005].
The rate of transport of Lucifer yellow is expressed as an apparent permeability
coefficient (Papp) which can be calculated according to the the formula displayed in Equation
6.4 [van de Waterbeemd and Testa, 2008]. Papp (units of cm s−1) is calculated from dQ/dT
which is the steady state flux across the membrane (µmol s−1), A which is the surface
area of the filter (cm2) and C0 which is the initial concentration in the donor chamber (in
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µmol cm−3). It is assumed that the sink concentration never exceeds 10% of the donor
concentration i.e. the sink conditions are fulfilled.
Papp =
(
dQ
dT
)(
1
A.C0
)
(6.4)
A reference value for Papp for Lucifer yellow across intact monolayers of kidney
proximal tubule cells is not known. Most published estimates are from companies special-
ising in transport assays across monolayers of Caco-2 cells. These estimates are around
1.1× 10−6 cm s−1 e.g. [NoAb BioDiscoveries, 2009; Marine Biotechnology Research Centre,
2009] for Caco-2 monolayers and from 1–9× 10−6 cm s−1 for ex vivo intestine membranes
[Huynh et al., 2002]. Estimates for Madin-Darby Canine Kidney cell monolayers are much
higher, for example 30× 10−6 cm s−1 [NoAb BioDiscoveries, 2009].
Cells to be assayed were seeded at around 30–50% confluence on the Transwell
membranes as described in the instructions from the manufacturer. The cells were allowed
to grow to confluence and then left for 7 days post-confluence with bi-daily medium changes
to allow complete tight junction formation. To assess the integrity of the membrane, the
medium in the apical compartment was replaced with medium supplemented with Lucifer
yellow dye (1 mg mL−1). The inserts were transferred to wells containing fresh medium and
placed on an orbital shaker at 120 revolutions min−1 in a humidified incubator at 37℃ for
1 hour. Following incubation, the contents of the apical and basal chambers were collected,
the cells washed once with warm medium to remove excess dye and then placed in new wells
with fresh medium to allow continued growth.
The apical and basal media collected were diluted to within the standard range into
fresh medium and pipetted in triplicate in wells in a black 96-well microplate. A standard
curve was constructed in the microplate in triplicate in the range of 0–0.25 mg mL−1 Lucifer
yellow in medium. Fluorescence was measured with an excitation at 410 nm (λmax = 425 nm)
and emission at 520 nm (λmax = 528 nm). A double reciprocal standard curve was plotted
with the reciprocal of fluorescence against the reciprocal of the standard concentration and
the LY concentrations of each sample deduced accordingly. As an additional check, the mass
balance (i.e. the total recovered Lucifer yellow in apical and basal chambers) was calculated
as a percentage of the total Lucifer yellow introduced to the system. Mass balances between
90–110% were considered acceptable. Wells with mass balances outside this range were
discarded from analysis.
Using the concentrations in each chamber and the time elapsed for transport, the
Papp for Lucifer yellow for the cells was deduced in accordance with Equation 6.4.
126
6.11.5 Epithelial transport studies
Monolayers of primary cells were grown as described above in each of four conditions
(−G−T, −G+T, +G−T and +G+T). On the day of assay, the Lucifer yellow test was
carried out as described above to ensure that the cells had formed confluent monolayers.
Medium was removed and the monolayers rinsed twice apically and basally in sterile Krebs-
Ringer solution at 37℃ to remove excess thiamine. Krebs-Ringer solution with a known con-
centration of tritiated thiamine was placed in the freshly aspirated apical chamber and the
insert placed in a well of a 12-well plate with fresh Krebs-Ringer solution at 37℃. The plate
was returned to a 37℃ incubator and placed on a rotating platform at 120 revolutions min−1.
At 15 min, a 10µL sample was removed from the apical chamber and the insert moved to a
second fresh well of Krebs-Ringer solution. The plate was again returned to the incubator.
This procedure was repeated at time points at 30, 45 and 60 min. Following the last time
point, the monolayers were rinsed with Krebs-Ringer solution and the procedure repeated
with a second concentration of thiamine in the apical chamber. 6 concentrations were as-
sayed: 10, 25, 50, 100, 150 and 200 nM—a range which significantly surpasses the expected
K m of transport, 70 nM [Ashokkumar et al., 2006]. Each well was used for all concentrations
with the lowest concentration first, rising to the highest concentration.
A simplified version of the same experiment was conducted in forward and reverse
orientations to compare transport in both directions (i.e. from basal to apical and vice
versa). The simplified version was chosen because it is not possible to replace the api-
cal chamber fluid repeatedly on such a short time-scale without excessive damage to the
monolayer. 15 nM 3H-thiamine was placed in the apical chamber and the accumulation
of 3H-thiamine in the basal chamber monitored over 20 min. The membranes were then
rested for 30 min at 37℃ in Krebs-Ringer solution with no thiamine present before 15 nM
3H-thiamine was placed in the basal chamber and the apical chamber accumulation moni-
tored over 20 min. The solutions collected from the apical and basal chambers were mixed
with scintillation fluid and the radioactivity counted. The Papp values for each well in each
direction were determined.
6.12 Protein assays
Protein concentration was assayed by one of two techniques. The majority of samples were
assayed using the Bradford technique and a minority assayed using the DC protein assay
kit where reagents were incompatible with the Bradford dye (e.g. high SDS concentration).
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6.12.1 Bradford assay
The Bradford protein assay is an absorbance assay based on the colour shift of the Coomassie
dye from a red form to a blue protein-bound form [Bradford, 1976]. Bradford dye was
purchased as a concentrate and was diluted prior to use according to the instructions from
the manufacturer.
Protein samples to be analysed were diluted to an within the standard range (be-
tween 0.1–1.2 mg mL−1) and 20µL pipetted in triplicate into the wells of a 96-well mi-
croplate. Standard solutions of bovine serum albumin (BSA) in the range above were also
pipetted in triplicate into the plate. BSA solutions were previously calibrated by UV absorp-
tion at 280 nm using an ε1% value of 6.6. Diluted Bradford dye (200 µL) was pipetted into
each well and mixed thoroughly. Absorbance at 595 nm was read immediately. A standard
curve was constructed and the concentration of protein in each sample deduced accordingly.
6.12.2 DC protein assay
Where buffer composition was incompatible with the Bradford dye, the BioRad DC protein
assay was used which is based on Lowry detection of protein using alkaline copper tartrate
solution and Folin reagent [Lowry et al., 1951]. This is also an absorbance-based assay with
three reagents which are combined according to protocol supplied by the manufacturer. A
diluted sample was pipetted into the wells of a 96-well microplate in triplicate. A standard
curve was constructed in the range of 0.2–1.5 mg mL−1 in the same buffer as the samples.
The DC protein assay kit reagents were pipetted into the wells and a blue colour developed
in proportion to the concentration of protein present. The absorbance of the plate was
measured at 690 nm immediately, a standard curve was constructed and the concentration
of protein in each sample deduced accordingly.
6.13 Glucose assay
Glucose concentration was assayed by an end-point enzymatic assay based on peroxidase and
glucose oxidase (PGO). The two sequential reactions shown below (Equations 6.5 and 6.6)
produce the chromophore oxidised o-dianisidine in direct correlation with the concentration
of glucose.
Glucose + 2H2O + O2
Glucose oxidase−−−−−−−−−−→ Gluconic acid + 2H2O2 (6.5)
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H2O2 + o-dianisidine (colourless)
Peroxidase−−−−−−−→ Oxidised o-dianisidine (coloured) (6.6)
A combined enzyme-colour reagent was prepared by dissolving one capsule of PGO
enzymes into water (100 mL) and adding o-dianisidine dihydrochloride solution (1.6 mL at
2.5 mg mL−1) according to the instructions from the manufacturer. Samples were diluted
to within the standard range (0–1.2 mM glucose) and 25µL of each diluted samples was
incubated in triplicate with 225 µL combined enzyme-colour reagent at room temperature
for 45 min in the well of a 96-well microplate. The absorbance was measured at 450 nm
with the absorbance at 690 nm measured as a reference wavelength. A standard curve was
constructed and the concentration of glucose in each sample deduced.
6.14 Thiamine supplementation trial
Diabetic patients from the Diabetes Clinic at the Sheikh Zayed Hospital, Lahore, Pakistan
were recruited between October and December 2006 for a trial on the effects of thiamine
on diabetic nephropathy. The main inclusion criteria were type 2 diabetes with persistent
microalbuminuria (albumin excretion rate (AER) 30–299 mg 24 h−1), age 35–65 years, a
diabetes duration ≥5 years, HbA1c ≤12.5% and a BMI 19–40 kg m−2. The main exclusion
criteria were significant comorbidities, known allergy or intolerance to thiamine, use of
thiamine supplements, participation in an intervention study within 30 days, recipients
of renal or pancreatic transplants, women who were pregnant or breastfeeding or of child
bearing age not using adequate contraceptive precautions.
Forty patients were recruited and randomly assigned (by random number table
method) to receive either placebo or 3 × 100 mg thiamine tablets per day for 3 months
followed by a 2 month washout period. Despite this dose of thiamine exceeding the RDI
by 200 times, no adverse effects were expected due to the very low oral toxicity of thi-
amine. Side effects have been observed with doses above 7000 mg day−1 [Expert Group On
Vitamins and Minerals, 2003] and sometimes with parenteral administration of the vitamin
[Haake et al., 1971; Wrenn and Slovis, 1992; Wrenn et al., 1989]. Any potential adverse
effects of the thiamine treatment were assessed by kidney function (serum creatinine and
urea nitrogen) and liver function (serum alanine transaminase, aspartate transaminase and
alkaline phosphatase activities and bilirubin) tests.
Twenty four hour urine and fasting blood samples were collected with informed
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consent from participants. Plasma and erythrocytes were separated by centrifugation and
stored at −80℃ immediately following collection and prior to analysis for thiamine metabo-
lites and other blood biochemistry markers. The trial was registered at the Clinical Trials
Registry—India (CTRI/2008/091/000112) and ethical approval for the study was given by
the Ethical/Protocol/Synopsis Committee of Sheikh Zayed Federal Postgraduate Medical
Institute, Lahore, Pakistan (Eth/P609/FPGMI/2006) [Rabbani et al., 2009].
6.15 Statistical analysis
For statistical purposes, n is considered to be a biological replicate which was treated sep-
arately during the course of an experiment and analysed separately. The limit to which
interpretation of n as a concept can go is ambiguous. No-one expects multiple different
vials of cells or reagents to be ordered from a supplier or multiple pieces of equipment to be
used for each assay yet obviously experiments need to be repeatable. It is to avoid ambiguity
that I have defined my use of n here.
In addition to biological replicates, some assays used technical replicates e.g. multi-
ple wells for a biological replicate in a microplate for a transketolase activity assay. In these
cases, a repeated measures ANOVA was used with appropriate post hoc tests to correctly
analyse the data produced.
For single comparisons between two sets of parametric data, a Student t-test was
conducted to determine significance. For multiple group comparisons, an ANOVA was per-
formed followed by either a Bonferroni or Tukey HSD post hoc tests for individual compar-
isons. The Bonferroni adjustment was chosen when only a limited number of comparisons
were being made or when unequal sample sizes prevented use of the Tukey comparison. All
statistical comparisons were made in SPSS, Gnumeric or GraphPad Prism.
For the Pakistan supplementation trial, statistical tests were all two-sided (<0.05).
Significances of differences between mean and median analytes of thiamine treatment and
placebo groups were determined using Student’s t-test and a Mann-Whitney U test, respec-
tively. Significances of differences from baseline and post-therapy and post-washout period
mean and median analytes were determined using a paired samples t-test and a Wilcoxon
signed-rank test, respectively. Correlation analysis was performed by calculating the Spear-
man rho statistic. Significance of difference of proportions was made by reference to Finney’s
2× 2 contingency tables [Rabbani et al., 2009].
All data are presented as means ± standard deviation unless otherwise specified.
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Results and Discussion
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Chapter 7
Immunohistochemistry
characterisation of human
kidney cells
The phenotypes of freshly isolated human proximal tubule epithelial cells (PTECs) were
characterized by immunohistochemistry (IHC). After kidney digestion and Percoll density-
gradient centrifugation, as described in Section 6.3, three fractions of cells were obtained.
Cells from each fraction were seeded onto glass slides, allowed to adhere, fixed with formalde-
hyde and then stained independently for aquaporin-1 (Aqp-1) and Tamm-Horsfall protein
(uromodulin or UMOD). In all cases, nuclei were stained blue by Meyer’s haematoxylin and
the antigen of interest was stained brown using DAB.
Aqp-1 is considered a marker for the proximal convoluted tubule and the descending
loop of Henle [Tanaka et al., 2008] and is not found in the distal tubules. UMOD is considered
a marker for the thick ascending limb of the loop of Henle [Sikri et al., 1981; Allen and Tisher,
1976] and is not found in proximal tubule cells or the glomeruli [Baer et al., 1997]. A
qualitative assessment of the abundance of staining on each slide was made as quantitative
data were unnecessary to correctly identify cell populations. Aqp-1 immunostaining was
weak in the top fraction of the Percoll density gradient with only a few cells stained (Figure
7.1). The middle fraction had a higher percentage of cells staining for Aqp-1 but still <30%,
likely due to contamination from the lower band of cells or from cells from the proximal
portion of the loop of Henle (Figure 7.2). Contamination is likely to have arisen due to the
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diffuse banding evident after Percoll centrifugation (Figure 6.1, page 88). A longer density-
gradient separation could have been used to provide more discrete fractions but was not
used because the longer centrifugation would lead to decreased cell viability with only a
marginal increase in the yield of PTECs. Near universal, high-intensity staining for Aqp-1
was evident in the lower fraction of cells (Figure 7.3). UMOD staining was absent or at very
low levels in all three fractions obtained (Figures 7.4, 7.5 and 7.6) which is consistent with
the absence of the medulla boundary zone (thick ascending loop of Henle).
To corroborate the location specificity of Aqp-1 and UMOD as reported in the
literature, paraffin-embedded sections of normal human kidney were stained for each protein.
Figure 7.7 shows the immunostaining pattern of Aqp-1 in normal human kidney. There was
heavy staining in the cortex and very little staining in the medulla. Figures 7.8 and 7.9 are
details of normal human cortex and medulla respectively. These show that Aqp-1 staining
was specific to the proximal tubules and not glomeruli or distal tubules. A series of similar
experiments with immunostaining for UMOD indicated that UMOD was mainly found in
the medulla (Figure 7.10). Closer examination of the cortex and the medulla (Figures 7.11
and 7.12 respectively) indicated a complete absence of staining in the cortex, including both
glomeruli and tubules, whilst staining is present in the medulla in the ascending limb of
Henle.
A negative control was performed for each culture condition, cell fraction or kid-
ney section assayed by immunohistochemistry by omitting the primary antibody from the
overnight incubation step. Negative controls gave no significant staining, see Figure 7.13.
By combining the staining patterns of UMOD and Aqp-1 in whole kidney sections with the
staining patterns in the cells from the different fractions of the Percoll density gradient, the
bottom fraction of cells could be identified as containing predominantly PTECs.
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Figure 7.1: Aqp-1 immunostaining in cells from the top fraction of the Percoll density
gradient. Stained cells are a small minority of the population. Magnification is 200x.
Figure 7.2: Aqp-1 immunostaining in cells from the middle fraction of the Percoll density
gradient. Stained cells comprise the minority of cells (possible contamination from the
bottom fraction). Magnification is 200x.
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Figure 7.3: Aqp-1 immunostaining in cells from the bottom fraction of the Percoll density
gradient. The staining is intense and near universal confirming this cell population is PTECs.
Magnification is 200x.
Figure 7.4: UMOD immunostaining in cells from the top fraction of the Percoll density
gradient. Staining is very weak. Magnification is 200x.
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Figure 7.5: UMOD immunostaining in cells from the middle fraction of the Percoll density
gradient. Staining is very weak. Magnification is 200x.
Figure 7.6: UMOD immunostaining in cells from the bottom fraction of the Percoll density
gradient. Staining is very weak. Magnification is 200x.
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Figure 7.7: Aqp-1 immunostaining in a normal human kidney section. The cortex and the
medulla are clearly delineated with heavy staining in the cortex and little in the medulla.
Magnification is 16x.
Figure 7.8: Aqp-1 immunostaining in a normal human kidney cortex section. There is heavy
staining in the proximal tubules, especially in the brush border. There is comparatively little
staining in the glomeruli. Magnification is 200x.
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Figure 7.9: Aqp-1 immunostaining in a normal human kidney medulla section. Staining is
very weak in the distal tubules and loops of Henle. Magnification is 200x.
Figure 7.10: UMOD immunostaining in a normal human kidney section. The cortex and the
medulla are clearly delineated with heavy staining in the medulla and absence of staining
in the cortex. Magnification is 16x.
138
Figure 7.11: UMOD immunostaining in a normal human kidney cortex section. There is no
significant staining in any part of the cortex. Magnification is 200x.
Figure 7.12: UMOD immunostaining in a normal human kidney medulla section. Staining
is strong in the ascending limbs of Henle. Magnification is 200x.
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Figure 7.13: Kidney extract cell culture IHC negative control sample image. No immunos-
taining was evident in any negative control slide. Magnification is 200x.
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Chapter 8
Immunohistochemistry thiamine
transporter staining
8.1 Immunostaining of kidney thiamine transporters
A qualitative assessment of the location of the thiamine transporters THTR-1 and THTR-
2 throughout the kidney was made in sections taken from five paraffin-embedded normal
human kidneys.
The typical immunostaining pattern observed for THTR-2 was for strong staining in
the proximal tubules, with the most intense staining at the apical membrane brush border.
There was no staining observed in the distal tubules and only very weak staining observed
in the glomeruli. Generally, only weak staining was seen at the basal membrane of PTECs.
In most PTECs, the cytoplasm stained to an intermediate intensity for THTR-2. This
cytoplasmic stain was often polarised, with darker staining towards the apical membrane of
the cells and lighter staining towards the basal membrane. This would be consistent with the
synthesis of THTR-2 and transport to the apical, but not the basal, membrane. Example
images from three different kidneys are given in Figures 8.1, 8.2 and 8.3. A wider field of
view of staining for THTR-2 in a kidney cortex is given in Figure 8.4. A more magnified
image of the staining in a fourth kidney cortex is given in Figure 8.5.
The immunostaining for THTR-2 in the medulla was much weaker than the staining
in the cortex. There was some weak apically-aligned staining in the epithelial cells of some
tubules, probably the proximal section of the descending loops of Henle. There was also
some weak and diffuse cytoplasmic staining in other tubules in the medulla. An image of
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THTR-2 staining in the medulla of a normal kidney is given in Figure 8.6. There was only
poor staining in smooth muscle lining arterioles in the kidney (Figure 8.7).
Work by Subramanian et al. [2006] in cell culture systems indicated that THTR-2 is
more predominantly located on the apical membranes of polarised cells. Also, the proximal
tubule is the region of the nephron responsible for re-absorption of the majority of valuable
small molecules from the ultrafiltrate. Thus the hypothesised location for THTR-2 is the
brush border of PTECs with little staining elsewhere. The observed staining patterns for
THTR-2 in the kidney sections corroborate this hypothesis. There is a strong apical polarity
for THTR-2 with high intensity staining evident on the apical faces of proximal tubule cells
and to a much lower extent, some cells in the medulla.
The typical staining pattern observed for THTR-1 was different to that observed for
THTR-2. The staining in the glomeruli was weak or absent and there was strong staining
in the proximal tubule epithelial cells, both similar to the staining patterns for THTR-2.
In contrast to the staining patterns for THTR-2, the proximal tubule epithelia were not
as markedly polarised although apical polarisation was still prominent in large numbers of
tubules. There was relatively strong cytoplasmic staining in the proximal tubule epithelia.
Strong staining was also seen in many distal tubule sections. Often this staining was observed
to occur on every other cell around the circumference of a tubule section (e.g. Figure 8.8).
Example staining patterns for THTR-1 in normal human kidney cortex sections from three
different kidneys are presented in Figures 8.8, 8.9 and 8.10. In the inner medullary region,
the loops of Henle did not stain for either THTR-1 or THTR-2 but the collecting ducts
stained strongly for THTR-1 but not THTR-2, see Figure 8.11.
Work by Subramanian et al. [2003] in cell culture systems indicated that THTR-
1 is more likely to be localised to both apical and basal membranes in polarised cells.
THTR-1 should also be predominantly located in the proximal tubule. This is not the case
when examining kidney sections. The localisation of THTR-1 in the distal tubules and
the collecting ducts was unexpected. Work by Mahajan and Acara [1994] used rat kidney
sections and reported that there was measurable thiamine uptake by the medulla although
this report may not be reliable as it was published before the discoveries of THTR-1 and
THTR-2 and says that there is no active uptake of thiamine in the kidney sections, either
cortical or medullary. In the cortex, there are cells at the most distal region of the ascending
limb of Henle that have extensive coverings of villi [Allen and Tisher, 1976] and it may be
these that are expressing THTR-1 in addition to the proximal tubules.
Negative control slides for every kidney stained were prepared by omitting the pri-
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mary antibody from the overnight incubation step. No staining was seen on any negative
control slide, see Figure 8.12.
Although it is possible to deconvolute multiply stained images such as these into
separate channels [Ruifrok and Johnston, 2001], these images cannot be used for secure
quantitation of antigen [van der Loos, 2008], because: (i) multiple steps of chromogen
production in the triple-stepped development are non-stoichiometric for antigen; and (ii) the
DAB chromophore does not follow the Beer-Lambert law—DAB colour is due to a scattering
of light rather than to absorbance. These limitations notwithstanding, qualitative analysis
of the images may still be performed.
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Figure 8.1: THTR-2 immunostaining in a normal human kidney cortex. Staining is relatively
weak in the glomerulus (blue circle) and the distal tubules (black arrows). There is heavy
staining in the crenellated brush borders in the proximal tubule epithelial cells (red arrows)
but relatively weak staining of the basal membrane of the same cells (green arrows). Scale
bar represents 100µm.
Figure 8.2: THTR-2 immunostaining in a second normal human kidney cortex. The staining
pattern is very similar to that seen in Figure 8.1. There is staining in the brush borders of
the proximal tubule epithelial cells (red arrows). There is no staining in the glomeruli (blue
circles), distal tubules (black arrows), smooth muscle (red circle) or the basal membranes
of the PTECs (green arrows). Scale bar represents 100 µm.
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Figure 8.3: THTR-2 immunostaining in a third normal human kidney cortex. Staining
similar to Figures 8.1 and 8.2 although stronger. Blue circle: glomerulus; red arrows:
PTEC brush border; green arrows: PTEC basal membrane; black arrows: distal tubules.
Scale bar represents 100 µm.
Figure 8.4: THTR-2 immunostaining in a third normal human kidney cortex. This image
is from the same kidney as Figure 8.3 but with a larger field of view. The staining pattern
is clear at this magnification. Scale bar represents 500 µm.
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Figure 8.5: THTR-2 immunostaining in a fourth normal human kidney cortex. There is
strong staining for THTR-2 in the apical membrane of the PTECs (red arrows). There is
no staining in the distal tubules (black arrows) or on the basal membrane of the proximal
tubule epithelium (green arrows). Scale bar represents 50µm
Figure 8.6: THTR-2 immunostaining in a normal human kidney medulla. The staining for
THTR-2 in the medulla is much weaker than in the cortex. There is weak staining present
on the apical membrane of some tubules (blue arrows), possibly the proximal portions of the
descending loops of Henle. There is no staining on the basal membranes of cells where apical
staining is present (pink arrow). Some other tubules have cytoplasm that stains weakly and
diffusely for THTR-2 (orange arrows). Scale bar represents 100 µm.
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Figure 8.7: THTR-2 immunostaining in smooth muscle in the kidney. There is only weak
staining in the smooth muscle that lines the arterioles within the kidney (black arrow).
There is strong staining in the adjacent proximal tubules. Scale bar represents 100µm.
Figure 8.8: THTR-1 immunostaining in normal human kidney cortex. There is staining
for THTR-1 on the apical membranes of the PTECs (red arrows). There is no staining on
the basal membranes of the same PTECs (green arrows). Some distal tubules have stained
weakly for THTR-1 (e.g. thick black arrow) but others stain for THTR-1 in a cell-specific
manner (thin black arrows). There is no staining for THTR-1 in glomeruli (blue circles) or
smooth muscle (red circle). Scale bar represents 100µm.
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Figure 8.9: THTR-1 immunostaining in a second normal human kidney cortex. The smooth
muscle did not stain (red arc) and the glomeruli (blue circles) were weakly stained, although
to a higher intensity than in Figure 8.8. The proximal tubules stained for THTR-1 with
more intense staining at the apical membranes (red arrows) than the basal membranes
(green arrows). In some proximal tubules the polarity of staining was more difficult to
discern (blue arrows). A high percentage of smooth-lumened tubules stained for THTR-1
(large black arrows) and in some cases, staining was cell-specific, as in Figure 8.8 (small
black arrows). Scale bar represents 100 µm.
Figure 8.10: THTR-1 immunostaining in a third normal human kidney cortex. There was
relatively weak staining in the glomeruli (blue circles) but heavy staining in the proximal
tubules. There was some polarisation evident in the PTECs but the difference between
staining intensity at the apical membranes (red arrows) and basal membranes (green arrows)
was not as clear as for the THTR-2 staining. The distal tubules have stained for THTR-1
in most cases (black arrows). The possibility of non-specific staining must be considered for
this image as the mean intensity is high. Scale bar represents 100 µm.
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Figure 8.11: THTR-1 immunostaining in a normal human kidney inner medullary region.
The loops of Henle (purple arrows) have not stained but the collecting ducts (orange arrows)
have stained for THTR-1. The staining in the collecting duct epithelia does not appear to
be polarised. Scale bar represents 100µm.
Figure 8.12: Kidney negative control slide. No immunostaining was observed in any region
of any negative control slide.
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8.2 Immunostaining of thiamine transporters in primary
PTECs
In addition to observing the staining pattern of transporters within whole kidney sections,
cultured cells were also stained. Human PTECs were grown in primary culture in four
combinations of glucose and thiamine concentration to compare subcellular localisation of
thiamine transporters as well as to gain a qualitative overview of expression in these condi-
tions. HK-2 cells were also stained for THTR-1 and THTR-2 to compare morphology with
the primary proximal tubule cell cultures.
The four conditions used for the primary cells were 5 mM glucose and 4 nM thiamine
(−G−T), 5 mM glucose and 4 µM thiamine (−G+T), 26 mM glucose and 4 nM thiamine
(+G−T) and 26 mM glucose and 4µM thiamine (+G+T). After three days in each of these
conditions, cells were seeded onto sterile glass slides and grown for two more days for a total
of five days’ culture in each condition. The HK-2 cells were grown only in −G−T conditions.
Cells were fixed in formaldehyde before staining for THTR-1 and THTR-2.
The HK-2 cells stained for THTR-1 in a diffuse manner over the plasma membrane
but with a heavier nuclear stain. The cells also show very heavy sub-nuclear staining areas,
probably nucleoli (Figure 8.13). There was no staining for THTR-2 evident in HK-2 cells
(Figure 8.14). Positive control normal kidney slides stained at the same time as the HK-2
cell slides stained as expected. This suggests that there is very little or no THTR-2 present
in the HK-2 cells; a result corroborated by western blot and mRNA quantitation (Section
9.1.2 on page 159).
Human PTECs in primary culture stained for both THTR-1 and THTR-2. Fig-
ures 8.15, 8.16, 8.17 and 8.18 give examples of staining patterns for THTR-1 in −G−T,
−G+T, +G−T and +G+T conditions respectively. Figures 8.19, 8.20, 8.21 and 8.22 are
staining patterns under the same conditions for THTR-2. Four slides for each antigen in
each condition were stained with representative slides shown here. The differences between
these images are not bold enough for strong conclusions to be drawn in a qualitative man-
ner. It could be argued that there is more nuclear stain relative to cytoplasmic stain in
the cells cultured in the low glucose conditions. Since the intensity of stain is not directly
proportional to amount of protein, such assertions are likely insecure from these images.
The images indicate no large difference in immunostaining location in the four conditions.
Notably, though, whilst there is some sub-nuclear compartmentalization of the staining in
the PTECs in primary culture, it is much diminished relative to the HK-2 cell images. Also,
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there is THTR-2 staining in the PTECs in primary culture where as there is no THTR-2
staining in the HK-2 cells.
All the cells in culture exhibited increased numbers of densely staining nucleoli rela-
tive to cells in kidney sections. Nucleoli are sub-regions of the nucleus where ribosomes are
manufactured [Rasˇka et al., 2006]. They fragment into 10 sections before mitosis, disappear
during DNA replication and then reform after cell division around 10 nuclear organising
regions—where clusters of rRNA genes are located—before rapidly coalescing into a single
entity. There are two factors which explain the increase in nucleoli in cultured cells: (i)
2 µm sections cut tangentially though tissues with 10µm diameter nuclei are likely to miss
small nucleoli whereas cells in culture are present in their entirety on the slide and, (ii)
cells in culture are dividing more rapidly than cells in a whole tissue which means increased
rates of protein synthesis and increased demand for ribosome synthesis leading to larger
nucleoli. The nucleoli stain more heavily than the surrounding nucleus with the basophilic
haematoxylin stain. The significance of the heavy nucleolar staining with the brown DAB
chromophore is unclear.
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Figure 8.13: THTR-1 immunostaining in HK-2 cells. There is some plasma membrane
staining but the majority of staining is nuclear and there are specific dark patches within
the nuclei. Magnification 630x.
Figure 8.14: THTR-2 immunostaining in HK-2 cells. No staining was evident in any HK-2
cell slide stained for THTR-2. Magnification 630x.
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Figure 8.15: THTR-1 immunostaining in human PTECs in primary culture in 5 mM glucose
and 4 nM thiamine conditions (−G−T). Magnification 200x.
Figure 8.16: THTR-1 immunostaining in human PTECs in primary culture in 5 mM glucose
and 4 µM thiamine conditions (−G+T). Magnification 200x.
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Figure 8.17: THTR-1 immunostaining in human PTECs in primary culture in 26 mM glucose
and 4 nM thiamine conditions (+G−T). Magnification 200x.
Figure 8.18: THTR-1 immunostaining in human PTECs in primary culture in 26 mM glucose
and 4 µM thiamine conditions (+G+T). Magnification 200x.
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Figure 8.19: THTR-2 immunostaining in human PTECs in primary culture in 5 mM glucose
and 4 nM thiamine conditions (−G−T). Magnification 200x.
Figure 8.20: THTR-2 immunostaining in human PTECs in primary culture in 5 mM glucose
and 4 µM thiamine conditions (−G+T). Magnification 200x.
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Figure 8.21: THTR-2 immunostaining in human PTECs in primary culture in 26 mM glucose
and 4 nM thiamine conditions (+G−T). Magnification 200x.
Figure 8.22: THTR-2 immunostaining in human PTECs in primary culture in 26 mM glucose
and 4 µM thiamine conditions (+G+T). Magnification 200x.
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Chapter 9
mRNA and thiamine
transporter protein abundance
in PTECs in vitro
9.1 mRNA quantitation
Primary PTECs and immortalised HK-2 cells were cultured for five days in four different
conditions: −G−T, −G+T, +G−T and +G+T. Cells were harvested, RNA was isolated and
mRNA was quantified by real-time qPCR. In each case, gene expression was normalised to
β-actin as a control using the Pfaﬄ method of quantitation [Pfaﬄ, 2001]. All ratios relative
to β-actin were then normalised to the −G−T control condition.
9.1.1 Primary PTEC mRNA quantitation in vitro
Figure 9.1 gives the relative gene mRNA abundance in the four conditions for the thiamine
transporters, THTR-1 and THTR-2, and the reduced folate carrier, RFC-1. For THTR-1,
there was a slight and significant decrease in expression level when the low glucose condition
was supplemented with excess thiamine (−19%; p < 0.01) which may be attributed to
down-regulation of the transporter in an abundant environment. THTR-1 and THTR-2
expression were both significantly decreased in the high glucose conditions with respect to
the low glucose conditions (THTR-1: −70 to −80%; p < 0.001. THTR-2: −48 to −54%;
p < 0.001). For both THTR-1 and THTR-2, additional thiamine did nothing to reverse
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the decrease in expression in the high glucose conditions. RFC-1 expression was decreased
in all conditions with respect to −G−T: −G+T, −24%; +G−T, −39%; +G+T, −32%
(p < 0.001). RFC-1 expression was also decreased 19% in +G−T with respect to −G+T
(p < 0.01). No other significant changes were observed.
The lower mRNA abundance of the transporters, particularly THTR-1 and THTR-2,
in the hyperglycaemic conditions supports the hypothesis that hyperglycaemia is causing
a decrease in thiamine re-absorption in the kidney. The fact that high thiamine supple-
mentation does nothing to ameliorate the decline is discussed in further detail in Section
14.4.
Figure 9.1: Thiamine transporter gene expression in primary PTECs in vitro. −G−T;
−G+T; +G−T; +G+T. ∗∗ = p < 0.01; ∗ ∗ ∗ = p < 0.001. n = 5 for all samples.
Gene expression of components of the hexosamine pathway-based hypothesis of re-
duction in renal thiamine reabsorption were also studied (Figure 9.2). The expression
of O-linked N -acetylglucosamine (O-GlcNAc) transferase (OGT) was decreased 19% in
−G+T with respect to −G−T (p < 0.05). Decreases in OGT expression of 55–64%
were observed in both high glucose conditions with respect to both low glucose conditions
(p < 0.001). O-GlcNAcase expression was significantly increased in +G+T with respect to
−G−T (+52%; p < 0.05). Glutamine fructose-6-phosphate amidotransferase (GFAT-1) ex-
pression was slightly decreased in −G+T with respect to −G−T (−24%; p < 0.05). GFAT-1
was more markedly decreased by 90–93% in the high glucose conditions with respect to the
low glucose conditions (p < 0.001). Sp1 also showed a marked decrease in expression in the
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high glucose conditions with respect to the low glucose conditions—decreased by 71–77%
(p < 0.001). Transketolase (TKT) expression was markedly decreased in all conditions with
respect to −G−T: −G+T, −38%; +G−T, −62%; +G+T, −59% (p < 0.001). There was a
significant decrease in TKT expression in +G−T (−39%) and +G+T (−34%) with respect
to −G+T (p < 0.001).
Figure 9.2: Hexosamine pathway-related gene expression in primary PTECs in vitro.
−G−T; −G+T; +G−T; +G+T. ∗ = p < 0.05; ∗ ∗ ∗ = p < 0.001. n = 5 for
all samples.
Gene expression was also studied in genes that had previously been found to be
responsive to hyperglycaemia (Figure 9.3). There was no significant difference between
collagen expression in the hyperglycaemic conditions and −G−T. Expression of collagen
IV was increased in the hyperglycaemic conditions with respect to −G+T (+G−T, +28%;
+G+T, +32%; both p < 0.05). Thioredoxin interacting protein (TXNIP) was profoundly
up-regulated in the hyperglycaemic conditions relative to the normoglycaemic conditions—
increased by 48–65 fold (p < 0.001); there was a slightly higher response in (+21%) in
+G+T versus +G−T (p < 0.05).
9.1.2 HK-2 cell mRNA quantitation in vitro
HK-2 cells were cultured for five days in four conditions (−G−T, −G+T, +G−T and
+G+T), as described above. Figure 9.4 gives relative gene expression for thiamine trans-
porter genes in HK-2 cells cultured in the four conditions. In contrast to the primary PTECs,
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there was a slight increase in relative expression of THTR-1 in the hyperglycaemic condi-
tions relative to the normoglycaemic conditions (increased 19–29%; p < 0.05 for all, p < 0.01
for two comparisons and p < 0.001 for the increase from −G+T to +G−T). There were
no significant differences in expression of THTR-2 between any of the conditions. RFC-1
expression was unaffected by changing conditions with the exception of an increase of 15%
in +G−T with respect to −G+T (p < 0.01).
The results for THTR-1 expression are counter-intuitive, especially considering the
decreased abundance of THTR-1 protein seen in the HK-2 cells in the same conditions
(Section 9.2, page 164). The absence of change in THTR-2 expression is not unexpected
given that there appears to be little or no THTR-2 present in HK-2 cells, as indicated by
immunohistochemistry. The counter-intuitive nature of many of the HK-2 cell results is
discussed in detail in Chapter 14.
Hexosamine pathway-related gene expression was also investigated in HK-2 cells
(Figure 9.5). OGT expression was increased slightly in hyperglycaemic conditions with
respect to normoglycaemic conditions (increased 22–28%; p < 0.01). oGlcNAcase expression
levels were increased in +G+T with respect to both −G−T and −G+T (+15% and +16%
respectively; p < 0.05). Expression of GFAT-1 was increased in hyperglycaemic conditions
with respect to normoglycaemic conditions (increased 31–36%; p < 0.01, except −G−T to
+G+T, p < 0.05). Neither Sp1 nor transketolase expression was changed in any condition.
Figure 9.3: Hyperglycaemia-related gene expression in primary PTECs in vitro. −G−T;
−G+T; +G−T; +G+T. ∗ = p < 0.05; ∗ ∗ ∗ = p < 0.001. n = 5 for all samples.
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These results are markedly different from those obtained in the primary PTECs. In
the HK-2 cells, OGT expression is increased in hyperglycaemia; in the primary cells OGT
expression is decreased in hyperglycaemia. The same is true for GFAT-1 expression: it
is increased in hyperglycaemia in the HK-2 cells yet profoundly decreased in the primary
PTECs under the same conditions. Sp1 and TKT are unaffected by hyperglycaemia in the
HK-2 cells yet both are down-regulated under the same conditions in the primary PTECs.
The only gene which has similar expression patterns in both HK-2 cells and primary PTECs
is O-GlcNAcase. The significance of these differences is discussed in more detail when
considering the different models of the diabetic kidney used in Chapter 14.
The expression of genes related to hyperglycaemia was also investigated (Figure 9.6).
Expression of collagen IV was unchanged in any condition. TXNIP expression was increased
in the hyperglycaemic conditions with respect to the normoglycaemic conditions (increased
59–71%, p < 0.001). The increase in TXNIP expression follows the same trend in HK-2
cells as in primary PTECs but the responses in the HK-2 cells are of much lower magnitude.
The TXNIP expression in primary PTECs was increased 48–65 fold in hyperglycaemic
conditions.
Figure 9.4: Thiamine transporter gene expression in HK-2 cells in vitro. −G−T; −G+T;
+G−T; +G+T. ∗ = p < 0.05; ∗∗ = p < 0.01; ∗ ∗ ∗ = p < 0.001. n = 4 for all samples.
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Figure 9.5: Hexosamine pathway-related gene expression in HK-2 cells in vitro. −G−T;
−G+T; +G−T; +G+T. ∗ = p < 0.05; ∗∗ = p < 0.01. n = 4 for all samples.
Figure 9.6: Hyperglycaemia-related gene expression in HK-2 cells in vitro. −G−T;
−G+T; +G−T; +G+T. ∗ ∗ ∗ = p < 0.001. n = 4 for all samples.
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9.1.3 Comparison of gene expression in HK-2 cells and human kid-
ney cortex
Total RNA was extracted from frozen human kidney cortex which had been stored at
−80℃ to prevent degradation. Cortex RNA was compared to that from HK-2 cells grown in
5 mM glucose and 4 nM thiamine (−G−T) by qPCR. The abundance of mRNA relative to
β-actin was determined for eight genes and the ratio of the abundance of mRNA in the kid-
ney to the abundance of mRNA in the cells was derived. This yields data on the normalised
relative abundance of each mRNA species in kidney and HK-2 cells (Figure 9.7).
As HK-2 cells are derived from a normal human kidney, the ratios are expected to
be close to unity. This is the case for the majority of genes studied with ratios from 0.73 for
GFAT-1 to 3.5 for Sp1. The ratio of abundance for THTR-2 is an exception; it is 120 times
relatively more abundant in kidney extract than in HK-2 cells. This is further evidence for
how far removed the HK-2 cell line has become from its source tissue and is discussed in
more detail in Chapter 14.
Figure 9.7: Gene expression in HK-2 cells in vitro compared to human kidney cortex. Note
the logarithmic y-axis. n = 1, only one human kidney was tested.
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9.2 Thiamine transporter protein abundance
The abundance of THTR-1 protein was assayed by western blot. Cell membrane extracts
were prepared from both primary PTECs and HK-2 cells in order to relatively enrich mem-
brane proteins above cytosolic proteins. The membranes were heat-denatured under reduc-
ing conditions before being separated using SDS-PAGE, transferred to a PVDF membrane
and blotted using appropriate antibodies followed by ECL-based detection. In all cases,
membranes were stripped, re-blocked and re-probed for β-actin as a loading control. Re-
sults are expressed as an arbitrary ratio of the two observed band densities.
9.2.1 Primary PTEC THTR-1 protein abundance in vitro
Primary PTECs were cultured in −G−T and +G−T for five days before harvesting and
analysis. These conditions were chosen to see the effect of elevated glucose at physiological
thiamine concentrations. THTR-1 abundance was decreased 77% in +G−T with respect to
−G−T (p < 0.05; Figure 9.8). Primary PTECs were also cultured in −G+T and +G+T
for five days. THTR-1 abundance was not significantly different between the two conditions
(p > 0.05; Figure 9.9).
Figure 9.8: THTR-1 abundance in primary PTECs cultured in low thiamine conditions
in vitro expressed as an arbitrary ratio of target intensity to β-actin intensity. −G−T;
+G−T. ∗ = p < 0.05. n = 3 for each condition.
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9.2.2 HK-2 cell THTR-1 protein abundance in vitro
HK-2 cells were cultured in a similar manner to primary PTECs in both −G−T and
+G−T conditions for five days before harvesting and analysis. THTR-1 abundance was
decreased 52% in +G−T with respect to −G−T (p < 0.05; Figure 9.10).
HK-2 cells were also cultured in −G+T and +G+T for five days to determine if
high thiamine effects a change in this response. THTR-1 abundance was decreased 53% in
+G+T with respect to −G+T (p < 0.05; Figure 9.11). Example images of bands are given
in Figure 9.12.
9.2.3 Discussion
The immunoblots obtained for the primary PTECs were not as easy to quantify as the
HK-2 cell immunoblots. This is because there were multiple bands present at approximately
55 kDa, the molecular mass of THTR-1. The bands were difficult to resolve because they
were not discrete (Figure 9.13).
Figure 9.9: THTR-1 abundance in primary PTECs cultured in high thiamine conditions
in vitro expressed as an arbitrary ratio of target intensity to β-actin intensity. −G+T;
+G+T. n = 3 for each condition.
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Figure 9.10: THTR-1 abundance in HK-2 cells cultured in low thiamine conditions in vitro
expressed as an arbitrary ratio of target intensity to β-actin intensity. −G−T; +G−T.
∗ = p < 0.05. n = 3 for each condition.
Figure 9.11: THTR-1 abundance in HK-2 cells cultured in high thiamine conditions in vitro
expressed as an arbitrary ratio of target intensity to β-actin intensity. −G+T; +G+T.
∗ = p < 0.05. n = 4 for each condition.
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The following observations were made regarding these blots:
(i) Correct identification of the THTR-1 band This was problematic and was solved
using a positive control prepared from the membranes of erythrocytes which are rich in
THTR-1. The fact that erythrocyte membranes are rich in THTR-1 was demonstrated by
fluorescent confocal microscopy imaging of kidney sections. When probed with an anti-
THTR-1 antibody, the kidney epithelial cells have a relatively weak signal intensity but
erythrocytes are clearly visible in the images (e.g. Figure 9.14). Figure 9.15 presents
an example of a blot performed with HK-2 cell membrane extracts and an erythrocyte
membrane extract. By comparing the apparent molecular mass of the true THTR-1 protein
with the the primary PTEC extract blots, it can be seen that the middle band of the three
in Figure 9.13 is at the correct molecular mass for THTR-1.
(ii) Antigen bands are not discrete An example densitometry analysis of lane 2 from
Figure 9.13 is given in Figure 9.16 and illustrates the problem of non-discrete bands. The
black line represents mean density of exposure of the film from the top to the bottom of the
lane. The coloured lines represent several options as to how the peaks should be individually
quantified with relevant background subtraction. The area bounded by the red drop lines
and the grey baseline was quantified in line with common practice on HPLC systems. This
analysis technique was used for all immunoblot densitometry analysis.
Figure 9.12: THTR-1 HK-2 cell immunoblot specimen bands. These two sets of bands
represent THTR-1 (upper bands) and β-actin (lower bands) which were quantified and
presented in Figure 9.11. In each blot, lanes 1–4 (the left-most bands) represent samples
from −G−T and lanes 5–8 (the right-most bands) represent samples from +G−T.
Figure 9.13: THTR-1 primary PTEC immunoblot specimen bands typical of those obtained
for primary PTEC THTR-1 immunoblot analyses. In this particular sample image, lanes 1
and 2 are samples from −G+T, lanes 3 and 4 are samples from +G−T and lanes 5 and 6
are samples from −G−T.
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Figure 9.14: Confocal fluorescence microscopy of THTR-1 immunostaining in a kidney
section. Cell nuclei are stained blue with DAPI. THTR-1 is stained red. Note the strong
staining in the erythrocytes. These are more clearly differentiated at the top of this image.
Figure 9.15: THTR-1 immunoblot positive control. Lanes 1–8 contain HK-2 cell membrane
extracts (lanes 1–4 from +G−T and lanes 5–8 from −G−T) and lane 9 contains an equal
amount of protein extracted from erythrocyte membranes.
Figure 9.16: Densitometry analysis of lane 2 from the THTR-1 immunoblot shown in Figure
9.13.
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(iii) Each of the three bands may represent isoforms of THTR-1 (splice variants
or post-translationally modified forms) If this is the case, the interpretation offered
here could be inaccurate as this thesis makes the assumption that the middle band alone
represents THTR-1. This possibility could only be explored through sequencing or tryptic
digest analysis of the bands—an avenue of research not further explored here.
These factors combined may contribute to the differences between THTR-1 abun-
dance in HK-2 cell primary PTEC membrane extracts. In the HK-2 cells extracts, THTR-1
abundance was decreased in both hyperglycaemic conditions, irrespective of thiamine con-
centration. In high glucose primary PTEC extracts, THTR-1 abundance did not decrease
in the high thiamine condition but did decrease in the low thiamine condition with respect
to the 5 mM conditions. The immunoblot images for the primary PTECs exhibited a poor
signal-to-noise ratio leading to higher uncertainties in the results. This may explain why a
significant difference was not observed in +G+T with respect to −G+T in primary PTECs.
In addition to problems identifying and resolving bands, it is not possible to com-
pare multiple western blots with each other. Western blot results from a single gel are
expressed as an arbitrary ratio of one intensity to another. This approach is useful for
intra-gel comparisons but not for inter-gel comparisons where slight differences between gels
(e.g. efficiency of antibody binding, temperature or exposure duration) will vary the ratio
obtained considerably. This is especially so for strongly binding antibodies—such as those
used against β-actin—which yield high signal intensities. These antibodies need short expo-
sures and slight variations in exposure duration give widely varying intensities and ratios.
The inability to combine gel images means that large numbers of samples cannot be quan-
tified in a relative manner. Two sizes of gel are commonly available for western blotting:
mini-gels (up to 10 samples) and large gels (up to 20 samples). Mini-gel blots can only com-
pare a maximum of 2 samples at n = 4 each. Large gels could be used for a maximum of 4
samples at n = 4 (allowing lanes for ladders) but larger gels give poorer immunoblot results
with higher errors. This is because the larger surface area requires a more antibody solution
which does not distribute as evenly over the membrane. High quality, strongly binding an-
tibodies (e.g. those available against β-actin) counter this problem but for other proteins,
such as THTR-1, antibodies were of insufficient quality to allow proper comparison.
Both the primary PTEC and the HK-2 cell THTR-1 abundance data, with the
exception of the high error primary PTEC blots in high thiamine conditions, support the
hypothesis that hyperglycaemia is decreasing the abundance of THTR-1. This is supported
by mRNA evidence in primary PTECs but not in HK-2 cells.
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Chapter 10
The hexosamine pathway,
glycosylation and Sp1 in PTECs
in vitro
10.1 Hexosamine pathway metabolite concentration
10.1.1 Primary PTEC hexosamine pathway metabolite concentra-
tion in vitro
Human PTECs grown in primary culture in the four conditions −G−T, −G+T, +G−T
and +G+T for five days were prepared for assay of the hexosamine pathway products UDP-
N -acetylglucosamine (UDP-GlcNAc) and UDP-glucose by HPLC. Results are expressed
as nmol metabolite per mg protein (quantified by Bradford assay) and are presented in
Figure 10.1. The amount of UDP-GlcNAc decreased slightly in +G−T with respect to
the low glucose conditions (−G−T, −22%; −G+T −23%; both p < 0.01). The amount of
UDP-GlcNAc increased 28% in +G+T with respect to +G−T (p < 0.01). The amount of
UDP-glucose increased in +G+T with respect to both −G+T (+16%; p < 0.05) and +G−T
(+26%; p < 0.001). No other changes were significant.
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10.1.2 HK-2 cell hexosamine pathway metabolite concentration in
vitro
There were no significant differences between any conditions in HK-2 cells (Figure 10.2). The
amount of each analyte was higher in HK-2 cells with respect to primary PTECs (UDP-Glc,
>2-fold higher; UDP-GlcNAc, ∼4-fold higher).
10.1.3 Hexosamine pathway metabolite assay controls
As a positive control for the assay, HK-2 cells were cultured with glucosamine hydrochloride
to bypass the initial step in the hexosamine biosynthesis pathway. The GFAT-catalysed re-
action forming glucosamine-6-phosphate from glutamine and fructose-6-phosphate has most
control over flux through the pathway [Virkama¨ki et al., 1997]. A typical pharmacological
dose for glucosamine is 1500 mg day−1 which if dissolved in a typical human’s 4.7 L of blood
gives a concentration of about 1.8 mM. Glucosamine (5 mM) was added for positive control
and produced an increase in UDP-GlcNAC of >44-fold relative to control (p < 0.001; Figure
10.3).
The effect of glutamine was also investigated. Four cell incubation conditions were
studied: low and high glucose concentration (5 and 26 mM, −/+G) and with or without
Figure 10.1: Hexosamine pathway metabolite abundance in primary PTECs in vitro.
UDP-glucose; UDP-N -acetylglucosamine. ∗ = p < 0.05; ∗∗ = p < 0.01; ∗∗∗ = p < 0.001.
n = 8 for each condition.
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2 mM glutamine supplementation (+/−Q). Each condition contained 4 nM thiamine. The
amounts of UDP-GlcNAc are given in Figure 10.4. The amount of UDP-GlcNAc was not
altered by glutamine supplementation in HK-2 cells. The amount of UDP-GlcNAc was de-
creased by 12–16% in hyperglycaemic conditions with respect to normoglycaemic conditions
(p < 0.05).
10.1.4 Discussion
The hexosamine biosynthesis pathway (HBP) has two starting metabolites: glucose and
glutamine (Figure 1.8). The study with glutamine supplementation has shown that the
cells are limited by neither glutamine nor glucose. The study bypassing GFAT activity
using glucosamine has demonstrated that the remainder of the HBP is unregulated and that
increased amounts of UDP-GlcNAc result if GFAT is bypassed. Therefore, the abundance
of metabolites from the HBP is limited solely by the activity of the highly regulated GFAT.
The prevailing evidence in the literature suggests that there is an increased flux
through the hexosamine pathway in hyperglycaemic conditions accompanied by an increase
in production of UDP-GlcNAc (Section 3.4). This has not been translated in these experi-
ments into increased absolute concentrations of UDP-GlcNAc in either the primary PTECs
or the HK-2 cells. The positive controls for the assay show that the cells are not constrained
Figure 10.2: Hexosamine pathway metabolite abundance in HK-2 cells in vitro. UDP-
glucose; UDP-N -acetylglucosamine. n = 4 for each condition.
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Figure 10.3: UDP-GlcNAc abundance in HK-2 cells supplemented with 5 mM glucosamine
in vitro. ∗ ∗ ∗ = p < 0.001. n = 4 for each condition.
Figure 10.4: UDP-GlcNAc abundance in HK-2 cells supplemented with 2 mM glutamine in
low and high glucose concentrations in vitro. −G−Q; −G+Q; +G−Q; +G+Q ∗ =
p < 0.05; ∗∗ = p < 0.01. n = 4 for each condition.
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by artificial limits such as lack of glutamine and that the assay is capable of detecting
changes in analyte concentration if they were present. Thus if the theory regarding in-
creased glycosylation is to stand to scrutiny then there must be increased activity of OGT,
the enzyme performing O-GlcNAcylation of proteins using UDP-GlcNAc as a substrate.
This could account for an unchanged or even decreased concentration of UDP-GlcNAc as
seen in the primary PTECs. The mRNA evidence shows that OGT is down-regulated in
hyperglycaemic conditions in the primary PTECs. OGT protein abundance and activity
have not been investigated. It is possible that the gene has been down-regulated in response
to the excess of glycosylation in the cell in a negative feedback mechanism. Another plausi-
ble scenario involves the corepressor mSin3A. mSin3A has been shown by Yao et al. [2007]
to exhibit a two-fold increase in modification by methylglyoxal in hyperglycaemia in mouse
kidney endothelial cells. The increase in glycation was shown to increase the binding of
mSin3A to OGT, increasing the activity of OGT. A similar scheme could be conceived in
our model system whereby the increased binding of glycated mSin3A to OGT could lead to
an increase in the activity of OGT despite a down-regulation of its gene. It may be that
binding of the corepressor to the OGT leads to an increased protein stability and decreased
degradation.
The differences between the HK-2 cell model and the primary PTEC model are
again highlighted by the differing relative amounts of each analyte. The amount of UDP-
GlcNAc in the HK-2 cells is ∼4-fold higher than that found in the primary cells and the
concentration of UDP-Glc is between 1.5–3-fold higher in the HK-2 cells. This is both
unexpected and difficult to rationalise given the identical culture and analysis conditions.
The result could be considered further evidence of the HK-2 cell line drifting genetically
further from its source material.
10.2 Sp1 and glycosylation
10.2.1 HK-2 cell Sp1 abundance and glycosylation in vitro
The glycosylation status of Sp1 was investigated by western blotting. HK-2 cells were
cultured in −G−T and +G−T media for five days prior to harvesting. On the day of
harvesting, nuclear extracts were prepared to concentrate Sp1 relative to other proteins. The
nuclear extracts were prepared for western blotting and blotted with a primary antibody
against O-GlcNAc. The membranes were stripped and re-probed for Sp1. The ratio of
density of O-GlcNAc to Sp1 is shown in Figure 10.5. The ratio of O-GlcNAc to Sp1 density
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increased 63% in +G−T with respect to −G−T (p < 0.01).
Figure 10.5: Glycosylation status of Sp1 in HK-2 cell nuclear extracts in vitro presented as
the ratio of O-GlcNAc to Sp1 band density after five days of culture. −G−T; +G−T.
∗∗ = p < 0.01;. n = 4 for each condition.
To determine if absolute amounts of Sp1 were affected by hyperglycaemic culture, a
second blot was performed with the same samples. This blot compared the ratio of Sp1 to
lamin A, a nuclear loading control (Figure 10.6). Relative amounts of Sp1 did not change
in HK-2 cells cultured in +G−T relative to −G−T (p > 0.05).
10.2.2 HK-2 cell O-GlcNAc transferase abundance in vitro
HK-2 cells cultured in −G−T and +G−T conditions for five days were lysed and a total pro-
tein extract prepared. Samples were analysed by western blotting to determine the amount
of OGT relative to the loading control β-actin (Figure 10.7). OGT relative abundance in
+G−T was 43% decreased with respect to −G−T (p < 0.01).
To test the effect of thiamine supplementation on the abundance of OGT in hyper-
glycaemic culture, HK-2 cell extracts were prepared after five days of culture in +G−T and
+G+T. Samples were analysed by western blotting to determine the amount of OGT rela-
tive to the loading control β-actin (Figure 10.8). There was no difference between relative
OGT abundance in either of the two hyperglycaemic conditions.
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Figure 10.6: Abundance of Sp1 in HK-2 cell nuclear extracts in vitro presented as a ratio of
Sp1 to lamin A band density after five days of culture. −G−T; +G−T. n = 4 for each
condition.
Figure 10.7: Abundance of OGT in HK-2 cell extracts from cells cultured in low thiamine
concentration (4 nM) in vitro presented as the ratio of OGT to β-actin image density after
five days of culture. −G−T; +G−T. ∗∗ = p < 0.01;. n = 4 for each condition.
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10.2.3 Discussion
These experiments were designed to test the theory that the hexosamine pathway is involved
in the down-regulation of the thiamine transporters. The data corroborates the theory that
O-GlcNAcylation of proteins is increased under hyperglycaemic conditions (Section 3.4).
However, the increase in the glycosylation status of Sp1 is in spite of the fact that HK-2 cells
under the same conditions did not demonstrate an increase in UDP-GlcNAc concentration.
This may be accounted for by an increase in either the abundance of or activity of OGT,
however these results demonstrate that the abundance of OGT is not increased in HK-2 cells
in hyperglycaemia. The abundance data presented here corroborate the mRNA evidence in
the primary PTECs but not the mRNA evidence in the HK-2 cells where there is a slight
increase in OGT mRNA abundance in hyperglycaemic conditions. To elucidate the exact
mechanisms involved here, studies on the turnover and activity of OGT would have to be
performed. These would be able to demonstrate if the activity of OGT had been increased
despite its lower abundance, thereby accounting for increased glycosylation of Sp1.
Figure 10.8: Abundance of OGT in HK-2 cell extracts from cells cultured in high glucose
concentration (26 mM) in vitro presented as the ratio of OGT to β-actin image density after
five days of culture. +G−T; +G+T. n = 4 for each condition.
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Chapter 11
Intracellular thiamine
metabolite concentration and
transketolase activity in PTECs
in vitro
11.1 Concentration of intracellular thiamine
Both primary PTECs and HK-2 cells were cultured for five days in the four conditions
(−G−T, −G+T, +G−T and +G+T) and the amount of intracellular thiamine and thiamine
phosphate esters assayed by HPLC. Protein concentrations were quantified by Bradford
assay and the results expressed as pmol analyte per mg protein.
11.1.1 Primary PTEC intracellular thiamine metabolite concentra-
tion in vitro
The amount of thiamine in primary PTECs is given in Figure 11.1. Thiamine was not
detectable in samples from either low thiamine condition (< 0.15 pmol per mg protein). The
amounts of thiamine were high in both high thiamine conditions but were 20% decreased in
+G+T with respect to −G+T (p < 0.001).
The amounts of TPP showed a similar trend to the amounts of cellular thiamine
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with the exception that TPP was detectable in the low thiamine conditions (Figure 11.2).
The amount of TPP was increased 210% in −G+T with respect to −G−T (p < 0.001) and
the amount of TPP was increased 180% in +G+T with respect to +G−T (p < 0.001). The
amount of cellular TPP was decreased 23% in +G+T with respect to −G+T (p < 0.001).
No other differences were significant. There was no thiamine monophosphate detectable in
any condition.
11.1.2 HK-2 cell intracellular thiamine metabolite concentration
in vitro
The amount of intracellular thiamine in −G+T was increased 65-fold with respect to −G−T
and 33-fold with respect to +G−T (both p < 0.001). The amount of intracellular thiamine
in +G+T was increased 71-fold with respect to −G−T and 38-fold with respect to +G−T
(both p < 0.001). No other changes were significant. The concentration of glucose had no
effect on the amount of thiamine in the HK-2 cells, unlike the primary PTECs.
Thiamine monophosphate was detectable in HK-2 cells, unlike in the primary PTECs
(Figure 11.4). The pattern is similar to that observed for intracellular thiamine. Both high
thiamine conditions had increased amounts of TMP with respect to both low thiamine
conditions (increased 160–240%; p < 0.001). No other changes were significant. The con-
Figure 11.1: Intracellular thiamine content of primary PTECs in vitro. −G−T; −G+T;
+G−T; +G+T. ∗ ∗ ∗ = p < 0.001. n = 8 for each condition.
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Figure 11.2: Intracellular thiamine pyrophosphate content of primary PTECs in vitro.
−G−T; −G+T; +G−T; +G+T. ∗ ∗ ∗ = p < 0.001. n = 8 for each condition.
Figure 11.3: Intracellular thiamine content of HK-2 cells in vitro. −G−T; −G+T;
+G−T; +G+T. ∗ ∗ ∗ = p < 0.001. n = 4 for each condition.
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centration of glucose had no effect on the amount of thiamine monophosphate in the HK-2
cells.
Figure 11.4: Intracellular thiamine monophosphate content of HK-2 cells in vitro. −G−T;
−G+T; +G−T; +G+T. ∗ ∗ ∗ = p < 0.001. n = 4 for each condition.
The amount of thiamine pyrophosphate present in the HK-2 cells in vitro is shown
in Figure 11.5. There was no difference in the amount of TPP present in the cells in either of
the low thiamine conditions. The amount of TPP in HK-2 cells in +G+T was increased 43%
with respect to −G+T (p < 0.05). The amount of TPP was increased 77% in −G+T with
respect to −G−T (p < 0.01) and the amount of TPP was increased 140% in +G+T with
respect to +G−T (p < 0.001). The pattern observed is similar to that seen for thiamine
monophosphate except that there are increased amounts of thiamine pyrophosphate present
in +G+T relative to −G+T.
11.1.3 Discussion
There are notable differences between the two model systems when comparing intracel-
lular thiamine concentrations. Firstly there is the difference in overall thiamine analyte
concentrations in each of the models. The intracellular thiamine metabolite concentra-
tion in −G−T was increased by 88% in the primary PTEC cultures with respect to the
HK-2 cell cultures (57.9±8.9 pmol mg protein−1 versus 30.7±4.2 pmol mg protein−1). In-
creases in the intracellular thiamine metabolite concentration were also observed in primary
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PTEC cultures with respect to the HK-2 cell cultures in other conditions: −G+T: 144%
increase (349±13 versus 142±18 pmol mg protein−1); +G+T: 42% increase (48.9±5.0 versus
34.2±5.8 pmol mg protein−1) and +G+T: 62% increase (273±3.5 versus 168±7.2 pmol mg
protein−1).
The proportion of the thiamine metabolite pool held in the form of TPP is also
increased in the primary PTEC cultures with respect to the HK-2 cell cultures. The entire
thiamine metabolite pool was held in the form of TPP in the low thiamine conditions in the
primary PTEC cultures whereas the HK-2 cells held a substantial portion of their thiamine
pool in the form of TMP and THM in the same conditions (TMP and THM comprised
22% and 25% of the thiamine metabolite pool in HK-2 cells cultured in −G−T and +G−T
conditions respectively versus 0% in the primary PTEC cultures in the same conditions).
The increases in intracellular thiamine metabolite concentration in the primary
PTEC cultures suggest two possible alternatives. The first is that primary PTEC cultures
have a higher concentration of thiamine-dependent enzymes which necessitates a higher
concentration of thiamine and a higher efficiency of conversion to TPP. This scenario may
suggest that the transketolase activity in the primary PTEC cultures would be higher than
that in the HK-2 cell cultures but this does not appear to be the case (Section 11.2). A
Figure 11.5: Intracellular thiamine pyrophosphate content of HK-2 cells in vitro. −G−T;
−G+T; +G−T; +G+T. ∗ = p < 0.05; ∗∗ = p < 0.01; ∗ ∗ ∗ = p < 0.001. n = 4 for
each condition.
182
second more likely explanation would be that the thiamine metabolism of the HK-2 cells has
drifted away from the native in vivo metabolism expected of PTECs after extended periods
in culture in high thiamine medium since isolation—normal tissue culture medium contains
∼6.5 µM thiamine. In an environment with such an abundance of thiamine, there is no selec-
tive pressure on the cells to maintain an efficient thiamine metabolism or transport system.
Thus it is likely that the cells respond in an abnormal manner when placed in medium with
a low thiamine concentration. The primary PTEC cultures have never been exposed to
non-physiological thiamine concentrations (except during experimental procedures) and are
thus more representative of in vivo metabolism.
In the primary PTEC cultures it can also be seen that high glucose causes a decrease
in total intracellular thiamine metabolite concentration (both TPP and free thiamine), but
only when cultured with a high thiamine concentration. Since TPP in synthesised from
free thiamine, it is possible that the decrease in TPP concentration is simply a result of
decreased thiamine availability as a substrate of thiamine diphosphokinase. To confirm or
refute this would require investigating the activity of thiamine diphosphokinase, a topic not
covered in this thesis. It is likely that the decrease in free thiamine in the high glucose
cultures is due to the decreased abundance of the thiamine transporters.
All results regarding intracellular thiamine metabolite concentrations discussed here
must also be considered with regard to the experimental conditions. The cells have been
cultured in a medium that is of a constant thiamine concentration for five days. This is
not analogous to the in vivo conditions where the cells would be exposed to a glomerular
ultrafiltrate only transiently before it leaves the body as urine. In the kidney, if uptake were
impaired it could potentially have a more marked effect than in this in vitro system where
even if thiamine transport were impaired, it is possible that an optimal internal thiamine
concentration could be achieved through extended exposure duration alone. One possible
factor which would partially correct for this is that the cells in vitro were growing exponen-
tially during the culture period, something that cells in vivo would not be doing. With cells
growing exponentially, intracellular volume would also be increasing exponentially and, with
no thiamine transport, intracellular concentration would decay exponentially. Thus it can
be seen that any defects in the uptake system could manifest as a decrease in intracellular
concentration, even in a “steady-state” culture system. This may be an explanation for the
decreased thiamine concentration observed in the +G+T condition relative to the −G+T
condition in the primary PTEC cultures. These deficiencies were partially addressed with
trans-membrane monolayer studies (Section 12.1, page 187).
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11.2 Transketolase activity
Assays for the activity of the TKT were performed on both primary PTECs and HK-2 cells.
In both cases, cells were incubated for five days in one of the four glucose and thiamine
concentration combinations (−G−T, −G+T, +G−T or +G+T). After culture, the cells
were harvested and assayed for both TKT activity and percentage saturation of the enzyme
with its TPP cofactor.
11.2.1 Primary PTEC transketolase activity in vitro
The TKT activities in human PTECs in primary culture are given in Figure 11.6. Only the
10% thiamine effect (i.e. unsaturation of TKT) in −G−T was significant (p < 0.01). TKT
activity was increased 12.5% in +G+T with respect to −G−T (p < 0.05). No other changes
in TKT activity were significant.
Figure 11.6: Transketolase activity in primary PTECs in vitro. TKT activity levels were
measured with and without additional TPP in each condition to assay the “thiamine effect”.
−G−T; −G+T; +G−T; +G+T. ∗ = p < 0.05; ∗∗ = p < 0.01. n = 8 for each
condition.
11.2.2 HK-2 cell transketolase activity in vitro
The TKT activities in HK-2 cells are given in Figure 11.7. TKT activity was decreased
35–39% in +G+T (with and without TPP) with respect to −G−T and −G+T (with and
without TPP; p < 0.001). TKT activity in +G−T (without TPP) was 21% decreased with
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respect to −G+T (without TPP; p < 0.05). There was no thiamine effect in any culture
condition.
Figure 11.7: Transketolase activity in HK-2 cells in vitro. TKT activity levels were measured
with and without additional TPP in each condition to assay the “thiamine effect”. −G−T;
−G+T; +G−T; +G+T. ∗ = p < 0.05; ∗ ∗ ∗ = p < 0.001; ### = p < 0.001 relative
to both low glucose TPP+ conditions. n = 4 for each condition.
11.2.3 Discussion
The 10% thiamine effect observed in the −G−T condition in the primary PTEC cultures
was the only significant thiamine effect observed. A thiamine effect of 10% falls within the
0–15% range expected in erythrocytes in normal individuals. The fact that no conditions
are markedly thiamine deficient is expected since the apo-TKT (without an attached TPP
moiety) is markedly less stable than the holo-enzyme form and is rapidly degraded [Jeyas-
ingham et al., 1986; Esakova et al., 2005]. In erythrocytes, where protein half life is the
same as the erythrocyte half life (i.e. around 50 days), this unsaturation is detectable after
extended periods. In cells with active protein synthesis and degradation systems, apo-TKT
would be degraded leading to a lower overall activity, not a thiamine effect.
Considering the primary PTEC cultures, there are no statistically significant differ-
ences in TPP-saturated TKT activity. This suggests that no condition is thiamine deficient,
an assertion corroborated by the intracellular concentrations of TPP which never drop below
24 pmol mg protein−1 under any condition. The stability of TKT activity across the four
conditions is in contrast to the data on the abundance of TKT mRNA in the primary PTEC
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cultures. The abundance of TKT mRNA in +G−T and +G+T was decreased 62% and 59%
respectively with respect to −G−T. The fact that the decreases in abundance of mRNA
do not translate into lower enzyme activities suggests that the stability of transketolase
has been markedly increased in the high glucose cultures. Alternative explanations such as
transketolase having a naturally long half life do not stand to scrutiny when considering the
exponential growth of cells in culture. The stability of transketolase was not investigated in
this thesis.
The results in the HK-2 cell cultures are again different to those obtained in the
primary PTEC cultures. The decrease in TKT activity in the HK-2 cells in the +G+T
condition relative to both the low glucose conditions is hard to rationalise. The cells in the
+G+T condition do not have a lower intracellular concentration of TPP and they do not
have a decreased abundance of TKT mRNA present. Other theories attempting to explain
the result would be unfounded speculation, especially considering that the same result was
not observed in the primary PTEC cultures. It is likely that the factor causing the decreased
TKT activity is peculiar to the HK-2 cell line and is not relevant in vivo.
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Chapter 12
Thiamine uptake and handling
in PTECs in vitro
12.1 Primary PTEC monolayer transport studies in vitro
12.1.1 Primary PTEC monolayer integrity
Transport experiments simulating in vivo conditions with cells grown on semi-permeable
supports, not solid surfaces, were conducted with primary PTECs. Primary PTEC mono-
layer integrity in Transwell inserts was assayed using Lucifer yellow prior to transport exper-
iments. The mean Papp for primary cells cultured under four conditions (−G−T, −G+T,
+G−T and +G+T) was found to be 8.3× 10−6 ± 2.3× 10−6 cm s−1 (mean ± SD). The
Papp for an empty Transwell insert with no cells was determined to be 4.8× 10−4 cm s−1
meaning that the monolayers had a Papp 1.7% that of the blank insert. There was no differ-
ence in Papp between the four culture conditions (p > 0.05) and no wells were discarded prior
to analysis due to high Papp. These Papp values are similar to those expected as discussed
in Section 6.11.4.
12.1.2 Monolayer [3H]thiamine transport studies in primary PTECs
in vitro
A transport experiment from the apical to the basal chamber was conducted with five
Transwell membranes of primary PTEC in each of the four conditions. Papp was determined
for the time 0–15 minutes after addition of the tritiated thiamine to the apical chamber.
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The experiment was repeated with 6 thiamine concentrations in the range of 10–200 nM.
All wells with a mass balance (i.e. total recovery of tritiated thiamine) outside the range
90–110% were discarded from analysis. The plot of Papp against thiamine concentration is
given in Figure 12.1. There are no significant differences between any pairs of conditions. In
addition, it is not possible to fit a curve describing Michaelis-Menten kinetics to these data
because the thiamine concentrations used do not exceed, or even approach, the apparent
K m. All disintegration rates recorded fell within the range 500–6500 disintegrations per
minute—within the linear range for the detector.
Figure 12.1: Papp for thiamine at different concentrations in primary PTECs in vitro.
−G−T; −G+T; +G−T; +G+T. n = 5 for each condition.
A similar set of membranes were assayed to quantify forward and reverse transport
under a single condition: 15 nM thiamine over 20 minutes. The mass balance for all wells
lay within 90–110%. The Papp values for all wells were calculated for both apical to basal
and basal to apical directions (Figure 12.2). There was no significant difference between
any of the groups’ apical to basal (forward) Papp values. The reverse (basal to apical) Papp
was increased in −G+T, +G−T and +G+T with respect to −G−T (+52%; p < 0.001).
Ratios of forward Papp to reverse Papp indicate the strength of the polarity of trans-
port (Figure 12.3). The ratios are strongly in favour of transport of thiamine from the
apical side to the basal side of the monolayers. The ratio was less in favour of apical to
basal transport in −G+T, +G−T and +G+T than in −G−T (ratios deceased 23–27%;
p < 0.001).
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Figure 12.2: Papp values for forward and reverse [3H]thiamine transport in primary PTEC
monolayers in vitro. The black line shows the Papp value for Lucifer yellow determined before
the transport experiments started for reference (8.3× 10−6 cm s−1). −G−T; −G+T;
+G−T; +G+T. ∗ ∗ ∗ = p < 0.001. n = 5
Figure 12.3: Papp ratios forward:reverse in vitro. −G−T; −G+T; +G−T; +G+T.
∗ ∗ ∗ = p < 0.001. n = 5
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12.1.3 Discussion
The published literature indicates that two K m values for thiamine uptake in PTECs should
be found: one in the nanomolar range and one in the low micromolar range. The exper-
iment was not designed to determine the K m value in the micromolar range but should
have been adequately powered to find a K m value at or around 70 nM [Ashokkumar et al.,
2006]. Instead of observing kinetics following the Michaelis-Menten equation, all four cul-
ture conditions showed first-order kinetics with rate of transport being directly proportional
to substrate concentration over the measured range. Since published evidence demonstrates
that thiamine transport is saturable, this leaves two options: (i) the model system analysed
does not have a K m value low enough to be near the highest 200 nM concentration used, an
unlikely scenario or, (ii) the experiment was flawed in some manner. It is possible that the
integrity of the membranes degraded during the lengthy procedure. Each monolayer was
used repeatedly with increasing concentrations of thiamine with rest periods in between.
Repeated changes of basal and apical fluid could have damaged the monolayers in a way
that was not noted because monolayer integrity was not determined after the experiment
was completed.
The separate monolayers used for single condition forward and reverse studies have
shown that forward Papp of thiamine (i.e. apical to basal) appears not to change in a manner
dependent on culture conditions whilst the reverse basal to apical Papp does. This leads to
a significant increase in forward transport in the −G−T condition relative to the other
three conditions. This lies in corroboration with other evidence, in HK-2 cells, showing a
decreased rate of net uptake in the high glucose conditions (below).
12.2 Rate of uptake of thiamine by HK-2 cells in vitro
Experiments with tritiated thiamine ([3H]thiamine) were performed to investigate if the
decrease in THTR-1 abundance observed in the HK-2 cells led to a decreased rate of uptake
of thiamine. HK-2 cells were cultured in 6-well plates for five days in four conditions (−G−T,
−G+T, +G−T and +G+T). [3H]thiamine uptake rate was assayed as described in Section
6.11.1. Nine wells in each condition were assayed for uptake rate and three further wells were
used as a negative control with non-radioactive thiamine to allow blanking of the samples
to background radiation levels. The uptake rates are given in Figure 12.4.
The uptake rates are identical in both 5 mM conditions (p > 0.05) but are decreased
significantly in +G−T with respect to the low glucose conditions (−31%; p < 0.001). The
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uptake rate in +G+T was decreased by 17% with respect to −G+T (p < 0.05) but the
decreased uptake rate in +G+T with respect to −G−T was not significant (p = 0.053).
The addition of thiamine to either the low or high glucose concentration conditions did not
alter [3H]thiamine uptake rate.
12.2.1 Discussion
The decreased rate of uptake of [3H]thiamine in HK-2 cells in hyperglycaemic conditions
corroborates evidence that there is a decreased abundance of THTR-1 in hyperglycaemic
conditions. The 31% decrease in uptake rate in +G−T with respect to −G−T does not
correspond exactly with the 53% decrease in abundance of THTR-1 seen in the same cells.
The results must be interpreted taking into account the simplistic nature of the uptake
model. PTECs in vivo use THTR-1 and THTR-2 to transfer thiamine from the apical
membrane to the basal membrane. HK-2 cells do not have a normal THTR-2 expression, as
indicated by qPCR and immunohistochemistry analysis. This leaves only THTR-1 taking
thiamine up on the apical face (exposed to the [3H]thiamine) and perhaps attempting to
expel thiamine from the basal membrane, adhering to the polystyrene sub-stratum. These
differences alone may explain the difference in magnitude between THTR-1 abundance and
thiamine uptake rate.
Figure 12.4: [3H]thiamine uptake rate into HK-2 cells in vitro. −G−T; −G+T;
+G−T; +G+T. ∗ = p < 0.05; ∗ ∗ ∗ = p < 0.001. n = 9 for each condition.
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12.3 Rate of release of thiamine from HK-2 cells in
vitro
The rate of release of thiamine from HK-2 cells cultured in the four conditions (−G−T,
−G+T, +G−T and +G+T) was studied by pre-loading cells with [3H]thiamine for 5 h and
then subjecting cells to a 10 min release period into fresh Krebs-Ringer solution containing
no thiamine. Full details of the method are given in Section 6.11.2 on page 124.
The results for release rates must be presented in the context of the total [3H]thiamine
taken up during the pre-loading period. This is because uptake rates during the pre-loading
period are unique to the relevant condition. In addition, as intracellular [3H]thiamine con-
centration rises during the pre-loading period, some will be pumped back out into the
medium. The net result is that there are different intracellular [3H]thiamine concentrations
for each condition at the start of the release period. By measuring [3H]thiamine released
from the cells into the Krebs-Ringer solution (Treleased) and final [3H]thiamine content of
the cells (Tafter), the initial [3H]thiamine content of the cells (Tbefore) could be deduced
(Figure 12.5). −G−T cells contained the most [3H]thiamine. With respect to −G−T,
the amount of intracellular [3H]thiamine is decreased in −G+T (−28%; p < 0.01), +G−T
(−35%; p < 0.001) and +G+T (−50%; p < 0.001). Intracellular [3H]thiamine in +G+T
was decreased by 31% with respect to −G+T (p < 0.01) and was decreased by 24% with
respect to +G−T (p < 0.05). There were no other significant differences. These data can
be considered as results to an extended uptake rate experiment over 5 h and show that both
glucose and thiamine affect the storage of thiamine during this uptake period. In both high
and low glucose, prior incubation in a high thiamine culture medium leads to lower accumu-
lation of thiamine (perhaps as a result of high intracellular thiamine concentrations). Also,
high glucose causes a decrease in thiamine accumulation, irrespective of thiamine status.
When compared to the dedicated 10 min uptake experiment performed, these results show a
similar trend but an increased magnitude. This increased magnitude could be attributable
to the longer uptake period.
The data in Table 12.1 indicates Tbefore as a percentage of the total [3H]thiamine
available in the system (1 mL × 15 nM; 15 pmol available [3H]thiamine). This confirms that
the [3H]thiamine in the medium is still greatly in excess during the pre-loading period since
in no condition do the cells contain more than 0.3% of available [3H]thiamine. Also in
Table 12.1 is data showing Treleased as a percentage of Tbefore. This value, T%, is calculated
from Equation 12.1 where Tafter is the amount of intracellular [3H]thiamine in the cells after
192
Figure 12.5: [3H]thiamine content of HK-2 cells in vitro before release window after pre-
loading with [3H]thiamine. −G−T; −G+T; +G−T; +G+T. ∗ = p < 0.05; ∗∗ =
p < 0.01; ∗ ∗ ∗ = p < 0.001. n = 3 for each condition.
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the release period has elapsed. These values all exceed 90% which means that <10% of
[3H]thiamine is released from the cells during the release window and that the data are for
intitial rate conditions.
T% =
Tafter
(Tafter + Treleased)
× 100 (12.1)
Condition [3H]thiamine taken
up (% available)
[3H]thiamine remaining in cells
(% intracellular [3H]thiamine at
start of release window)
−G−T 0.28% 95.1%
−G+T 0.27% 94.0%
+G−T 0.21% 93.2%
+G+T 0.21% 92.3%
Table 12.1: [3H]thiamine handling in HK-2 cells in vitro
The release rates from the pre-loaded HK-2 cells can be expressed as absolute release
rates (in fmol 10 min−1 mg protein−1; Figure 12.6) or as a release rate constant, Kr (in
min−1; Figure 12.7), derived from:
Release rate = Tbefore ×Kr
Figure 12.6: [3H]thiamine absolute release rate from HK-2 cells in vitro. −G−T; −G+T;
+G−T; +G+T. n = 3 for each condition.
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These results show that the absolute release rate is independent of intracellular
[3H]thiamine concentration. This could be attributed to the polarised HK-2 cells not being
able to release thiamine from their basal faces (due to occlusion by a solid sub-stratum) and
releasing thiamine in a uniform, and perhaps uncontrolled, manner from their apical faces.
The release rate constant (Figure 12.7) is increased in +G+T with respect to −G−T
(+57%; p < 0.001) and with respect to −G+T (+29%; p < 0.01). Also, the release rate
constant is increased in +G−T with respect to −G−T (+38%; p < 0.01). The higher
release rate constants are attributable to a similar absolute release rate combined with a
lower intracellular [3H]thiamine concentration prior to eﬄux (Tbefore).
It is important to remember that these data represent only the initial rate of eﬄux
from the cells. This is likely to be the fastest rate because at the start, the cells have the
highest intracellular concentration of [3H]thiamine. If each eﬄux ratio were to be multiplied
by 30 (5 h uptake ÷ 10 min release) then values would range from 1.5–2.5 representing an
eﬄux rate faster than the accumulation rate. In reality, the eﬄux rate would drop as the
intracellular concentration of the [3H]thiamine was reduced.
Figure 12.7: [3H]thiamine release rate constant from HK-2 cells in vitro. Kr = (release
rate/Tbefore). −G−T; −G+T; +G−T; +G+T. ∗∗ = p < 0.01; ∗ ∗ ∗ = p < 0.001. n
= 3 for each condition.
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Chapter 13
Double blind placebo-controlled
trial of thiamine
supplementation in patients
with type 2 diabetes and
microalbuminuria
13.1 Patient characteristics
In the Pakistan thiamine intervention trial placebo group there were 11 male and 9 female
patients (age 52.4±8.7 years and BMI 28.3±4.4 kg m−2). In the thiamine treatment group
there were 10 male and 10 female patients (age 52.7±8.4 years and BMI 28.1±4.6 kg m−2).
Throughout the duration of the study, nine patients in the thiamine treatment group and
three in the placebo group were receiving insulin therapy (p < 0.05). There were no other
significant differences between the groups with regard to therapeutic agents taken. One
patient achieved glycaemic control through diet alone; all other patients received therapeutic
hypoglycaemic agents (sulphonylureas, metformin and thiazolidinediones). Nine patients
in the placebo group and eight in the thiamine treatment group received therapy with
antihypertensive agents. Three patients in the thiamine treatment group and one in the
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placebo group were receiving statins at baseline compared with seven and two respectively
after three months and seven and three after the washout period from 3–5 months. One
patient in the thiamine treatment group was receiving antihyperlipidaemic fibrate therapy.
Whilst these patient therapies are not all in line with current recommendations for best
clinical practice [American Diabetes Association, 2009] they are typical for treatments found
on the Indian sub-continent; as a comparison, see the Chennai Urban Rural Epidemiology
Study [Unnikrishnan et al., 2007]. The patient characteristics at baseline are presented in
Table 13.1.
There was no significant difference between the groups for any clinical chemical
variable at baseline. The median plasma thiamine concentration of diabetic patients was
7.5 nM, markedly lower than the normal range of healthy human volunteers we saw in our
survey in Colchester (44.6–93.7 nM) [Thornalley et al., 2007]. The median urinary thiamine
excretion was 1.38 µmol 24 hours−1. This value is in excess of the 0.2 µmol 24 hours−1 value
suggested by Finglas [1993] as a minimum for indicating adequate dietary sufficiency. On
this basis, all patients in this study had adequate dietary thiamine intake. One patient had
a plasma thiamine concentration above the normal range and a urinary thiamine output 30-
fold greater than the normal mean [Thornalley et al., 2007], consistent with prior thiamine
supplementation, and was excluded from the data analysis.
At baseline, there was a negative correlation of plasma thiamine concentration with
thiamine clearance (r = −0.52; p < 0.01) and a positive correlation of urinary thiamine
excretion and thiamine clearance (r = 0.52; p < 0.01). There was no significant difference
in the plasma thiamine concentration, urinary thiamine excretion and renal clearance of
thiamine for patients with and without antihypertensive therapy. There were negative
correlations of plasma thiamine concentration and urinary thiamine excretion with plasma
von Willebrand factor (vWF) (r = −0.41 and −0.42, respectively; p < 0.05). There was a
significant negative linear regression of soluble vascular cell adhesion molecule-1 (sVCAM-1)
on plasma thiamine [sVCAM-1 (ng mL−1) = 687 − (5.5 × plasma thiamine (nmol L−1));
p < 0.05]. These results corroborate findings made previously by this group [Thornalley
et al., 2007].
Multivariate analysis was not conducted on the data from this trial. A study such
as this one would lend itself to multivariate analysis as there are multiple factors which have
been measured and could have an influence on the final endpoint. A univariate analysis
assumes that one factor (the increase in plasma thiamine concentration) is responsible for
the change in urinary albumin excretion. A multivariate analysis would confirm or refute
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this and provide evidence of contributions to the endpoint from other factors.
13.1.1 Clearance rate definition
For clarification, the thiamine clearance rate is a measure of how fast thiamine is being
removed from the blood by the kidneys. It is measured in mL min−1 which represents a
time-averaged clearance rate over the measurement time (e.g. 1 day). The clearance rate is
calculated using the following formula:
Clearance (mL min−1) =
Concentration urine (mM)×Urine flow (mL min−1)
Concentration plasma (mM)
The thiamine excretion rate is a measure of the amount removed from the body
in a given time e.g. µg day−1. It is derived from the product of urinary concentration
and urinary volume per unit time. The fractional excretion of thiamine is the ratio of
thiamine excreted by the kidneys to the total amount of thiamine filtered by the kidneys.
It is calculated in two parts with the amount of thiamine excreted forming the numerator
and the denominator being the total amount of thiamine filtered by the kidneys (glomerular
filtration rate × plasma thiamine concentration). When appropriately cancelled, the formula
for determining fractional excretion is:
FEthiamine = 100× [Thiamine]urine × [Creatinine]plasma[Thiamine]plasma × [Creatinine]urine
13.2 Effect of therapy with high-dose thiamine on type
2 diabetes patients
Thiamine treatment for 3 months increased the median plasma concentration of thiamine
by 10-fold and urinary excretion of thiamine by 29-fold (Table 13.1 and Figure 13.1). All
liver function tests were within the normal range, indicating the expected absence of adverse
effects of treatment with thiamine. This demonstrates that it is sufficient to use a simple
and inexpensive oral dosing regime to counter plasma thiamine deficiency.
The primary endpoint of this study was the effect of thiamine supplementation
on UAE. After the treatment period, patients receiving thiamine therapy had decreased
median UAE, with respect to patients receiving the placebo (30.1 versus 35.5 mg 24 h−1;
p < 0.01). UAE was decreased significantly with respect to baseline in the patients treated
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for 3 months with thiamine (−17.7 mg 24 h−1; p < 0.001) but not in patients treated with
placebo. The decrease was maintained after the washout period when the decrease in urinary
albumin in the patients treated with placebo also became significant (Table 13.1 and Figure
13.2). The time course of changes in UAE in patients treated with thiamine and placebo
showed a progressive decrease in UAE with time throughout the treatment period. Linear
regression of UAE in relation to treatment time indicated that the rate of decrease in UAE
was increased about fourfold in patients treated with thiamine with respect to placebo
(−5.62 versus −1.52 mg 24 h−1 month−1; Figure 13.2). Since there was a large dispersion
of baseline UAE data and it was the response to therapy rather than the absolute change
in UAE that was of most interest in this study, plots of each patient’s response to therapy
relative to their own baseline were constructed (Figure 13.3). These plots show that all
diabetic patients receiving therapy had decreases in their UAE whilst patients receiving a
placebo varied in their response over the treatment period. These decreases in UAE were
in addition to those attributable to renin-angiotensin-aldosterone system (RAAS) blockade
by angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers
(ARBs; Figure 13.4). Median UAE rates for patients receiving thiamine supplementation
decreased from 44.8 to 29.8 mg 24 h−1 in the ACE-I/ARB therapy subset (−33%; n = 6;
Figure 13.1: Effect of high-dose thiamine on plasma thiamine concentration in type 2 di-
abetes patients (median values). The normal median plasma thiamine concentration from
Thornalley et al. [2007] is indicated by the black dashed line. Therapy; Placebo. ∗∗∗ =
p < 0.001 with respect to both placebo group after therapy and therapy group at baseline.
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p < 0.05) and from 43.7 to 30.1 mg 24 h−1 in the subset not receiving ACE-I/ARB therapy
(−31%; n = 13; p < 0.01).
Figure 13.2: Effect of high-dose thiamine on UAE in type 2 diabetes patients. Data represent
the change from baseline of UAE in type 2 diabetic patients receiving thiamine (black
squares) or placebo (white squares). Data are median values. ∗ = p < 0.05; ∗∗ = p < 0.01;
∗ ∗ ∗ = p < 0.001 with respect to baseline. # = p < 0.05; ## = p < 0.01 with respect to
baseline change for the placebo.
There was no significant effect of thiamine supplementation on glycaemic control,
dyslipidaemia, blood pressure, GFR or markers of vascular dysfunction during the treatment
period. After the washout period, fasting plasma glucose was decreased with respect to
baseline concentration in the thiamine treatment and placebo groups (p < 0.05) and HbA1c
was decreased with respect to baseline and 3 months after therapy in the thiamine treatment
group (p < 0.01). At this time, total cholesterol and LDL-cholesterol increased in patients
treated with placebo, and LDL-cholesterol decreased in patients who had received thiamine
therapy. HDL-cholesterol decreased significantly from baseline after the 3 month treatment
period in patients treated with both thiamine (−16%; p < 0.05) and placebo (−22%; p <
0.01). HDL-cholesterol returned to baseline values in both groups after the washout period.
Patients receiving placebo showed significant increases in triacylglycerol from baseline after
the 3 month treatment and washout periods (+18% and +30%, respectively; p < 0.05).
Patients receiving thiamine had a significant increase in systolic BP after the washout period
(+7.1%; p < 0.05). After the washout period, there was also a decrease from baseline
and post-therapy concentrations of sVCAM-1 in patients receiving thiamine (−107 and
−73 ng mL−1 respectively; p < 0.05) (Table 13.1).
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Figure 13.3: Individual changes in UAE of patients receiving placebo (top; p > 0.05) or
thiamine therapy (bottom; p < 0.001). Median values are indicated by black horizontal
bars.
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In order to explain why the effects of the supplementation continue into the washout
period, it is necessary to consider the biological half-life of thiamine. This is only two days
in the plasma [Weber and Kewitz, 1985] but the overall biological half-life is much longer at
9–18 days [Ariaey-Nejad et al., 1970]. The plasma concentration and urinary excretion of
thiamine in the thiamine treatment arm of the study return to baseline concentrations after
the washout period but it is reasonable to assume that the tissue concentration of thiamine
remained elevated for at least one half-life which may explain the extra benefit obtained by
patients during the washout. This extension of the therapeutic affect may have contributed
to the decrease in median plasma sVCAM-1 concentration which only achieved significance
after the washout period.
The placebo effect observed, which is often present in such trials, may be potentially
explained by two factors. The first is a possible increase in the quality of primary care
afforded to patients whilst participating in the trial. The second is that patients on the
trial may be more acutely aware of their health. As a result they may be making more of a
concious or unconcious effort to follow good practice with regard to diet, exercise and so on
whilst on the trial. Either of these factors could contribute to the effects seen.
This pilot study has demonstrated that high dose thiamine therapy at 3 × 100 mg
daily decreased UAE in type 2 diabetes patients with microalbuminuria after 3 months of
therapy. In 35% of cases after 3 months’ therapy, a regression to a normal albumin excretion
Figure 13.4: Effect of ACE-I/ARB therapy on UAE. Data represent the median UAE for
patients receiving thiamine therapy with (black bars) and without (white bars) concomitant
ACE-I/ARB therapy. ∗ = p < 0.05; ∗∗ = p < 0.01.
203
rate from microalbuminuria was observed. The study also confirmed previous reports that
diabetic patients have a low plasma thiamine concentration and the correlation between
plasma thiamine and sVCAM-1 concentrations [Thornalley et al., 2007]. Since this was
a pilot-scale project, a larger study will be needed to confirm the therapeutic effects of
thiamine in diabetic patients.
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Chapter 14
General discussion
The aim of this project was to investigate the link between diabetes and thiamine status,
specifically the role of the kidney in the state of plasma thiamine deficiency seen in diabetic
patients [Thornalley et al., 2007]. This link was investigated using a multi-strategy approach.
The location of the thiamine transporters THTR-1 and THTR-2 was investigated in normal
kidneys by immunohistochemistry. Secondly, many aspects of thiamine metabolism in low
and high glucose and low and high thiamine concentrations were investigated in vitro in
PTECs, both HK-2 cell line cells and those freshly isolated from a human kidney. Finally,
the effect of thiamine supplementation on nephropathy in patients with type 2 diabetes was
investigated in a supplementation trial based in Pakistan.
14.1 Comparison of model systems
Three different models of diabetes have been used throughout this thesis. The most relevant
of these is not semantically speaking a model for diabetes but rather a model for the entire
diabetic population. These are the patients who volunteered for the Pakistan thiamine
supplementation trial. Since there is no abstraction between the experimental volunteer
and the target of the research, patient volunteers are the gold standard for experimentation.
Many experiments though require more abstract models to avoid technical, financial or
ethical constraints. This abstraction requires that the results of such experiments, and their
implications and limitations, are interpreted accordingly.
The other two models used herein are the in vitro cell systems. Both the human
PTEC primary cultures and the HK-2 cell line cultures are representative of the epithelium
of the human proximal tubule. However, they have been treated very differently since
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extraction from a kidney. These differences in treatment are important since they affect
the cells and thus also the experimental results gained from them. One major difference
is that the cells in the HK-2 cell line were immortalised shortly after removal from the
kidney. The immortalisation used viral transduction with the HPV 16 E6 and E7 genes.
E6 acts with the host E6 associated protein to ubiquitinate the tumour suppressor p53,
thereby targeting it for degradation [Mu¨nger and Howley, 2002; Hawley-Nelson et al., 1989].
E7 competitively inhibits the binding of the transcription factor E2F-1 to retinoblastoma
protein (pRb) which would normally act to suppress its activity. With no pRb bound,
E2F-1 acts with its binding partner DP-1 to transactivate its targets which promote cell
cycle progression by stimulating the G1/S transition and S-phase progression [Mu¨nger and
Howley, 2002; Halbert et al., 1991]. E6 and E7 have also been implicated in the decreased
expression of TGF-βR1 [Hypes et al., 2009]. This transduction process applied a selective
pressure to the cells during the transduction period and removed certain selective pressures
after transduction: with p53 effectively inactive, mutations due to genetic instability which
would normally cause a cell to undergo apoptosis are allowed to persist. If such mutations
confer even a slight selective advantage over the wild-type cells then the mutated cells will
easily out-compete the wild-type within a few generations [Masters, 2002; Capes-Davis et al.,
2010].
As well as the selective pressures of the immortalisation procedure, the HK-2 cells
have been removed from the kidney for an extended period of time. Such cells would
normally have been stored in a liquid nitrogen cryostore for large portions of that time.
However, there remains the possibility of large periods of time when the cells were under
culture. The HK-2 cell line was first established in 1993 [Ryan et al., 1994] yet it is not stated
exactly which cells were deposited with the ATCC, only that the cells had been growing in
their laboratory for periods of more than one year. It is thus possible that the original frozen
cells deposited with the ATCC were one year old. The ATCC will have defrosted these to
expand the stocks and then re-frozen again. Upon receipt from the ATCC, I defrosted,
re-froze and defrosted the cells again. This is three freezings and three defrostings in a best-
case scenario assuming optimal handling since extraction. Each of these freezings exposed
the cells to cryoprotectants such as DMSO and it is clear from survival rates of only 70–90%
upon defrosting that freezing applies a substantial selective pressure on the cells. The nature
of this selective pressure can not be readily known.
The situation is further complicated by the composition of routine commercially
available tissue culture medium. The concentrations of thiamine (6.5 µM) and glucose
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(>15 mM) amongst others are chosen to aid growth in an in vitro environment. During
cell culture with a physiological 5 mM glucose, the concentration of glucose in the medium
dropped to between 3.5–4 mM after 24 hours depending on the confluence of the cells. Thus,
medium was changed daily to prevent extreme hypoglycaemia. Daily medium changes would
be an inconvenient expense for many experiments which is why routine culture medium is
supplied with a higher glucose concentration. However, knowledge of why the concentrations
are non-physiological does not alter the fact that both glucose and thiamine concentrations
are above the normal physiological upper limit (thiamine concentrations should be in the
low nanomolar range and glucose concentrations should ideally be lower than 6.1 mM [World
Health Organization, 2006]). These high concentrations pose specific problems to research.
At such concentrations of thiamine, a cell needs no active transport mechanism for the vita-
min since sufficient acyclic, unionised thiamine could diffuse directly across the membrane.
This means that all the aforementioned selective pressures have been applied in an envi-
ronment where there is no need for the cells to maintain a normal thiamine metabolism. It
is indeed advantageous, evolutionarily, for cells to stop manufacturing thiamine transport
proteins since they are metabolically costly to synthesise and unnecessary. This is most
evident observing the expression of THTR-2 in HK-2 cells. THTR-2 is an important part
of normal cellular thiamine transport and yet appears to be completely absent in the HK-2
cells. Immunohistochemistry images do not show the presence of any THTR-2 and real time
qPCR results comparing HK-2 cells to human kidney cortex stored at −80℃ show that the
kidney has 120× the relative abundance of THTR-2 mRNA transcript compared to β-actin.
It is likely that a mutation that stops cells expressing THTR-2 would provide a selective
advantage in such a system because the protein is not necessary and by not expressing it
the new population of cells would be able to grow quicker and out-compete the wild-type
cells.
The PTECs extracted from the human kidney and grown in primary culture are
very different from the HK-2 cells. They have never been exposed to non-physiological
concentrations of any metabolite, growth factor, vitamin or similar compound. They were
growing in primary culture within 48 hours of the death of the donor and were only exposed
to high glucose and thiamine concentrations as part of an experimental procedure. However,
these cells are not free of potential problems. The kidney they were isolated from was
chilled on ice immediately after removal and remained on ice without a circulatory system
for the duration of transport to the laboratory. They were digested from the kidney using
type 2 collagenase, which despite being more highly purified than type 1 collagenase, still
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contains residual clostripain activity. Clostripain, also known as endoproteinase Arg-C, is a
sulphydryl proteinase that cleaves proteins on the carboxyl peptide bond of arginine residues.
This means that proteins expressed on the cell surface other than the collagen in the ECM
will have been partially hydrolysed. It is impossible to know what effect this will have had
on the cells. Although it is likely that effects would have been short-lived and confined to
the first few generations of cells grown in vitro, trypsin was subsequently routinely used to
separate the cells from the substratum during passaging. This would have further damaged
the cells in ways that were unknown in common with every in vitro cell experiment. Other
selective pressures applied during the isolation of the kidney proximal tubule cells include
their shaking in a water bath during the digestion period, their chilling to 4℃ and their
separation in Percoll at 30 000× g. This centrifugal force is not as devastating as first
imagined because the cells are buoyant meaning that the force is applied only across the
narrow diameter of each cell. The effects of the shaking, chilling, spinning and re-warming
are not known and can not be controlled for.
From this discussion it is clear that the two cell models are not equal. The human
proximal tubule epithelium primary cell cultures represent only a relatively small abstraction
from the in vivo diabetic kidney proximal tubule and so are likely to produce results more
representative of in vivo conditions. The HK-2 cell line has been manipulated relatively
extensively since its removal from a kidney and is thus even further removed from a diabetic
kidney. This abstraction is often tolerated throughout in vitro research because cell line
models offers an ease of use and availability far above that of primary cell cultures.
14.2 Experimental and analytical decisions
It is important to be able to justify experimental choices made throughout the period of
study. These choices can be subdivided into those about which experiments were performed
and those which guide experimental design. To begin, there were differences between ex-
periments performed in the HK-2 cells and experiments performed in the primary cultures
of PTECs. For example, there was no analysis of glycosylation performed in the primary
PTEC cultures, nor was the abundance of Sp1 analysed. This can be explained by cir-
cumstance. The original research plan was to use solely the HK-2 cell model as this was
commercially available. This meant that for the early part of the research, all experiments
were conducted in HK-2 cells. The opportunity for using freshly isolated PTECs cells was
welcomed but unplanned. The decision was made to attempt the same experiments in cells
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in primary culture as those conducted in the HK-2 cell model. At all times the experimental
choices were guided by the original hypothesis for the project. Thus, after PTEC charac-
terisation, the abundance of THTR-1, the mRNA quantitation data, intracellular thiamine
concentrations, intracellular hexosamine pathway product concentrations, transketolase ac-
tivity and [3H]thiamine handling were prioritised. The differences between HK-2 cells and
the fresh PTECs were marked which has serendipitously revealed that the HK-2 cell model
may not be suitable for many of the in vitro investigations.
14.2.1 Cell culture methods
It is equally important to discuss the choices made for individual experiments. One common
element to all in vitro work conducted was the use of cell culture. In the case of both cell
types, culture was carried out in an identical manner to ensure comparability between the
results. Each harvest of cells was preceded by five days of culture in the relevant experimental
culture condition. This five day period was chosen based on the doubling time of the cells
(around 24–30 hours). Assuming pure exponential growth with a 24 hour doubling time,
there are 32× the starting number of cells at the point of harvest than at the start of the
incubation; a 30 hour doubling time yields 16× as many cells in the same period. This is
important because it allows sufficient dilution of the original cell stock for factors such as
protein turnover not to be critically important. By way of example, if cells were at near
confluence and then exposed to an experimental condition which caused decreased expression
of protein x, unless protein x was actively degraded, the decreased expression may not be
represented by decreased abundance in the cells at harvest. The effective dilution of protein
and metabolites (by exponential growth of both intracellular volume and membrane area
under culture) means that even if protein x is not actively degraded, an effect on expression
should translate to an observable change in protein abundance. In reality, many proteins
have a relatively short half-life, but this was not investigated so could not be relied upon.
The same principle of exponential decay applies to intracellular metabolite concentration.
In addition to the extended culture periods for each experiment, HK-2 cells were
cultured in 5 mM glucose, 4 nM thiamine medium for a minimum of two weeks after removal
from the cryostore. This extended period of culture was intended to ameliorate the effect
of any “metabolic memory” that the cells may have had from previous culture in high
glucose and high thiamine conditions [Ceriello et al., 2009]. There is no precedent for how
long cells should be cultured to remove any possible memory effect and there is no known
way to quantify any potential memory although there is evidence that memory may be
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epigenetically mediated [Siebel et al., 2010; Tonna et al., 2010]. The two week period was
an arbitrary decision based on the rate of growth of the cells. Assuming exponential growth
with a relatively slow 30 hour doubling time, cells grown for two weeks will have grown to
2((14×24)/30) or around 2300× their original number over 11 generations. Given that it is not
possible to assay effectiveness of this treatment, the only guarantee of using cells that have
no metabolic memory of previous conditions is to use cells isolated from a human kidney
which have never been exposed to non-physiological concentrations of either thiamine or
glucose.
Another factor which should be considered with regard to cell culture is the potential
for 26 mM glucose to cause an effect in cells by osmotic stress alone. If this were the case
then any high concentration sugar would cause effects in a similar manner to d-glucose. This
can be controlled for using d-mannose or l-glucose as an osmotic control to d-glucose. Such
a control was performed but only with the HK-2 cells and only when quantifying mRNA
abundance. The cells were grown in 5 mM glucose medium and the hexose concentration
was raised to 26 mM by addition of d-glucose, l-glucose or d-mannose. A PBS blank was
also performed. There was no difference between PBS, l-glucose or d-mannose treated cells
in expression of 6 representative genes. To be rigorous, an osmotic control should have been
used in all situations where cells were exposed to high glucose concentrations.
14.2.2 Discrepancies between the HK-2 cell and the primary cell
cultures
The results presented throughout this thesis demonstrate several differences between the
two cellular model systems and many have been discussed in individual sections. One set
of results, the mRNA abundance data from the qPCR experiments, are of particular note.
The gene TXNIP was included in the mRNA analysis because it is a useful positive control
for exposure to hyperglycaemia. Qi et al. [2007] demonstrated an 11–12-fold increase in
expression in TXNIP in HK-2 cells cultured for 11 days in 30 mM glucose relative to 5 mM
glucose. The results for expression of TXNIP in HK-2 cells presented in Figure 9.6 only
showed a 1.6–1.7-fold increase after culture in 26 mM glucose for 5 days. In contrast, the
primary cell cultures showed a 48–65-fold increase in expression of TXNIP under the same
conditions (Figure 9.3). In all other cases, the HK-2 cell results show similar signs of being
decreased in magnitude relative to the primary cell result. In some cases, the HK-2 cell
result is opposite to the primary culture result e.g. the GFAT-1 mRNA abundance in the
primary cell cultures was ablated by 90% in the hyperglycaemic cultures—a strong response.
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The same results in the HK-2 cell line shows a relatively mild 30% increase in abundance.
The fact that the HK-2 cells do not exhibit a marked change in gene expression in
response to a 26 mM glucose assault in a manner similar to the primary cell cultures suggests
that they have somehow become adapted to the higher glucose conditions. They do respond
in some cases but only in a muted fashion. It is conceivable that have adapted to routine
high glucose culture so much that even periods of extended culturing in 5 mM glucose can
not promote a marked change in gene expression when cells are returned to 26 mM glucose
culture.
The case for abnormal thiamine handling in HK-2 cells is strongest when data from
immunohistochemical and qPCR are combined to corroborate the lack of the THTR-2 trans-
porter, an important part of thiamine transport in vivo: the abundance of mRNA for
THTR-2 in the HK-2 cells is less than 1/100 of that found in normal kidney cortex and there
is no evidence of immunostaining for THTR-2 in HK-2 cells. Further evidence from intracel-
lular thiamine metabolite concentrations suggests that the interconversion of the thiamine
metabolites is not the same as in vivo. When cultured in physiological concentrations of
thiamine, the HK-2 cells maintain a substantial portion of their thiamine pool in the forms
of TMP (22–25%) and THM (22–26%)—something not seen in the primary PTEC cultures
where all thiamine is held in the form of TPP in the low thiamine conditions. Since the aim
of this thesis was to investigate thiamine mis-handling in diabetes, it would be improper
to rely upon results generated in a model system which clearly doesn’t represent in vivo
thiamine handling prior to experimental manipulation.
14.3 Effects of hyperglycaemia on PTECs in vitro
The effects of hyperglycaemia on the PTECs in vitro were not all concordant and in keep-
ing with the proposed hypothesis of hexosamine pathway activation and down regulation
of thiamine transporter expression in model hyperglycaemia. There is strong evidence sup-
porting our hypothesis explaining why diabetic patients are thiamine deficient—decreased
renal re-uptake of thiamine—but the evidence does not support the mechanistic hypothe-
sis regarding why thiamine transport becomes deficient. Our hypothesis proposes that the
plasma thiamine deficiency is caused by decreased renal re-uptake of thiamine elicited by a
decrease in abundance and expression of thiamine transporters. Primary PTECs cultured
in hyperglycaemic primary culture exhibit substantial decreases in abundance of mRNA for
both the main thiamine transporters, THTR-1 and THTR-2, with a smaller decrease for
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the TMP-transporting RFC-1. These decreases are mirrored by a decrease in abundance of
THTR-1 as demonstrated by western blotting, and a shift in the (apical to basal):(basal to
apical) Papp ratio away from apical to basal transport of thiamine across monolayers. These
steady state observations alone could potentially explain the decreased plasma thiamine
concentration in diabetic patients—the decrease in mRNA abundance of THTR-1 in the
primary cultures is approximately equal to the decreases in abundance of THTR-1 protein
in the same cells which in turn is approximately equal to the plasma thiamine deficiency
seen in diabetic patients surveyed in Colchester [Thornalley et al., 2007]. It is unfortunate
that the monolayer experiments designed to determine parameters of transport kinetics of
thiamine across monolayers of PTECs were not successful. No experiment yielded a K m
or a V max value for thiamine transport which leaves most kinetic questions unanswerable.
The intracellular concentration of thiamine pyrophosphate is not altered in +G−T relative
to −G−T in the primary PTEC cultures (discussed detail in Section 11.1). Also TKT
activity is also unchanged in hyperglycaemic culture (discussed in Section 11.2) despite
down-regulation of TKT mRNA in primary PTECs in high glucose conditions.
Whilst the data may support our hypothesis as to why diabetic patients are thi-
amine deficient, they do not support it regarding how this deficiency is brought about.
The hexosamine-pathway based theory posited in Chapter 5 proposes that an increased
flux through the hexosamine pathway causes increased O-GlcNAcylation of target proteins
including Sp1 which in turn leads to decreases in expression of the thiamine transporters.
The evidence against our hypothesis includes the unchanged or decreased intracellular UDP-
GlcNAc concentrations, the profound down-regulation of GFAT (−90%; the enzyme with
most control of flux through the HBP), the down-regulation of OGT (responsible for O-
GlcNAcylation of proteins), and the down-regulation of Sp1 in primary PTECs exposed to
hyperglycaemia. There is also a trend for increased expression of O-GlcNAcase, the enzyme
responsible for removal of O-GlcNAc residues from proteins. Combined, these data suggest
that the flux through the hexosamine pathway may be decreased in hyperglycaemia in the
primary PTECs. Even though functional data on Sp1, OGT, O-GlcNAcase and GFAT are
not available in primary PTECs, alternative hypotheses must be sought to attempt to tie
these disparate observations together.
14.3.1 Alternative hypotheses
Down-regulation of Sp1 The transcription rate of the genes for THTR-1 and THTR-2
(SLC19A2 and SLC19A3 ) is dependent on the transcription factor Sp1. Although Sp1
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glycosylation has been shown to be important in the regulation of many genes, it has not
been demonstrated for these two genes. Instead, what has been shown is that the transcrip-
tion of SLC19A2 is increased in a dose-dependent manner by the addition of Sp1 and that
the transcription of SLC19A3 is dependent on a GC box element bound by both Sp1 and
Sp3 (Section 2.8.4). Perhaps then, it is the abundance of Sp1—and not the glycosylation
status—which is important in determining transcription rate of the SLC19A2 and SLC19A3
genes. Sp1 expression was decreased in the primary PTECs exposed to hyperglycaemia. It
was not decreased in the HK-2 cells in the same conditions but neither was the abundance
of Sp1 protein. My opinions regarding the use of the HK-2 cell model are discussed above.
Nicola´s et al. [2003] studied the transcriptional regulation of the Sp1 gene and
identified binding sites for Sp1 and Sp3, nuclear factor Y (NF-Y), activator protein 2 (AP-2),
CCAAT/enhancer-binding protein (C/EBP) and E2F transcription factors. Increased Sp1
gene expression was observed upon overexpression of Sp1 (in a positive feedback mechanism),
NF-Y and E2F. The activation of Sp1 transcription by Sp1 overexpression was countered
by simultaneous Sp3 overexpression. Nicola´s et al. [2003] conclude that the expression of
Sp1 is dependent on the relative abundance of Sp1, Sp3, E2F and NY-F proteins in the cell
with only Sp3 down-regulating Sp1 expression.
The balance of evidence in the primary PTECs is in support of decreased O-GlcNAc-
ylation in hyperglycaemia. This would potentially lead to the decreased glycosylation of Sp1.
Hypoglycosylated Sp1 is unstable and rapidly targeted for degradation in the proteasome
[Han and Kudlow, 1997] which would initiate a feedback loop whereby Sp1 is degraded,
leading to decreased transcription of Sp1. The decreased abundance of Sp1 could then be
responsible for the decreased abundance of the thiamine transporters.
Poor hexosamine pathway activity in hyperglycaemia There is strong evidence
that the flux through the HBP is increased in hyperglycaemic conditions in a wide variety
of cell types including bovine aortic endothelial cells [Du et al., 2000], pancreatic β-cells
[Kaneto et al., 2001], cardiomyocytes [Clark et al., 2003], lymphocytes [Srinivasan et al.,
2007] and mesangial cells [Kolm-Litty et al., 1998; Zheng et al., 2008]. However, little
evidence has been published regarding podocytes or proximal tubules. Recent work in
podocytes has indicated that GFAT-1 activity is low and that they may need to take up
exogenous glucosamine to increase O-GlcNAcylation in vivo [Rogacka et al., 2010]. Work
by Rocco et al. [1992] demonstrated that hyperglycaemia induces TGF-β expression in a
mouse proximal tubule cell line but gave no indication of increased hexosamine pathway
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flux. Glucosamine has also been shown to activate TGF-β expression in proximal tubule
cell lines [Schleicher and Weigert, 2000] but addition of exogenous glucosamine is highly
removed from in vivo conditions. It is certainly a possibility that hexosamine pathway flux
is not increased in proximal tubule cells in hyperglycaemic conditions in vivo, indeed the
intracellular UDP-GlcNAc concentrations and mRNA evidence presented herein suggests a
decrease in flux through the HBP.
GFAT has a high degree of control over flux through the hexosamine pathway and is
a finely regulated enzyme. The layers of GFAT regulation include its low affinity for both its
substrates (3–10 mM), allosteric feedback inhibition by its ultimate product UDP-GlcNAc
and cAMP-dependent phosphorylation which increases its activity [Schleicher and Weigert,
2000]. The promoter elements for the mouse GFAT-1 gene were investigated by Sayeski et al.
[1997] who concluded that the promoter does not have a TATA box but does have several
GC boxes within a rich GC domain. Sp1 binds to three elements in this promoter and plays
a key role in the regulation of GFAT-1 transcription but the authors conclude that there
are other proteins involved in regulation of transcription which remain unidentified. The
evidence presented in Chapter 10 showing UDP-GlcNAc abundance in PTECs supplemented
with glucosamine, glutamine and glucose has confirmed that GFAT activity is crucial in
controlling the intracellular concentration of UDP-GlcNAc. The biological half life of GFAT
in adipocytes was estimated to be less than 1 hour by Marshall et al. [1991] and there was a
strong correlation between GFAT activity and expression found in lymphocytes [Srinivasan
et al., 2007]. Even if the biological half-life of GFAT was 10× longer in PTECs than in
adipocytes, then despite the lack of protein evidence, it is reasonable to assume that GFAT
activity will be decreased in line the decrease in its expression after five days of culture in
hyperglycaemic conditions. In the absence of data on total cellular glycosylation, it is highly
unreasonable to assume that flux through the hexosamine pathway and cellular glycosylation
are increased given the mRNA and UDP-GlcNAc concentration data.
If increased flux through the hexosamine pathway is not responsible for down-
regulation of THTR-1 and THTR-2 then this may also explain why the expression of the
thiamine transporters is not restored by addition of high dose thiamine. The hexosamine
pathway-based theory proposes that transketolase activation by addition of thiamine diverts
glucose away from the HBP, thereby lowering cellular O-GlcNAcylation. However, if cellular
O-GlcNAcylation is not responsible for the down-regulation of THTR-1 and THTR-2 then
there is no reason that high thiamine should restore their expression. This is something
borne out by all results in this thesis: high dose thiamine does not correct hyperglycaemia-
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induced dysfunction in PTECs. High dose thiamine may still be affecting flux through the
HBP in other cell types (e.g. mesangial cells), something that may be behind the mechanism
of thiamine therapy in type 2 diabetes patients with microalbuminuria.
PKC activation Another proposed mechanism of hyperglycaemia-mediated damage in
diabetes is the activation of protein kinase C (Section 1.7.3). PKC activation has been
linked to decreased activity and expression of the reduced folate carrier, RFC-1 [Halwachs
et al., 2007]. The genes SLC19A2 and SLC19A3 for THTR-1 and THTR-2 are in the same
family as the gene SLC19A1 for RFC-1. It is therefore at least possible that the decreases
in THTR-1 and THTR-2 expression are due to increased activity of protein kinase C in
hyperglycaemia, something that would require further investigation to confirm or refute.
14.4 Effect of high thiamine supplementation
This thesis has demonstrated two incongruous results upon thiamine supplementation in
diabetic model systems. The data from the Pakistan thiamine supplementation trial have
demonstrated that thiamine has a beneficial effect on the rate of urinary albumin excretion,
halting its increase or even lowering it. Conversely, in vitro work has shown that thiamine
supplementation does not have a noticeable effect on hyperglycaemia-induced changes. For
example, there is no restoration in abundance of thiamine transporter mRNA or protein
when PTECs exposed to hyperglycaemia are supplemented with thiamine.
These observations are at odds with one another. It was proposed that hypergly-
caemia was the cause of the diabetic thiamine deficiency in the manner shown in Figure
14.1. The hypothesis was that supplementation with thiamine would intervene with this
spiral at the point of reduced transketolase activity: high thiamine supplementation should
increase the activity of the enzyme transketolase. This in turn would allow a greater flux
through the reductive pentose phosphate pathway, increasing the flux from glycolysis to
relatively low reactivity metabolites such as ribose-5-phosphate. However, when measuring
transketolase activity in the primary cell cultures, there is no decrease observed in hyper-
glycaemic conditions and no increase in activity in high thiamine conditions. There are at
least three explanations for this conundrum.
Thiamine therapy affects glomerular and not tubular cells It is possible that
thiamine supplementation is not affecting proximal tubules, either in diabetic patients or
in vitro. The trial in Pakistan assessed urinary albumin excretion without assessing the
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kidney tissue directly. It is generally accepted that the cells of the glomeruli play the major
part in the excretion of albumin into the urine with the tubules playing a more minor role
(discussed in Section 1.6.2.5). This opens the possibility that thiamine therapy is affecting
the glomerular cells (or a subset thereof) and not the tubules. This would also explain why
thiamine therapy does nothing to reverse the underlying cause of the deficiency—patients
receiving thiamine therapy in the Pakistan trial saw no reduction in the clearance rate
of thiamine at the end of the washout period relative to baseline. Thiamine clearance is
solely determined by the rate of re-absorption by the proximal tubules since it is filtered
completely in the glomerulus. Perhaps thiamine therapy only serves to replenish the vitamin
faster than it can be lost through the kidneys. In this manner, a normal or even elevated
plasma thiamine concentration (and by extension, glomerular cell concentration) can be
maintained despite high losses in the urine. This is corroborated by the evidence in this
thesis that thiamine thiamine supplementation does nothing to correct hyperglycaemia-
induced thiamine mishandling in PTECs in vitro.
Artefacts of in vitro culture are obscuring the effect of thiamine The steady
state conditions of the in vitro experiment may be confounding the results. It could be that
in vivo, a decreased thiamine transporter expression markedly decreases the intracellular
Figure 14.1: Thiamine deficiency spiral beginning with hyperglycaemic assault and ending
trapped in a low thiamine state.
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concentration of thiamine in the PTECs. In vitro, the decreased abundance of thiamine
transporters does not present a functional problem to the cell because they are continually
bathed in a constant thiamine concentration. Even with a low uptake rate, it may be
possible for cells to acquire an optimal intracellular concentration of thiamine. Both of these
possibilities could be investigated further using an in vivo model of diabetes and measuring
thiamine status and transketolase activity in tubules and glomeruli (see Appendix C).
Thiamine therapy primarily affects TPP-dependent enzymes other than TKT
Transketolase was chosen as a representative of TPP-dependent enzymes but it is also possi-
ble that another enzyme such as pyruvate dehydrogenase or α-ketoglutarate dehydrogenase
is affected by a thiamine deficiency. Work by Tylicki et al. [2008] has demonstrated that
thiamine supplementation can increase both PDH and α-KGDH activity in rat hearts fol-
lowing myocardial infarction. By extension, it is possible that thiamine supplementation is
having a similar effect in the kidney but this has not been investigated. If this were the case
then it may be possible that PDH or α-KGDH activity is diminished in the PTECs in vitro
when exposed to hyperglycaemic conditions and that the high thiamine supplementation
corrects this deficiency. However, since the published literature is so sparse, without study
of the activities of TPP-dependent enzymes other than TK in vitro, and perhaps in vivo,
this possibility remains only a speculation.
In summary, there is a discrepancy between the beneficial effect of thiamine in vivo
and the absence of any effect of thiamine on PTECs in vitro. Three main possibilities
present themselves as explanations of this conflict. The first is that the supplementation
is not affecting tubules at all, but rather mesangial cells or other glomerular cells. The
second is that there is a problem with the in vitro experimental design which is masking
any effect that would be seen in vivo and the third is that the involvement of other TPP-
dependent enzymes is masking the effects in vitro since only TK was investigated. Of course,
a combination of these factors is also possible.
14.5 Benfotiamine intervention trials
Our thiamine intervention trial has shown a beneficial effect of thiamine supplementation
on UAE in type 2 diabetic patients. Recently, Alkhalaf et al. [2010] published a trial
investigating the effect of the thiamine monophosphate derivative Benfotiamine on UAE
and the tubular damage marker kidney injury molecule 1 (KIM-1) in patients with type
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2 diabetes and nephropathy. Patients recruited to the study had a UAE between 15–
300 mg day−1 despite treatment with ACE inhibitors or angiotensin receptor blockers. 86
patients were randomized to treatment (3× 300 mg oral Benfotiamine daily) or placebo arms
and the study was carried out over 12 weeks with measurements at baseline, 6 weeks and
termination.
At baseline, there was no difference in whole blood or plasma thiamine concen-
tration between the therapy arm and the placebo arm. The plasma thiamine concentra-
tions were 31.8±7.7 nM in the therapy arm and 31.6±9.8 nM in the placebo arm. Whole
blood thiamine concentrations were 126±23 nM in the therapy arm and 122±23 nM in the
placebo arm. Supplementation with Benfotiamine increased the whole blood thiamine con-
centration relative to the placebo at both 6 weeks and 12 weeks; p < 0.001 (6 weeks:
290±21 nM versus 124±25 nM; 12 weeks: 300±0 nM versus 138±30 nM). The authors did
not report plasma thiamine concentrations at 6 or 12 weeks. The Benfotiamine supplemen-
tation also increased erythrocyte transketolase activity (0.41±0.10 mU mgHb−1 at baseline
and 0.53±0.15 mU mgHb−1 at 12 weeks in the therapy arm; 0.38±0.11 mU mgHb−1 at base-
line and 0.41±0.10 mU mgHb−1 at 12 weeks in the placebo arm; p < 0.001).
These improvements in thiamine status did not translate to improvements in the
primary endpoints of the study, however. There was no significant decrease in UAE in the
therapy arm relative to the placebo arm (p = 0.36). The change in the UAE from baseline to
12 weeks was −18 mg day−1 in the therapy arm and −1 mg day−1 in the placebo arm. Like-
wise there was no difference in KIM-1 excretion between therapy and placebo (p = 0.12).
These results are in contrast to the results we obtained in Pakistan (Chapter 13, [Rabbani
et al., 2009]). There are several differences between the two studies which may explain
this discrepancy. A key difference is that the two studies use different therapies: Benfoti-
amine and thiamine. Benfotiamine is a thiamine monophosphate derivative and markedly
increases the plasma thiamine monophosphate concentration in a way that thiamine does
not (demonstrated in rats by Babaei-Jadidi et al. [2004]). Thiamine monophosphate can be
taken up into cells by the reduced folate carrier (RFC-1). Once in the cells, there is no direct
mammalian enzymatic route to convert TMP to TPP, instead TMP is dephosphorylated
to thiamine and then pyrophosphorylated to TPP by thiamine pyrophosphokinase (Figure
2.6, page 38). Thiamine pyrophosphokinase is non-competitively inhibited by TMP (K i
= 200 µM) and it is thus conceivable that the influx of TMP is preventing its enzymatic
conversion to the active TPP. Of course, there are a large number of hydrolases which are
capable of dephosphorylating TMP to THM so the effect of this inhibition may be miti-
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gated. Studies in streptozotocin-induced diabetic rats investigating the effects of thiamine
and Benfotiamine on dyslipidaemia also show that thiamine alone, and not Benfotiamine,
is able to counter dyslipidaemia [Babaei-Jadidi et al., 2004].
The two trials differ also in the extent of albuminuria exhibited at baseline. The
median UAE at baseline in our study was 44 mg day−1 (33–121 mg day−1) in the thiamine
therapy arm and 51 mg day−1 (33–122 mg day−1) in the placebo arm. These values are only
half the magnitude of the those reported by Alkhalaf et al. [2010] despite that 100% of their
patients were receiving ACE-I and ARB therapy compared to fewer than 50% in our trial
in Pakistan. It is thus possible that the effect of thiamine is only noticeable in patients with
early nephropathy and that the benefit is of limited effect for patients with more advanced
nephropathy. In vivo studies such as those conducted by Babaei-Jadidi et al. [2003] that
show a beneficial effect of thiamine on the progression of DN began supplementation with
thiamine soon after induction of diabetes, before nephropathy was present.
Another factor which could explain the difference between the results of the two
trials is the different genetic background of the two groups of participants. The trial con-
ducted by Alkhalaf et al. [2010] recruited people in the Netherlands of European descent
and our trial recruited people of Pakistani descent. It is unknown what effect differences in
genetics, diet, local health-care or baseline prevalence of thiamine deficiency could have on
the trial outcomes. The patients recruited for the Dutch study had a mean plasma thiamine
concentration at baseline of 31.8±7.7 nM for the Benfotiamine arm and the 31.6±9.8 nM in
the placebo arm, higher than we reported in Pakistan but still lower than our estimate of a
normal plasma thiamine concentration of 64.1±12 nM [Thornalley et al., 2007].
Two further pilot-scale trials investigating Benfotiamine intervention in patients
with microalbuminuria and either type 1 (Oslo study; clinical trials identifier NCT00117026)
or type 2 diabetes (Melbourne study) are due to report soon.
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Chapter 15
Conclusions
This project was divided into two main parts: the investigations on why diabetic patients
are thiamine deficient and the study of thiamine therapy in diabetic patients with microal-
buminuria. The in vitro investigations were conducted with immortalised HK-2 PTECs
and primary PTECs from a healthy human kidney and were based around the hypothe-
sis that the decreased plasma thiamine concentration seen in diabetic patients was caused
by an increase in flux through the hexosamine biosynthesis pathway leading to increased
O-GlcNAcylation of the transcription factor Sp1 which in turn led to a down-regulation of
the thiamine transporters THTR-1 and THTR-2.
One of the most important results from these studies was the marked difference
between the two cellular models of diabetes. The extended periods of time that the HK-2
cells have spent removed from a human kidney has allowed them to drift genetically from
their original genotype. The nature of routine tissue culture conditions—with high thi-
amine and glucose concentrations—has modified the selective pressures experienced by the
HK-2 cells and yielded a cell model no longer suitable for the study of thiamine handling
in hyperglycaemia. The HK-2 cells are completely deficient in THTR-2 and have markedly
different thiamine handling characteristics, as exemplified by the ratios of thiamine metabo-
lites held intracellularly. In addition, the HK-2 cells hold higher intracellular concentrations
of hexosamine pathway products and have a different ratio of UDP-GlcNAc to UDP-glucose.
These results present the quality of the HK-2 cell data as being of very poor quality and
thus untrustworthy for further interpretation.
The results from the primary PTECs provide evidence as to why diabetic patients are
thiamine deficient. There was a marked 48–80% decline in thiamine transporter expression
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in primary PTECs when exposed to hyperglycaemia, irrespective of thiamine concentration.
This decline in expression was accompanied by a 77% decline in THTR-1 abundance in
high glucose conditions. Also, the ratio of forward to reverse Papp values for monolayers of
primary PTECs cultured in hyperglycaemia shifted in favour of less apical-to-basal transport
in hyperglycaemia. Combined, these data provide strong evidence that there is a diminished
rate of uptake of thiamine in proximal tubule epithelial cells in hyperglycaemic conditions.
This project has also yielded interesting data with regard to the hexosamine pathway-
based theory of reduction of expression of thiamine transporters. Rather than an increase in
flux through the hexosamine pathway, the evidence presented herein supports a decreased
flux. There was a 90% decrease in mRNA abundance of GFAT, the enzyme with most
control over flux through the HBP, accompanied by decreases in mRNA abundance for
OGT and Sp1 in hyperglycaemic conditions. There was a trend for increased abundance
of O-GlcNAcase mRNA in hyperglycaemia. In addition, the intracellular concentrations
of UDP-GlcNAc were decreased in +G−T relative to −G−T. Even without protein abun-
dance or activity data, these suggest a down-regulation in the flux through the hexosamine
pathway which does not corroborate the original hypothesis.
Alternative explanations for the decreased abundance of THTR-1 and THTR-2 in-
clude the possibility that it is Sp1 abundance, not glycosylation status that is the important
factor. If flux through the hexosamine pathway is decreased, then Sp1 is likely to become
hypoglycosylated and prone to proteolytic degradation. This decrease in Sp1 would be
self-reinforcing because Sp1 protein is able to promote transcription of the Sp1 gene.
One factor that should not be forgotten is that the primary PTECs were extracted
from only one human kidney and there remains a possibility (however remote) that the
donor did not have a normal thiamine metabolism. This could only be investigated by
comparison with multiple kidneys.
The placebo-controlled thiamine supplementation trial in type 2 diabetic patients
with microalbuminuria has shown that 3× 100 mg oral thiamine daily for three months
restores plasma thiamine to a normal concentration, despite the increased renal clearance of
the vitamin found in diabetic patients. This restoration of plasma thiamine concentration
was accompanied by a decrease in urinary albumin excretion after 1–3 months of therapy.
After three months, 35% of patients receiving thiamine had regressed from microalbuminuria
to normoalbuminuria.
221
15.1 Further work
Many questions regarding the role of hyperglycaemia in diabetic thiamine deficiency remain
unanswered after these investigations and there look to be several promising research topics
for the future. Type 2 diabetic patients with early-stage nephropathy have been shown to
benefit from thiamine therapy in the placebo-controlled supplementation trial in Pakistan.
This trial yielded promising data but was still only of pilot scale with 20 patients recruited
to each arm of the study. The findings must be repeated with a larger sample population
to confirm the benefit of thiamine to diabetic patients. Further studies would benefit from
including patients from a wide variety of ethnic backgrounds with nephropathy covering a
wider range of urinary albumin excretion values. The inclusion of type 1 diabetic patients
would be a valuable addition to any future study.
In addition to work furthering investigation of thiamine as a therapeutic agent, much
work still remains on elucidating the mechanism behind the thiamine deficiency. This thesis
has demonstrated a decreased abundance of SLC19A2 and SLC19A3 genes accompanied
by a decrease in THTR-1 protein in primary PTECs in hyperglycaemia. Quantitation of
the abundance of THTR-2 in the same system is of high importance to corroborate the
mRNA evidence. To thoroughly investigate the hexosamine pathway-based theory, the
abundance and activity of GFAT protein as well as abundance of Sp1 should be established
in primary PTECs. Also, direct assessment of total cellular O-GlcNAcylation by means of
western blot would confirm or refute the evidence that there is a decreased flux through
the hexosamine pathway in hyperglycaemia in PTECs. Likewise to test if O-GlcNAcylation
itself causes down-regulation of THTR-1 and THTR-2, primary PTECs could be incubated
with glucosamine to boost the HBP or an inhibitor of GFAT such as azaserine to inhibit the
HBP and the abundance of THTR-1 and THTR-2 assayed. Another interesting research
topic would be to examine the timecourse that these changes happen over. How long an
incubation in high glucose is sufficient to lead to a decrease in expression and abundance
of thiamine transporters? Perhaps simulation of elevated post-prandial glucose could be
examined to see if that has an effect on the thiamine transporters.
Moving beyond in vitro studies, studies in animal models of diabetes would be in-
valuable in understanding the mechanisms involved on a whole-body scale. Work conducted
with cells growing in a flask provides valuable information but cannot hope to recreate the
complexities and intricacies of a diabetic animal. There are currently two active projects
within the research group which are studying streptozotocin-induced diabetic rats in the
hope of answering some of the outstanding questions. The first project is investigating
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the effects of thiamine supplementation or tight glycaemic control on the expression and
abundance of thiamine transport systems in the glomeruli, tubules, retina, sciatic nerve and
other tissues. The second in vivo project is investigating whole body thiamine handling
by injecting stable isotopically labelled [13C]thiamine and monitoring transport of thiamine
into key organs or excretion from the body in diabetic and control animals. Between them,
these two studies should reveal crucial information on the handling of thiamine in both
healthy animals and diabetic animals (see Appendix C for further details of ongoing work).
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Appendix A
Supplementary statistical data
The table in this appendix includes exact p-values and differences for all comparisons made
within this thesis. All important statistical data is discussed in the main text. Each row
has a figure and page reference followed by a base condition and a target condition. The
effect % is the change from the base condition to the target condition. Effect percentages
and p-values are given to two significant figures.
Table A.1: Supplementary statistical information
Figure Page Base condition Comparison Effect (%) p value
9.1 158 THTR-1 −G−T THTR-1 −G+T −19% 0.0046
9.1 158 THTR-1 −G−T THTR-1 +G−T −76% 1.5× 10−10
9.1 158 THTR-1 −G−T THTR-1 +G+T −80% 6.5× 10−11
9.1 158 THTR-1 −G+T THTR-1 +G−T −70% 1.1× 10−8
9.1 158 THTR-1 −G+T THTR-1 +G+T −76% 3.7× 10−9
9.1 158 THTR-1 +G−T THTR-1 +G+T −18% 0.79
9.1 158 THTR-2 −G−T THTR-2 −G+T −8.7% 0.16
9.1 158 THTR-2 −G−T THTR-2 +G−T −53% 1.9× 10−9
9.1 158 THTR-2 −G−T THTR-2 +G+T −54% 1.5× 10−9
9.1 158 THTR-2 −G+T THTR-2 +G−T −48% 2.7× 10−8
9.1 158 THTR-2 −G+T THTR-2 +G+T −49% 2.0× 10−8
9.1 158 THTR-2 +G−T THTR-2 +G+T −2.1% 0.99
9.1 158 RFC-1 −G−T RFC-1 −G+T −24% 2.2× 10−5
9.1 158 RFC-1 −G−T RFC-1 +G−T −39% 5.0× 10−8
9.1 158 RFC-1 −G−T RFC-1 +G+T −32% 5.9× 10−7
9.1 158 RFC-1 −G+T RFC-1 +G−T −19% 0.0051
9.1 158 RFC-1 −G+T RFC-1 +G+T −11% 0.15
9.1 158 RFC-1 +G−T RFC-1 +G+T +10% 0.32
9.2 159 OGT −G−T OGT −G+T −19% 0.013
9.2 159 OGT −G−T OGT +G−T −63% 2.1× 10−8
9.2 159 OGT −G−T OGT +G+T −64% 1.5× 10−8
9.2 159 OGT −G+T OGT +G−T −54% 3.1× 10−6
9.2 159 OGT −G+T OGT +G+T −56% 2.0× 10−6
9.2 159 OGT +G−T OGT +G+T −3.9% 0.99
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9.2 159 oGlcNAcase −G−T oGlcNAcase −G+T +9.2% 0.93
9.2 159 oGlcNAcase −G−T oGlcNAcase +G−T +39% 0.078
9.2 159 oGlcNAcase −G−T oGlcNAcase +G+T +52% 0.015
9.2 159 oGlcNAcase −G+T oGlcNAcase +G−T +27% 0.23
9.2 159 oGlcNAcase −G+T oGlcNAcase +G+T +39% 0.050
9.2 159 oGlcNAcase +G−T oGlcNAcase +G+T +9.1% 0.83
9.2 159 GFAT-1 −G−T GFAT-1 −G+T −24% 0.019
9.2 159 GFAT-1 −G−T GFAT-1 +G−T −93% 3.0× 10−9
9.2 159 GFAT-1 −G−T GFAT-1 +G+T −93% 3.2× 10−9
9.2 159 GFAT-1 −G+T GFAT-1 +G−T −91% 2.1× 10−7
9.2 159 GFAT-1 −G+T GFAT-1 +G+T −90% 2.2× 10−7
9.2 159 GFAT-1 +G−T GFAT-1 +G+T +4.9% 1.0
9.2 159 Sp1 −G−T Sp1 −G+T −17% 0.24
9.2 159 Sp1 −G−T Sp1 +G−T −77% 5.6× 10−7
9.2 159 Sp1 −G−T Sp1 +G+T −76% 6.6× 10−7
9.2 159 Sp1 −G+T Sp1 +G−T −72% 1.3× 10−5
9.2 159 Sp1 −G+T Sp1 +G+T −71% 1.6× 10−5
9.2 159 Sp1 +G−T Sp1 +G+T +4.3% 1.0
9.2 159 TKT −G−T TKT −G+T −38% 3.5× 10−7
9.2 159 TKT −G−T TKT +G−T −62% 2.6× 10−10
9.2 159 TKT −G−T TKT +G+T −59% 6.1× 10−10
9.2 159 TKT −G+T TKT +G−T −39% 8.6× 10−5
9.2 159 TKT −G+T TKT +G+T −34% 4.3× 10−4
9.2 159 TKT +G−T TKT +G+T +8.8% 0.83
9.3 160 Coll IV −G−T Coll IV −G+T −16% 0.21
9.3 160 Coll IV −G−T Coll IV +G−T +7.6% 0.78
9.3 160 Coll IV −G−T Coll IV +G+T +12% 0.46
9.3 160 Coll IV −G+T Coll IV +G−T +28% 0.038
9.3 160 Coll IV −G+T Coll IV +G+T +33% 0.013
9.3 160 Coll IV +G−T Coll IV +G+T +4.0% 0.95
9.3 160 TXNIP −G−T TXNIP −G+T −10% 1.0
9.3 160 TXNIP −G−T TXNIP +G−T +4800% 1.2× 10−10
9.3 160 TXNIP −G−T TXNIP +G+T +5800% 6.9× 10−12
9.3 160 TXNIP −G+T TXNIP +G−T +5300% 1.1× 10−10
9.3 160 TXNIP −G+T TXNIP +G+T +6500% 6.7× 10−12
9.3 160 TXNIP +G−T TXNIP +G+T +21% 0.014
9.4 161 THTR-1 −G−T THTR-1 −G+T −5.3% 0.72
9.4 161 THTR-1 −G−T THTR-1 +G−T +22% 0.0046
9.4 161 THTR-1 −G−T THTR-1 +G+T +19% 0.011
9.4 161 THTR-1 −G+T THTR-1 +G−T +29% 8.0× 10−4
9.4 161 THTR-1 −G+T THTR-1 +G+T +26% 0.0018
9.4 161 THTR-1 +G−T THTR-1 +G+T −2.1% 0.96
9.4 161 THTR-2 −G−T THTR-2 −G+T −0.036% 1.0
9.4 161 THTR-2 −G−T THTR-2 +G−T +3.9% 0.88
9.4 161 THTR-2 −G−T THTR-2 +G+T +9.8% 0.29
9.4 161 THTR-2 −G+T THTR-2 +G−T +3.9% 0.87
9.4 161 THTR-2 −G+T THTR-2 +G+T +9.8% 0.28
9.4 161 THTR-2 +G−T THTR-2 +G+T +5.7% 0.67
9.4 161 RFC-1 −G−T RFC-1 −G+T −5.3% 0.42
9.4 161 RFC-1 −G−T RFC-1 +G−T +9.3% 0.064
9.4 161 RFC-1 −G−T RFC-1 +G+T +2.9% 0.81
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9.4 161 RFC-1 −G+T RFC-1 +G−T +15% 0.0040
9.4 161 RFC-1 −G+T RFC-1 +G+T +8.6% 0.11
9.4 161 RFC-1 +G−T RFC-1 +G+T −5.9% 0.26
9.5 162 OGT −G−T OGT −G+T +3.3% 0.93
9.5 162 OGT −G−T OGT +G−T +28% 0.0010
9.5 162 OGT −G−T OGT +G+T +26% 0.0020
9.5 162 OGT −G+T OGT +G−T +24% 0.0028
9.5 162 OGT −G+T OGT +G+T +22% 0.0055
9.5 162 OGT +G−T OGT +G+T −1.6% 0.98
9.5 162 oGlcNAcase −G−T oGlcNAcase −G+T −1.6% 0.98
9.5 162 oGlcNAcase −G−T oGlcNAcase +G−T +9.4% 0.21
9.5 162 oGlcNAcase −G−T oGlcNAcase +G+T +15% 0.031
9.5 162 oGlcNAcase −G+T oGlcNAcase +G−T +11% 0.12
9.5 162 oGlcNAcase −G+T oGlcNAcase +G+T +16% 0.016
9.5 162 oGlcNAcase +G−T oGlcNAcase +G+T +4.8% 0.66
9.5 162 GFAT-1 −G−T GFAT-1 −G+T −2.7% 0.99
9.5 162 GFAT-1 −G−T GFAT-1 +G−T +33% 0.0086
9.5 162 GFAT-1 −G−T GFAT-1 +G+T +31% 0.012
9.5 162 GFAT-1 −G+T GFAT-1 +G−T +36% 0.0049
9.5 162 GFAT-1 −G+T GFAT-1 +G+T +35% 0.0068
9.5 162 GFAT-1 +G−T GFAT-1 +G+T −1.2% 1.0
9.5 162 Sp1 −G−T Sp1 −G+T +15% 0.83
9.5 162 Sp1 −G−T Sp1 +G−T +40% 0.16
9.5 162 Sp1 −G−T Sp1 +G+T −8.0% 0.97
9.5 162 Sp1 −G+T Sp1 +G−T +22% 0.50
9.5 162 Sp1 −G+T Sp1 +G+T −20% 0.58
9.5 162 Sp1 +G−T Sp1 +G+T −34% 0.073
9.5 162 TKT −G−T TKT −G+T +14% 0.083
9.5 162 TKT −G−T TKT +G−T +0.13% 1.0
9.5 162 TKT −G−T TKT +G+T +15% 0.070
9.5 162 TKT −G+T TKT +G−T −12% 0.087
9.5 162 TKT −G+T TKT +G+T +0.52% 1.0
9.5 162 TKT +G−T TKT +G+T +15% 0.073
9.6 162 Coll IV −G−T Coll IV −G+T −7.0% 0.78
9.6 162 Coll IV −G−T Coll IV +G−T +6.2% 0.83
9.6 162 Coll IV −G−T Coll IV +G+T −8.1% 0.69
9.6 162 Coll IV −G+T Coll IV +G−T +14% 0.32
9.6 162 Coll IV −G+T Coll IV +G+T −1.2% 1.0
9.6 162 Coll IV +G−T Coll IV +G+T −13% 0.26
9.6 162 TXNIP −G−T TXNIP −G+T −7.2% 0.73
9.6 162 TXNIP −G−T TXNIP +G−T +59% 9.2× 10−6
9.6 162 TXNIP −G−T TXNIP +G+T +59% 9.2× 10−6
9.6 162 TXNIP −G+T TXNIP +G−T +72% 2.8× 10−6
9.6 162 TXNIP −G+T TXNIP +G+T +72% 2.8× 10−6
9.6 162 TXNIP +G−T TXNIP +G+T −0.011% 1.0
9.8 164 Primary −G−T Primary +G−T −77% 0.048
9.9 165 Primary −G+T Primary +G+T −15% 0.68
9.10 166 HK-2 −G−T HK-2 +G−T −52% 0.017
9.11 166 HK-2 −G+T HK-2 +G+T −53% 0.029
10.1 171 UDP-Glc −G−T UDP-Glc −G+T −5.6% 0.70
10.1 171 UDP-Glc −G−T UDP-Glc +G−T −13% 0.062
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10.1 171 UDP-Glc −G−T UDP-Glc +G+T +9.0% 0.32
10.1 171 UDP-Glc −G+T UDP-Glc +G−T −8.3% 0.43
10.1 171 UDP-Glc −G+T UDP-Glc +G+T +16% 0.038
10.1 171 UDP-Glc +G−T UDP-Glc +G+T +26% 8.1× 10−4
10.1 171 UDP-GlcNAc −G−T UDP-GlcNAc −G+T +1.8% 0.99
10.1 171 UDP-GlcNAc −G−T UDP-GlcNAc +G−T −22% 0.0030
10.1 171 UDP-GlcNAc −G−T UDP-GlcNAc +G+T −0.39% 1.0
10.1 171 UDP-GlcNAc −G+T UDP-GlcNAc +G−T −24% 0.0013
10.1 171 UDP-GlcNAc −G+T UDP-GlcNAc +G+T −2.2% 0.98
10.1 171 UDP-GlcNAc +G−T UDP-GlcNAc +G+T +28% 0.0035
10.2 172 UDP-Glc −G−T UDP-Glc −G+T +10% 0.70
10.2 172 UDP-Glc −G−T UDP-Glc +G−T +25% 0.075
10.2 172 UDP-Glc −G−T UDP-Glc +G+T +23% 0.12
10.2 172 UDP-Glc −G+T UDP-Glc +G−T +14% 0.39
10.2 172 UDP-Glc −G+T UDP-Glc +G+T +12% 0.54
10.2 172 UDP-Glc +G−T UDP-Glc +G+T −2.0% 0.99
10.2 172 UDP-GlcNAc −G−T UDP-GlcNAc −G+T +16% 0.34
10.2 172 UDP-GlcNAc −G−T UDP-GlcNAc +G−T −2.3% 0.99
10.2 172 UDP-GlcNAc −G−T UDP-GlcNAc +G+T −2.3% 0.99
10.2 172 UDP-GlcNAc −G+T UDP-GlcNAc +G−T −16% 0.24
10.2 172 UDP-GlcNAc −G+T UDP-GlcNAc +G+T −16% 0.24
10.2 172 UDP-GlcNAc +G−T UDP-GlcNAc +G+T −0.0088% 1.0
10.3 173 Control Glucosamine +4400% 2.4× 10−6
10.4 173 UDP-GlcNAc −G−Q UDP-GlcNAc −G+Q −0.33% 1.0
10.4 173 UDP-GlcNAc −G−Q UDP-GlcNAc +G−Q −12% 0.013
10.4 173 UDP-GlcNAc −G−Q UDP-GlcNAc +G+Q −16% 0.0017
10.4 173 UDP-GlcNAc −G+Q UDP-GlcNAc +G−Q −12% 0.015
10.4 173 UDP-GlcNAc −G+Q UDP-GlcNAc +G+Q −16% 0.0020
10.4 173 UDP-GlcNAc +G−Q UDP-GlcNAc +G+Q −4.4% 0.64
10.5 175 HK-2 −G−T HK-2 +G−T +63% 0.0098
10.6 176 HK-2 −G−T HK-2 +G−T +6.4% 0.83
10.7 176 HK-2 −G−T HK-2 +G−T −43% 0.0070
10.8 177 HK-2 +G−T HK-2 +G+T +6.0% 0.82
11.1 179 THM −G−T THM −G+T Incalculable 1.6× 10−12
11.1 179 THM −G−T THM +G−T Incalculable 1.0
11.1 179 THM −G−T THM +G+T Incalculable 4.7× 10−12
11.1 179 THM −G+T THM +G−T −100% 1.6× 10−12
11.1 179 THM −G+T THM +G+T −20% 1.0× 10−5
11.1 179 THM +G−T THM +G+T Incalculable 5.3× 10−12
11.2 180 TPP −G−T TPP −G+T +210% 7.4× 10−10
11.2 180 TPP −G−T TPP +G−T −16% 0.39
11.2 180 TPP −G−T TPP +G+T +140% 1.5× 10−7
11.2 180 TPP −G+T TPP +G−T −73% 3.5× 10−10
11.2 180 TPP −G+T TPP +G+T −23% 8.7× 10−5
11.2 180 TPP +G−T TPP +G+T +180% 4.9× 10−8
11.3 180 THM −G−T THM −G+T +6500% 1.0× 10−6
11.3 180 THM −G−T THM +G−T +84% 1.0
11.3 180 THM −G−T THM +G+T +7100% 2.7× 10−6
11.3 180 THM −G+T THM +G−T −97% 1.1× 10−6
11.3 180 THM −G+T THM +G+T +10% 0.73
11.3 180 THM +G−T THM +G+T +3800% 3.1× 10−6
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11.4 181 TMP −G−T TMP −G+T +240% 2.3× 10−5
11.4 181 TMP −G−T TMP +G−T +20% 0.87
11.4 181 TMP −G−T TMP +G+T +220% 2.6× 10−4
11.4 181 TMP −G+T TMP +G−T −64% 5.0× 10−5
11.4 181 TMP −G+T TMP +G+T −5.5% 0.94
11.4 181 TMP +G−T TMP +G+T +160% 5.7× 10−4
11.5 182 TPP −G−T TPP −G+T +77% 0.0075
11.5 182 TPP −G−T TPP +G−T +5.4% 0.99
11.5 182 TPP −G−T TPP +G+T +150% 1.3× 10−4
11.5 182 TPP −G+T TPP +G−T −40% 0.012
11.5 182 TPP −G+T TPP +G+T +43% 0.022
11.5 182 TPP +G−T TPP +G+T +140% 1.8× 10−4
11.6 184 −TPP −G−T −TPP −G+T +31% 0.81
11.6 184 −TPP −G−T −TPP +G−T +11% 0.50
11.6 184 −TPP −G−T −TPP +G+T +13% 0.018
11.6 184 −TPP −G+T −TPP +G−T −15% 0.95
11.6 184 −TPP −G+T −TPP +G+T −14% 0.13
11.6 184 −TPP +G−T −TPP +G+T +1.1% 0.31
11.6 184 +TPP −G−T +TPP −G+T +13% 0.99
11.6 184 +TPP −G−T +TPP +G−T +9.7% 1.0
11.6 184 +TPP −G−T +TPP +G+T −1.0% 0.88
11.6 184 +TPP −G+T +TPP +G−T −3.2% 0.98
11.6 184 +TPP −G+T +TPP +G+T −13% 0.97
11.6 184 +TPP +G−T +TPP +G+T −9.8% 0.85
11.6 184 −TPP −G−T +TPP −G−T +10% 0.0096
11.6 184 −TPP −G+T +TPP −G+T −3.8% 0.72
11.6 184 −TPP +G−T +TPP +G−T +9.0% 0.16
11.6 184 −TPP +G+T +TPP +G+T −1.9% 0.62
11.7 185 −TPP −G−T −TPP −G+T +4.9% 0.92
11.7 185 −TPP −G−T −TPP +G−T −17% 0.14
11.7 185 −TPP −G−T −TPP +G+T −36% 4.1× 10−4
11.7 185 −TPP −G+T −TPP +G−T −21% 0.036
11.7 185 −TPP −G+T −TPP +G+T −39% 7.3× 10−5
11.7 185 −TPP +G−T −TPP +G+T −22% 0.099
11.7 185 +TPP −G−T +TPP −G+T +2.1% 0.99
11.7 185 +TPP −G−T +TPP +G−T −18% 0.11
11.7 185 +TPP −G−T +TPP +G+T −35% 3.0× 10−4
11.7 185 +TPP −G+T +TPP +G−T −19% 0.060
11.7 185 +TPP −G+T +TPP +G+T −37% 1.4× 10−4
11.7 185 +TPP +G−T +TPP +G+T −22% 0.10
11.7 185 −TPP −G−T +TPP −G−T +1.2% 0.86
11.7 185 −TPP −G+T +TPP −G+T −1.6% 0.78
11.7 185 −TPP +G−T +TPP +G−T +0.72% 0.95
11.7 185 −TPP +G+T +TPP +G+T +1.8% 0.87
12.4 191 HK-2 −G−T HK-2 −G+T +0.39% 1.0
12.4 191 HK-2 −G−T HK-2 +G−T −31% 1.1× 10−4
12.4 191 HK-2 −G−T HK-2 +G+T −17% 0.053
12.4 191 HK-2 −G+T HK-2 +G−T −31% 9.6× 10−5
12.4 191 HK-2 −G+T HK-2 +G+T −17% 0.046
12.4 191 HK-2 +G−T HK-2 +G+T +21% 0.12
12.4 191 HK-2 −G−T HK-2 −G+T +0.39% 1.0
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12.4 191 HK-2 −G−T HK-2 +G−T −31% 1.1× 10−4
12.4 191 HK-2 −G−T HK-2 +G+T −17% 0.053
12.4 191 HK-2 −G+T HK-2 +G−T −31% 9.6× 10−5
12.4 191 HK-2 −G+T HK-2 +G+T −17% 0.046
12.4 191 HK-2 +G−T HK-2 +G+T +21% 0.12
12.5 193 HK-2 −G−T HK-2 −G+T −28% 0.0014
12.5 193 HK-2 −G−T HK-2 +G−T −35% 3.4× 10−4
12.5 193 HK-2 −G−T HK-2 +G+T −50% 2.2× 10−5
12.5 193 HK-2 −G+T HK-2 +G−T −8.9% 0.55
12.5 193 HK-2 −G+T HK-2 +G+T −31% 0.0060
12.5 193 HK-2 +G−T HK-2 +G+T −24% 0.037
12.6 194 HK-2 −G−T HK-2 −G+T −13% 0.42
12.6 194 HK-2 −G−T HK-2 +G−T −9.6% 0.62
12.6 194 HK-2 −G−T HK-2 +G+T −22% 0.080
12.6 194 HK-2 −G+T HK-2 +G−T +3.4% 0.98
12.6 194 HK-2 −G+T HK-2 +G+T −11% 0.62
12.6 194 HK-2 +G−T HK-2 +G+T −14% 0.41
12.7 195 HK-2 −G−T HK-2 −G+T +22% 0.055
12.7 195 HK-2 −G−T HK-2 +G−T +38% 0.0027
12.7 195 HK-2 −G−T HK-2 +G+T +57% 1.6× 10−4
12.7 195 HK-2 −G+T HK-2 +G−T +13% 0.18
12.7 195 HK-2 −G+T HK-2 +G+T +29% 0.0041
12.7 195 HK-2 +G−T HK-2 +G+T +13% 0.089
12.2 189 A to B −G−T A to B −G+T +11% 0.50
12.2 189 A to B −G−T A to B +G−T +17% 0.20
12.2 189 A to B −G−T A to B +G+T +15% 0.30
12.2 189 A to B −G+T A to B +G−T +4.8% 0.89
12.2 189 A to B −G+T A to B +G+T +3.0% 0.97
12.2 189 A to B +G−T A to B +G+T −1.7% 0.93
12.2 189 B to A −G−T B to A −G+T +52% 6.5× 10−4
12.2 189 B to A −G−T B to A +G−T +52% 6.2× 10−4
12.2 189 B to A −G−T B to A +G+T +52% 6.1× 10−4
12.2 189 B to A −G+T B to A +G−T +0.18% 1.0
12.2 189 B to A −G+T B to A +G+T +0.27% 1.0
12.2 189 B to A +G−T B to A +G+T +0.095% 1.0
12.3 189 Ratio −G−T Ratio −G+T −27% 1.4× 10−4
12.3 189 Ratio −G−T Ratio +G−T −23% 7.9× 10−4
12.3 189 Ratio −G−T Ratio +G+T −25% 2.7× 10−4
12.3 189 Ratio −G+T Ratio +G−T +4.6% 0.76
12.3 189 Ratio −G+T Ratio +G+T +2.7% 0.98
12.3 189 Ratio +G−T Ratio +G+T −1.8% 0.93
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Appendix B
Primer sequences
Table B.1: Primer sequences
Gene Direction Sequence
THTR-1 Forward ACCCCAGCTTCTAACCACCT
THTR-1 Reverse GGCGAGAGGAGTAGCACATC
THTR-2 Forward CTGGCTCTGGTGGTCTTCTC
THTR-2 Reverse AGGCATAGCGTTCCACATTC
RFC-1 Forward CCATGGTCCTGTCTGTCCTT
RFC-1 Reverse TAGCGCTCCTTAGACCCTGA
OGT Forward GCAACCTAGCCAATGCTCTC
OGT Reverse GCAGCAAACTCTGGGAAGAC
oGlcNAcase Forward GTCTTAGGGGACATGGCAGA
oGlcNAcase Reverse ACAACATGCCTGAACCAACA
GFAT-1 Forward GATTCTGCTGGTGTGGGATT
GFAT-1 Reverse AGGACTGGGTTCTCCATGTG
Sp1 Forward TGCAGCAGAATTGAGTCACC
Sp1 Reverse CACAACATACTGCCCACCAG
TKT Forward CATCTCCGAGAGCAACATCA
TKT Reverse TTGTATTGGCGGCTAGTTCC
Collagen IV Forward TGGTCCAAGAGGATTTCCAG
Collagen IV Reverse TCATTGCCTTGCACGTAGAG
TXNIP Forward CTGGCGTAAGCTTTTCAAGG
TXNIP Reverse AGTGCACAAAGGGGAAACAC
β-actin Forward GGACTTCGAGCAAGAGATGG
β-actin Reverse AGCACTGTGTTGGCGTACAG
230
Appendix C
Other experiments undertaken
Other than the experiments described in this thesis, others have been carried out but not
included in the main text body. These experiments have not been included because they
represent part of larger projects with multiple researchers involved and sample analysis has
not progressed to a sufficient level to enable meaningful conclusions to be drawn. Continuing
work by colleagues in the Protein Damage and Systems Biology research group will bring
these projects to fruition. They are included here to allow the interested reader to see the
future experimental framework.
C.1 In vivo thiamine metabolism
Two projects using streptozotocin-induced diabetic rats have reached practical completion
but samples remain to be analysed. The first project was designed to investigate the effects
of three treatments on thiamine metabolism in diabetic rats. The three treatments were oral
thiamine therapy for a 6 week period, intensive glycaemic control (achieved via subcuta-
neous implantation of slow-release insulin implants), and restoration of normoglycaemia by
administration of phloridzin, an inhibitor of renal glucose re-uptake. Each of these groups
were compared to normal control rats and diabetic control rats. Samples harvested were
renal glomeruli, total renal cortex, retinas, lenses, sciatic nerve, liver, heart, small intestine,
brain, skeletal muscle, urine, plasma and erythrocytes. Abundance of thiamine, activity of
thiamine-dependent enzymes, abundance of thiamine transporters, mRNA abundance for
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genes related to thiamine metabolism and routine biochemical measurements will be made
for each of the samples where relevant.
The second project was designed to investigate thiamine handling and partitioning in
normal and diabetic animals with the aim of constructing a mathematical model of thiamine
metabolism. Control and diabetic animals were kept for six weeks after induction of diabetes.
After this period, each animal had [13C]thiamine injected intraperioneally at 0.1 mg kg−1.
Animals were sacrificed in satellite groups at 0.75, 1.5, 3, 6, 12, 24 and 48 h. Tissues were
harvested as for the first project and stored immediately at −80℃. These will be analysed
by HPLC to determine total thiamine content and by LC-MS/MS to determine the ratio
of [12C]thiamine to [13C]thiamine. This data will be used to construct the mathematical
model of thiamine metabolism.
C.2 Residual binding domain computation
Bioinformatic approach to studying the proteome offer a vast often untapped potential.
Gallet et al. [2000] published a method to use a plot of amino acid hydrophobicity (H)
versus mean hydrophobic moment (µH) for any protein sequence in the absence of structural
information, and identify in general terms which amino acids are likely to lie in particular
domains. For example, amino acids with a high hydrophobicity and a low mean hydrophobic
moment are likely to lie in a membranous region whereas residues with a high hydrophobicity
and mean hydrophobic moment are likely to lie on the surface of proteins. Also, residues
lying in an area to the left of centre are said to lie in the receptor binding domain (RBD)
and are likely to be involved in protein-protein interactions. In particular, arginine residues
within the RBD have been implicated in being both chemically active within the enzyme
and prone to modification by methylglyoxal and thus of high importance for investigation.
I have been working with a bioinformatician developing a system to automate interrogation
of the entire Swiss-Prot database for amino acid residues that are in the RBD and highly
probable to be targets for glycation whilst combining factors such as predicted secondary
structure.
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